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Chapter 1 
1.1  Measuring benefits in the delivery of health care 
Health economics is concerned with issues related to scarcity in the allocation of health 
care. The basic tasks of any economic evaluation are to identify, measure, value, and 
compare the costs and benefits of alternatives being considered. Traditional means of 
measuring benefits in the delivery of health care have concentrated on improvements in 
health outcomes using clinical outcomes and Quality Adjusted Life Years (QALY). The 
QALY is a measure of the quantity of life gained weighted by the quality of that life [1]. 
QALYs are extensively used in economic analyses in health care. They claim to capture 
the health outcome benefits caused by an intervention [2-4]. However, benefits of a health 
care intervention or service can be many-sided, e.g. containing non-health outcomes (e.g. 
amount of information) and process characteristics (e.g. treatment location, route of drug 
administration, patient experienced burden of testing). For instance, is ‘reduction of dying 
from cervical cancer’ the only screening characteristic that is considered by women 
attending a cervical cancer screening programme? Evidence shows that, within the 
context of cervical cancer screening, women’s preferences for various programmes are 
also determined by other characteristics than the reduced chance of dying from cervical 
cancer [5]. Individuals are willing to trade changes in health outcome (change in chance of 
dying from cervical cancer) with process characteristics (time between smears, time for 
results, chance of being recalled, chance of abnormality, cost of each smear). This is just 
one example that illustrats that utility (benefit, satisfaction) of an intervention is derived 
from both health outcomes and process- and non-health outcomes. Other studies showed 
that this result is not specific to cervical cancer screening [6-12]. This suggests that, 
assuming the goal of health interventions or services is to maximise utility, the value of 
process attributes and non-health outcomes should be considered alongside health 
outcomes [13]. These might be relevant for individuals’ preferences and acceptability for 
specific health care interventions (i.e. demand-led health care), and for some interventions 
that do not provide reduction in morbidity or mortality (e.g. cosmetic surgery).   
 
 
1.2 Discrete choice experiments 
The discrete choice experiment (DCE) approach provides opportunities for evaluation of 
process effects and non-health outcomes additional to traditional QALY analysis. A DCE 
is a technique for investigating individual preferences. The technique of DCE has its 
origin in mathematical psychology. The DCE method has been employed by companies 
to investigate the relative importance of the characteristics of their products influencing 
consumers’ demand [2]. The results are potentially useful to define optimal strategies for 
improvement of the products and hence to maximize sales. Market researchers first used 
this technique [14]. Nowadays DCEs have also been used widely in transport economics [15] 
and environmental economics [16].  
In a DCE individuals are offered a series of choice sets. They are asked to choose in each 
choice set between two or more  alternatives. See Table 1.1 for an example of a choice set 
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Table 1.1  Example of a DCE choice set concerning alternative modes of transport to work. 
 
 
Attributes 
Car Train 
Duration of transport 20 min 25 min 
Walk to/from transportation 0 min 3 min 
Price € 10  € 4  
My choice □ □ 
 
                            Attribute                                      Alternative                     Attribute level 
 
concerning alternative modes of transport to work. The technique of DCE is an attribute-
based measure of benefit, based on the assumptions   that,   first,   alternatives can  be  
described  by  their characteristics, known as attributes, and second, an individual’s 
valuation (i.e., benefit, utility, satisfaction or preference) depends upon the levels of these 
attributes (see Table 1.1). Responses of a DCE are modelled within a benefit (or 
satisfaction) function which provides information on whether or not the given attributes 
are important; the relative importance of attributes; the rate at which individuals are 
willing to trade between attributes; and overall benefit scores for alternatives [2, 17, 18].  
The technique of DCE was introduced in health care in the early 1990s [2]. It provides 
opportunities for evaluation whether a given health, non-health or process attribute of a 
health care intervention or service is important; the relative importance of these various 
attributes; and the trade-offs individuals are made between these attributes. In 
comparison to other stated preferences techniques (e.g. willingness to pay methods to 
assess the monetary value of alternatives, conjoint analysis methods and the visual 
analogue scale to rank, rate or scale alternatives, and standard gamble and time trade-off 
methods to assess the risk-benefit trade-off of alternatives), a DCE presents a reasonably 
straightforward task and one which more closely resembles a real world decision (i.e., 
trading off health outcomes, process attributes and/or non-health outcomes) [19].  
 
 
1.3 Theoretical aspects of discrete choice experiments 
The DCE approach combines random utility theory with consumer theory, experimental 
design theory and econometric analysis. There are key developments taking place in other 
areas of economics outside health economics, particularly concerning experimental design 
and methods of analysis [20]. Before introducing some of these technical aspects, a 
theoretical background of DCE is given first.  
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1.3.1 Theoretical background 
In a DCE in health care individuals are offered a series of choices between two or more 
health care interventions, services or policies that have different combinations of attribute 
levels. (See Table 1.2 for an example of a choice set in health care, taken from a DCE 
study to evaluate preferences for the provision of benign prostatic hyperplasia drug 
treatment [10]). Analysing the responses allows for evaluation of the relative importance of 
the attributes for respondents’ preferences, and for evaluation of the trade-offs that 
individuals make between the attributes. The latter are reflected by the marginal rates of 
substitution (MRS) between these attributes. Thus, the MRS of attribute Y for attribute X 
is the amount of attribute Y that an individual is willing to exchange for attribute X. For 
example, looking at Table 1.2, the MRS between the attributes ‘sexual side effects from 
treatment’ and ‘time to improvement in symptoms’ reflects how much longer individuals 
say to be willing to wait for symptom improvement (in months) to avoid sexual side 
effects. If cost is included as an attribute the willingness to pay (WTP) can be estimated as 
well [2]. For example, it is possible to evaluate how much individuals express to be willing 
to pay (in British Pounds) to avoid sexual side effects based on responses to the choice 
set presented in Table 1.2. 
The discrete choices observed in a DCE are assumed to reveal an underlying (latent) 
utility function. An individual acting rationally is expected to evaluate the available 
alternatives  in  each  choice  set  and  to  choose  the  alternative  which gives the greatest 
 
 
Table 1.2  Example of a DCE choice set in health care regarding preferences for the provision of 
benign prostatic hyperplasia drug treatment (source: [10])  
 
Characteristics of treatment Treatment A Treatment B No treatment 
Time to improvement in 
symptoms 3 months 1 month 
No 
improvement 
Treatment reduces the size of 
prostate No Yes No 
Sexual side effects from treatment Decreased sexual desire None None 
Non-sexual side effects from 
treatment Headache Dizziness None 
Cost of treatment per month £30 £50 £0 
Chance of having Acute Urinary 
Retention after 2 years 
2% 2% 4% 
Chance of requiring surgery after 
2 years 
4% 6% 4% 
Which drug treatment  
would you prefer? □ □    □ 
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relative utility, by making trade-offs across the different health outcomes, non-health 
outcomes and/or process attributes. Thus, an individual will choose alternative A over B, 
if U (XA, Z) > U (XB, Z), where U represents the individual’s indirect utility function 
from certain alternatives, XA the attributes of alternative A, XB the attributes of 
alternative B, and Z socioeconomic characteristics of the individual that influence his/her 
individual’s utility function of alternative 
l 
sues see Louviere et al. [17]; Hensher et al. [21]; Bliemer and Rose [22]; and Ryan et al. [23].  
Taking stock of the way in which DCE studies build up in the literature is 
portant. 
utility.  
Choices observed in DCEs are analysed using random utility theory (i.e. an error term is 
included in the utility function to reflect the unobservable factors in the individual’s utility 
function). Thus, an individual will choose alternative A over B, if V (XA, Z) + εA > V 
(XB, Z) + εB, where V is the measurable component of utility estimated empirically, and 
εA and εB reflect the unobservable factors in the 
A and B respectively (XA, XB and Z defined as above).  
For further details on how to conduct a DCE and detailed explanations of theoretica
is
 
 
1.3.2 Methodological advances 
Since DCEs were introduced in health economics in the early 1990s, they have become 
increasingly popular in health care settings. This is shown by the increased growth of 
published DCEs in a various range of journals in recent years [7, 9, 10, 24-29]. However, the 
most recent overview of published DCEs dates from 2003 [20] and an overview of more 
recent applications of DCE in health economics is lacking (i.e. which issues are 
addressed?). Also it is not known to what extent technical practice of DCE in health 
economics are following developments taking place in other disciplines or areas of 
economics. 
im
 
 
1.3.3 Labelled or unlabelled DCE 
A specific question that arises in the application of DCE is whether to present the choice 
sets in a labelled or unlabelled form. The unlabelled form involves assigning unlabelled 
alternatives in the choice set, such as ‘alternative A’, ‘alternative B’ and so on (see Table 
1.2 for example). The labelled form involves assigning labels that communicate 
information regarding the alternative (see Table 1.1. for example). In marketing 
applications, labels tend to consist of brand names and logos, which consumers have 
learnt to associate with different product characteristics and feelings. In the context of 
health economics, labels tend to consist of generic or brand-name medications, specific 
screening tests (e.g. colonoscopy, sigmoidoscopy), specific treatments (surgery vs 
conservative), or other descriptors. An advantage of assigning labels is that alternatives 
will be more realistic and the choice task less abstract, which may add to the validity of 
the results (i.e., responses reflect better the real preference structure) and hence, the 
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results may be better suitable to support decision-making at the policy level. However, by 
far most commonly applied DCEs in health economics used unlabelled alternatives. In 
health economics, the differences between labelled and unlabelled DCEs in various 
aspects of feasibility, trading-behaviour, and convergent validity have not been empirically 
vestigated. 
resses 
ealth economics, and to 
roblems in health care for 
lth care in various aspects of 
feasibility, trading-behaviour, and convergent validity. 
 progress in these key areas, and identifies important lessons learnt and to be 
ealth outcomes and 
terminants of the preference differences found between patients and GPs 
(Chapter 4).  
in
 
 
1.4  Objectives of the thesis 
The application of DCE to the field of health care seems promising. This thesis add
theoretical aspects and applications of DCE in health care. Its mains objectives are: 
 
1. To provide an overview of current DCE practice in h
compare and assess progress in methodological advances. 
2. To study the usefulness of DCE for real choice p
measuring benefits beyond health outcomes.  
3. To compare labelled versus unlabelled DCEs in hea
 
 
1.5 Structure of the thesis 
This thesis consists of three parts. Part one (Chapter 2) provides the reader an overview 
of current DCE practice in health economics. These current DCEs (2001-2008) were 
systematically reviewed and compared with previous DCE practice in health care (1990-
2000). Extracted data concentrate on key issues concerning experimental design and 
choice set construction, estimation procedures, and validity. In doing so this chapter 
assesses
learnt. 
Part two of this thesis (chapters 3-8) describes four applications of DCEs developed for 
real choice problems in health care to measure benefits beyond health outcomes. These 
four problems illustrate the potential of DCE to include non-h
process effects of health care interventions in preference elicitation.  
The first DCE focuses on preferences for preventive osteoporosis drug treatment. 
Various practice guidelines recommend a case-finding approach to identify persons with a 
high risk of osteoporotic fractures. However, the usefulness of this approach depends on 
whether the identified persons are willing to take preventive osteoporosis drug treatment, 
and on what conditions. The DCE was therefore a relevant addition to QALY analysis, 
because it could include process attributes of drug treatment to elicit the relative weights 
that patients place on various aspects of preventive drug treatment for osteoporosis 
(Chapter 3), the relative weights that general practitioners place on these aspects and to 
evaluate the de
 14 
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The second DCE focuses on preferences for brace treatment for idiopathic scoliosis 
patients. There are two treatments for idiopathic scoliosis patients, namely brace 
treatment and surgery. Brace treatment can be burdensome, whereas its effectiveness has 
been unproven so far. This raised the question how effective brace treatment should be 
for idiopathic scoliosis patients to consider a brace as a reasonable form of treatment. The 
DCE was therefore a relevant addition to QALY analysis, because it could take into 
account the ‘burden of treatment’ (i.e. wearing the brace; and thus process attributes) in 
the preferences (Chapter 5).  
The third DCE concerns breast reconstruction modalities. Multiple techniques are 
available for breast reconstruction. Each technique has its own (dis)advantages. 
Complementary to the medical analysis performed by the plastic surgeon regarding which 
breast reconstruction type individual patients could undergo, patients’ preferences for the 
procedure they would opt for are also important determinants. To get insight into 
patients’ benefits for breast reconstruction modalities, QALY-measurement is 
inappropriate. Namely, all benefits of breast reconstruction modalities are ‘non-health’ 
(such as cosmetic result of breast reconstruction) or process (burden of treatment (e.g. 
more than one surgery), and use of autologous tissue). Therefore the DCE instead of 
QALY analysis allowed to get insight into benefits for breast reconstruction modalities 
(Chapter 6).  
And finally, a fourth DCE concerns on estimating public’s preferences for colorectal 
cancer screening. Several European countries including the Netherlands are currently 
considering a nation-wide screening programme. The programme will probably be based 
on a standardized protocol with a single screening test. The uptake of a specific screening 
test will ultimately determine the population health benefit of a CRC screening 
programme. A DCE was undertaken to get insight in the determinants of uptake for 
various screening tests. Again, the DCE was a relevant addition to QALY analysis, 
because it gave the possibility to take process attributes of colorectal cancer screening 
tests (e.g., screening interval, preparation, location of screening) into account (Chapters 7 
and 8). 
Part three (Chapter 9) describes an empirical comparison between a labelled and an 
unlabelled DCE in various aspects of feasibility, trading-behaviour, and convergent 
validity by investigating individuals’ preferences for colorectal screening programmes. 
This thesis ends with a discussion of the theoretical and practical results and presents a 
number of conclusions and recommendations (Chapter 10). 
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Applying discrete choice experiments to 
value health and health care: a review of the 
literature 
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Chapter 2 
Summary 
Discrete choice experiments (DCEs) have become a commonly used instrument in health 
economics research. This paper updates a review of published papers between 1990-2000 
for the years 2001-2008. Based on this previous review, and a number of other key review 
papers, consideration is given to 3 issues: experimental design; estimation procedures; and 
validity of responses. We identified 114 DCEs, covering a range of policy questions much 
broader than valuing patient experience factors. These included valuing health outcomes, 
trade-offs between health outcomes and patient experience factors, estimating utility 
weights within the Quality Adjusted Life Year framework, understanding labour-market 
choices, developing priority setting frameworks, and doctor’s preferences for patient’s 
treatment. Recently published DCEs in health economics made more use of foldover 
methods and the D-efficient criterion for optimal design. We also note an increase in the 
use of models with greater flexibility, such as nested logit, latent class logit, and mixed 
logit. There has been a shift towards statistically more efficient designs and richer 
econometric models. However, much progress has still to be made towards assessment of 
external validity, and incorporation of DCE results into a decision-making framework by 
policy makers.  
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2.1 Introduction 
Discrete choice experiments (DCEs) have become a commonly used technique in health 
economic research, addressing a wide range of important policy questions [1]. The 
technique is an attribute-based measure of benefit, based on the assumptions that, health 
care interventions, services or policies, can be described by their attributes and, second, an 
individual’s valuation depends upon the levels of these attributes. Within a DCE 
respondents are asked to choose between two or more alternatives. The resulting choices 
reveal an underlying (latent) utility function. The approach combines random utility 
theory with consumer theory, experimental design theory and econometric analysis. 
Details on conducting a DCE and theoretical issues are covered elsewhere [1-5].  
Ryan and Gerard [6] identified a number of key methodological issues in their review of 
the application of DCEs in health between 1990 and 2000. These were echoed by others 
in the same field [1, 5, 7-10]. Recently, Guttman et al. [11] updated the initial work of Ryan and 
Gerard [6] by counting the key characteristics of DCEs used. Lancsar and Louviere [12] 
developed a checklist of issues to consider when developing or reviewing the quality of a 
DCE. Finally, Louviere and Lancsar [13] surveyed the current state-of-the-art, discussed 
key issues needing further research and emerging research trends, and suggested ways to 
move various aspects of DCEs towards best practice. Although these papers have made 
very useful contributions to the health economics literature, an extended systematic 
review on current DCE practice is still lacking. We aimed to review current DCEs in 
health economics, with an in depth focus on the issues ‘experimental design’; ‘methods of 
analysis’; and ‘validity’ [6]. We report on the methods and general results in Section 2, and 
compare the status of the three key issues between 1990-2000 and 2001-2008 in Section 3. 
Section 4 provides a discussion, suggestions for future research and some concluding 
remarks. 
 
 
2.2 Review of DCEs between 2001 and 2008 
 
2.2.1 Literature search 
We conducted a systematic review of current published DCE health economics studies, 
using Medline to identify English language DCE studies available in print or online 
between 2001 and 2008. Although this was a narrower search of databases than the 
baseline study it was expected to identify the large majority of the health related DCE 
studies published during the period. We used the same search terms as Ryan and Gerard 
[6] (These were: "discrete choice experiment(s)",  "discrete choice modelling", "discrete 
choice modeling", "stated preference", "part-worth utilities", "functional measurement", 
"paired comparisons", "pairwise choices", "conjoint analysis", "conjoint measurement", 
"conjoint studies", and "conjoint choice experiments”), leading to inclusion of studies if 
choice-based (studies that used Best Worst Scaling were not included (see Flynn et al.  [14], 
for further details), published as a full text article, and applied to a health care topic. Two 
 23 
Chapter 2 
of the authors (EWBG & MLEB) extracted data on three methodological key issues: 
‘experimental design’; ‘methods of analysis’; and ‘validity’. 
 
 
2.2.2 Background results  
The search generated 682 possible references. After reading abstracts or full articles, 121 
references relating to 114 original studies met the inclusion criteria. The Appendix shows 
the full list of references (2009 references are the published versions of the papers 
available online at the time of the search between 01-01-2001 and 31-12-2008), and    
……   … 
 
 
Table 2.1  Discription of DCE studies 
 
N=34  (%) (%)
Country of origin* UK 20 (59) (48)
US 7 (21) (12)
Australia 6 (18) (11)
Canada 1 (  3) (  5)
Denmark 0 (  -) (  4)
Netherlands 0 (  -) (  4)
Germany 0 (  -) (  3)
Other (Switzerland, China, Italy, France, 
Russia, Japan, Sweden, Spain, Zambia, 
Ghana, Nepal, Malawi)
0 (  -) (11)
Main objective** Patient and consumer experience' 
factors (A)
12 (35) (35)
Valuing health outcomes (B) 3 (  9) (  7)
Trade-offs health outcomes and 
experience factors (C)
14 (41) (33)
Estimating utility weights within QALY 
framework (D)
0 (  -) (  2)
Job-choices (E) 2 (  6) (  4)
Developing priority setting frameworks 
(F)
2 (  6) (  5)
Health professional's preferences for 
treatment or screening options for 
patients (G)
1 (  3) (15)
Other (H) 0 (  -) (  4)
*    Percentages do not up to 100% exactly due to rouding error.
**   Totals do not up to 100% as each study can have more than one main objective
Item Category
Baseline: Current:
1990-2000 2001-2008
N=114
55
14
13
40
13
6
5
5
3
2
17
4
8
38
5
6
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demonstrates the breadth of applications (there has been a move from the term ‘conjoint 
analysis’ to ‘Discrete Choice Experiments’ (DCEs) and ‘Stated Preference Discrete 
Choice modelling’ (SPDCM)). As discussed by Ryan and Gerard [6], DCEs were 
introduced into health economics in the early 1990s as a method to go beyond the Quality 
Adjusted Life Years (QALYs), and consider broader aspects of value. More specifically, 
DCEs were proposed as a technique to value what might be termed patient experience 
factors [15-16]. A large number of studies in health still addressed issues such as the relative 
importance of patient experience attributes, trade-offs between attributes, willingness to 
pay for marginal changes in attributes as well as the overall monetary value of different 
configurations of services (studies A1-A40). However, within an economic evaluation 
framework, DCEs are now used to value health outcomes (studies B1-B8); the trade-offs 
individuals make between health outcomes and patient experience factors (studies C1-
C38) and, more recently, to estimate utility weights within the QALY framework (D1 and 
D2). Applications have also extended beyond economic evaluation, to investigate labour-
market choices amongst health care professional (studies E1-E5), priority setting 
frameworks at the local/national level (studies F1-F6) and preferences regarding clinical 
decision making (studies G1 and G17).  
The UK remained the major contributor to the literature when we compared the years 
1990-2000 to 2001-2008, with the US, Australia, and Canada also being major 
contributors (Table 2.1). However 26 studies (23%) were conducted in countries where              
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the technique had not been applied in the baseline review. These included high income, 
middle income and low income countries. Figure 2.1 shows that the number of 
applications of DCEs in health is gathering pace – many more studies were published in 
the period 2006-2008 (73 studies) as in the previous five years (2001-2005; 41 studies). 
 
 
2.3 Key issues arising from baseline review 
2.3.1 Experimental design and choice set construction 
A crucial aspect of constructing a DCE is defining the choices in order that parameter 
estimates are reliable. A full factorial design includes all possible combinations of 
attributes and levels for making profiles or choice sets. This often results in a large 
number and experimental design methods are used to create smaller fractional factorial 
designs. When employing fractional factorial designs the researchers’ task is to select an 
experimental design and construct choices to minimise the variation in relevant parameter 
estimates [1].   
Recent years have seen rapid developments in experimental design methods employed, 
including orthogonal and D-efficient designs. Orthogonal designs are often based on 
orthogonal arrays from design catalogues (e.g. Hahn and Shapiro [17]), statistical programs 
(e.g. SPEED [18]); SPSS, (SPSS Inc., Chicago, IL, USA)) or web-sites (Sloane [19]). These 
arrays have the properties of orthogonality (attributes are statistically independent of one 
another) and level balance (levels of any given attribute appear the same number of 
times). If a binary choice DCE is employed (a binary choice is where respondents are 
presented with a number of profiles (one at a time) and asked if they would 
choose/participate, with possible responses being ‘yes’ or ‘no’), then the profiles 
generated from the orthogonal design are the choices (e.g., studies C2, C34, F4, G9 and 
H3).  
Where choices present two or more options, choice sets must be created. Whilst initial 
methods for doing this included random pairing of a set of orthogonal choices (e.g. 16 
profiles from an orthogonal array would be randomly allocated into 8 choices) or the use 
of a constant comparator (which may have been taken from the orthogonal array or have 
been the current situation), the period since the previous review has seen the 
development of alternative methods. Louviere et al. [2] propose two methods to move 
from an orthogonal array to a set of choices: foldover (each of say 16 profiles are paired 
with their foldover (foldover is a mirror image of the original design [2, 20]; (e.g., in case of 
two level attributes replace each 0 with 1, and each 1 with 0; in the case of three level 
attributes replace each 0 with 1, 1 with 2, and 2 with 0) to create 16 choice sets) or 
foldover with random pairing (here an orthogonal array of say 16 profiles are randomly 
paired with their foldover). Readily available designs are available using these methods [20-
25], as well as help from experts (see software of Street and Burgess [26]).  
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More recently statistically efficient designs have been developed [20-22, 27]. Statistical 
efficiency may be measured in a number of ways (see Liang et al. [28] for more details). The 
D-efficiency criterion (precision of parameter estimates) has been the more popular 
criterion, primarily because it is computationally less cumbersome. Here the variance–
covariance matrix is minimized. Zwerina et al. [29] developed a computer generated 
statistically D-efficient design using Cook and Nachtsheim’s [30] modified Fedorov [31] 
algorithm. Here the algorithm searches for a choice design which minimizes the D-error 
or equivalently maximizes the D-efficiency for the nonlinear multinomial logit choice 
model.  This is readily available within SAS software [32]. 
When deriving efficient designs it has been common to assume, a priori, that parameters 
are zero. A recent development is to use prior assumptions about parameters [33-41]. It is 
argued that the statistical efficiency of designs can be improved using informative priors 
since choices can be derived that rule out dominant alternatives and maximize the 
information obtained from each choice situation [42]. If there is no prior information a 
design could be created using zero priors, and given to a small sub-sample (e.g. 10%) of 
the study’s subjects. The estimated parameters from this sample could subsequently be 
used as priors to create a revised efficient design which could then be given to the 
remaining sample (e.g., 90%) [42]. 
 
2.3.1.1 Experimental design and choice set construction in practice 
As with the previous review, main effects fractional factorial designs still dominate (Table 
2.2). Forty-two studies (37%) did not report the design source. In studies that reported 
the design source, software packages remain the most popular design source (59 studies; 
52%); 22 studies (20%) reported using SPEED to create an orthogonal array and 14 
studies (12%) used SPSS. When using these orthogonal main arrays, choice sets still need 
to be created. Current practice has changed with respect to this. The less efficient random 
pairing method is less commonly used, and there has been a move towards foldover 
methods and D-efficient designs. For example, 12 studies used foldover methods (study 
A27 used foldover with random pairing; studies A21, A32, A36, C24, C26, C31, C33, D2, 
F2, F3, and F6 paired the profiles with their foldover) or used specific software to create 
orthogonal choices (five US studies used Sawtooth software to create orthogonal choices 
(A39, B4, C21, C29, and H2). This software is used extensively in market research. It 
might be worth exploring further for relevance to health economics applications given the 
completeness of the package – however this software is yet not too for conjoint studies 
only so therefore limited). All 14 studies employing D-efficient designs used SAS software 
to create choices (studies A20, A25, A30, A34, A35, A38, B5, C27, C38, F1, G10, and 
G15) or gave no further details (studies A5 and A37). There had been no application of 
designs incorporating a priori assumptions for parameter estimates and a further 32 
studies (28%) which did not report sufficient detail of the design method used.  
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Table 2.2  Experimental design and construction of choice sets 
 
Item
N=34 (%) N=114 (%)
Full factorial 4 (12) 0 (  -)
Fractional factorial 25 (74) 114 (100)
Not clearly reported 5 (15) 0 (  -)
Main effects only 25 (74) 100 (89)
Main effects, 2-way interactions 2 (  6) 6 (  5)
Not applicable 4 (12) 0 (  -)
Not clearly reported 3 (  9) 8 (  7)
Software package 19 (56) 59 (52)
   SPEED 13 (38) 22 (19)
   SPSS 2 (  6) 14 (12)
   SAS 0 (  -) 14 (12)
   SAWTOOTH 2 (  6) 5 (  4)
   Other 2 (  6) 0 (  -)
   No further details 0 (  -) 4 (  4)
Catalogue 2 (  6) 6 (  5)
Website 0 (  -) 3 (  3)
Expert 4 (12) 4 (  4)
Not clearly reported 9 (26) 42 (37)
Orthogonal rays
     One profile per choice set                 3 (  9) 12 (11)
     (e.g. binary choices)
     Random pairing 18 (53) 19 (17)
     Pairing with constant comparator 6 (18) 23 (20)
     Foldover - random pairing 0 (  -) 1 (  1)
     Foldover   0 (  -) 11 (10)
D-efficiency (SAS) 0 (  -) 14 (12)
Other (pragmatically chosen) 4 (12) 2 (  2)
Not clearly reported 3 (  9) 32 (28)
Notes: * Percentages do not up to 100% exactly due to rounding error
Design type
Design plan
Design source
Design method*
Baseline: Current:
1990-2000 2001-2008
 
 
2.3.2  Estimation procedure 
Responses from the choices are modelled within a random utility theory (RUT) 
framework [43]. Here it is assumed that whilst the individual knows the nature of her utility 
function, the researcher does not. Therefore, as shown in Equation 1, the latent utility of 
an alternative i in a choice set Cn (as perceived by individual n) is decomposable into two 
additively separable parts: (i) a systematic (explainable) component specified as a function 
 28 
Applying discrete choice experiments in health and health care 
 
of the attributes of the alternatives V(Xin, β); and (ii) a random (unexplainable) 
component ε in representing unmeasured variation in preferences. 
 
 
Uin = V(Xin, β) + ε in  
 
(Eq. 1) 
 
It is assumed that individual n will choose alternative i if that alternative maximizes her 
utility amongst all alternatives in the choice set Cn.  
The starting point of model selection is the choice of the error distribution (and the 
distribution of the differences in errors of the alternatives). This determines whether it is 
appropriate to use probit, logit, multinomial logit or more advanced models. When the 
choice faced by respondents in a DCE is binary or if the choice set includes only two 
‘forced’ alternatives (i.e. would you choose alternative A or B), binary probit or logit 
models are appropriate. Early studies in health predominantly focused on binary choice or 
‘forced’ choice, using these (random effects; i.e. using panel specification) logit or probit 
models to analyse the response data [6]. As more studies began to collect multinomial 
rather than binary choice data (e.g., by including neither or opt-out options to allow for 
realism), the binary logit/probit models were inappropriate, and the workhorse to analyse 
multinomial choice has been the McFadden’s multinomial logit (MNL) [43]. The MNL has 
four important assumptions: (i) identically distributed errors (i.e., constant error variance 
or homoscedasticity); (ii) independent errors (i.e., independence of irrelevant alternatives 
(IIA); thus assuming that all options are equal substitutes); (iii) no panel data (i.e., no 
correlation allowed for within responses); and (iv) no taste variation (i.e. homogenous 
preferences across respondents). However, the assumptions of MNL may be restrictive in 
describing human behaviour and in turn may restrict the realism of the policy analysis that 
follows. Therefore, much research effort has been (and continues to be) devoted to 
increasing the behavioural realism of choice models.  
Figure 2.2 shows three alternative families of models which were developed to relax the 
restrictions of the McFadden’s MNL model (see Ryan et al. [1] for more details): (i) the 
heteroscedastic models, which relax the assumption of identically distributed errors; (ii) 
the generalised extreme value (GEV) models, which relax the IIA assumption partially [44, 
45] (e.g. the nested logit model (NL)); and (iii) the flexible models, which relax the 
assumptions of independent errors and allow for random taste variation (MNL, GEV and 
heteroscedastic models allow for heterogeneous preferences using sub-group analysis; the 
key contribution of the flexible models is that sub-groups do not have to be identified in 
advance, the data does this) and for multiple observations as well (e.g. mixed logit model 
(MXL) and latent class model (LCM)).  
More recently it has been argued that the normal mixing distribution commonly used in 
the MXL is mis-specified [46-50]. More specifically, it is argued that much of the 
heterogeneity in attribute weights is accounted for by a scale effect, with the scale varying 
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across individuals. However, the “scale” is not identified in discrete choice data – a 
problem that is typically resolved by normalizing it to a constant. Fiebig et al. [50] found 
that models that account for scale heterogeneity (i.e., ‘generalised’-MNL or ‘scale 
heterogeneity’-MNL) are preferred to the MXL.  
 
 
2.3.2.1  Methods of analysis used in practice 
Five studies in the current review period used the NL model (A18, C17, C20, C36, and 
C37) compared to none in the baseline period (Table 2.3). In these studies it was assumed 
that the alternatives of the given health service were closer substitutes than ‘opting out’ 
(i.e. no health service). Use of the nested logit model also allowed testing whether the 
levels of attributes within an alternative affected the decision to attend a health care 
intervention/service. For example, Study C17 showed that the attributes offered by the 
cervical screening programs did not influence a woman’s decision to participate, and 
therefore altering the screening attributes will have no impact on uptake.  
The LCM was applied in one study in the current review (Study A34), giving insight into 
preference distribution for the attributes of a general practitioner appointment. Significant 
preference heterogeneity for the attributes of a general practitioner appointment included 
in the experiment was found, and the LCM led to a significant improvement in fit 
compared to the logit model. In this LCM model the class membership probability was a 
function of constants only, implying that the probability of belonging to each class was 
….  
Table 2.3  Estimation procedures 
 
Item Category
N=34 (%) N=114 (%)
Estimation procedure* 6 (18) 8 (  7)
18 (53) 47 (41)
1 (  3) 13 (11)
1 (  3) 6 (  5)
6 (18) 25 (22)
0 (  -) 5 (  4)
1 (  3) 6 (  5)
0 (  -) 1 (  1)
1 (  3) 4 (  4)
2 (  6) 4 (  4)Not clearly reported
Other**
Latent class (LCM)
Mixed logit (MXL)
Nested logit (NL)
MNL
Random effects logit
Logit 
Random effects probit
Probit
Baseline:
1990-2000 2001-2008
Current:
 
 
Notes:  * Totals do not up to 100% as each study can use more than one estimation procedure  
……  ** OLS; Generalised estimating equations; Monte Carlo Markov Chain Algorithms; Cox 
……        proportional hazard model  
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constant across individuals. This assumption can be relaxed by including socio-
demographic characteristics in the class membership model. Investigating the probability 
of belonging to a given class is an advantage of LCM compared with MXL.   
Six studies in the current review period employed the MXL model (A30, A34, A38, C16, 
C19, and C25), compared to one in the baseline review. All six studies found evidence of 
preference heterogeneity. Studies A30, A34, A38, and C16 reported that the MXL 
resulted in an improvement in goodness of fit compared to the binary logit or MNL. For 
example, study A30 found that the attribute ‘group meetings’ for cardiac rehabilitation 
activity was insignificant when analysed using a logit model, but highly significant with a 
large standard deviation using MXL; two-thirds of the variation showed a positive 
preference for the attribute and one-third a negative preference. The MXL model 
provided therefore additional policy relevant information as well as a better fit to the data 
than a simple model.  
The MXL has a number of disadvantages such as what parameters to randomised, what 
distributions to impose, and the amount of choice data. These were borne out in the 
applications. Study C19 faced a relatively small sample size (n=57); therefore only the 
intercepts were assumed random. Study A30 assumed all parameters to be normally 
distributed, thus allowing positive or negative preferences, and noted that other 
distributions such as lognormal or some bounded distribution would be preferable. For 
example, Study C16 assumed that the price proxy (cost attribute) and the waiting time for 
results of genetic carrier testing was normal distributed when positive values would not be 
expected. Issues are also raised when estimating WTP using the MXL model. Study A34 
showed that the MXL, where the cost coefficient was allowed to vary, had a markedly 
better fit than the MXL in which the cost coefficient was fixed. However, for estimating 
WTP a fixed cost coefficient seems to be better, since this: i) ensures that the coefficient 
has the correct sign; and ii) implies WTP is normally distributed if the remaining 
coefficients are normally distributed [51].  
 
 
 
2.3.3 Validity  
Given DCEs rely on responses to hypothetical data, investigating validity of responses is 
crucial. Table 2.4 presents a summary of tests of validity. The best test demonstrates 
external validity: i.e. whether or not behaviour stated in a hypothetical context is carried 
through into the choices made in the real world. External validity is perhaps the single 
most important research question for DCE in health economics. Yet very little research 
has been undertaken. This probably reflects the difficulty of investigating this issue in 
publicly provided health care systems where respondents have limited choice and usually 
do not pay at the point of consumption (although there are exceptions to this rule). In the 
only study identified which attempted to test external validity, Telser and Zweifel [52] 
aimed to study the external validity of preferences for hip protectors. Their study related 
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WTP values estimated in a DCE (the stated choice) to the same respondents’ later 
willingness to participate in a wearing trial of two months’ duration (the actual choice). 
Whilst this study provides some insight into validity, a limitation was that we do not know 
if respondents actual WTP was as stated in the stated preference experiment. Hence, this 
study was not comparing the performance of stated preference to actual behaviour. 
Evidence of internal validity of DCEs is more common, including tests of theoretical 
validity (whether the parameters move in the expected direction) and tests of the standard 
assumptions on individual preferences (non-satiation, transitivity, Sen’s expansion and 
contraction properties [53]; and compensatory decision-making). Tests of theoretical 
validity are easily performed within a study, and the results continue to be encouraging, 
with coefficients moving in the expected directions. Non-satiation continues to be the 
most common internal test, despite concerns of being too easy to pass [54] and not being 
essential for rationality [5]. However, transitivity, a fundamental test of rationality when 
using the preference based approach to preference elicitation [5], does not seem to be 
growing in use, perhaps reflecting the difficulty of applying this test within a DCE. Two 
studies had employed rationality tests from choice theory, based on Sen’s contraction 
consistency principle (studies D2 and H1). Tests of compensatory decision making 
(whether respondents consider all the attributes when making choices) continue to be 
investigated by investigating whether respondents always chose according to the best level 
of a given attribute. Such a decision-making pattern is taken as evidence of non- 
………… 
 
Table 2.4  Validity 
 
 
N=34 (%) N=114 (%)
Validity* External validity tests 0 (  -) 0 (  -)
Internal validity tests
    Theoretical 22 (65) 64 (56)
    Non-satiation 15 (44) 56 (49)
    Transitivity 3 (  9) 5 (  4)
    Sen’s expansion and contraction 0 (  -) 2 (  2)
    Compensatory decision making 12 (35) 36 (32)
Use of qualitative Increasing face validity
methods*     Attribute selection 6 (18) 79 (69)
    Level selection 6 (18) 38 (33)
    Pre-testing questionnaire 16 (47) 36 (32)
Strengthen understanding responses
    Debriefing choices 0 (  -) 5 (  4)
Item Current:
2001-2008
Category Baseline:
1990-2000
 
 
Note: * Totals do not add to 100% as each study can use validity tests and/or qualitative ..            
methods for more than one category 
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compensatory decision-making. However, Ryan and Gerard [6], noted that such tests are 
limited since compensatory behaviour may also result in such a choice pattern. Further, 
even if respondents are not trading, and marginal rates of substitution therefore cannot be 
estimated, these preferences are still important from a policy perspective [5].  
Once respondents have been identified who ‘fail’ the axioms of economic theory, the 
question is raised of what to do with them. Testing for internal validity should not 
automatically lead to deleting responses based on ‘irrational’ preferences or ‘not-
compensatory’ decision making. However, 30 out of 74 studies that tested for such 
internal validity deleted responses a priori to the analyses (e.g.,  studies A7, A22, A25, B2, 
C5, C30, E3, and G5), which may result in the removal of valid preferences, induce 
sample selection bias, and reduce the statistical efficiency and power of the estimated 
choice models [5]. A number of studies reported separate analyses to investigate the 
implication of retaining these subjects with dominant preferences, and reported that the 
findings were not (dramatically) different whether or not these subjects were retained (see 
A23, A26, B6, B7, C3, C18, and C21). 
Qualitative work has been proposed to develop the attributes and levels within a DCE 
(increasing the face validity, Coast and Horrocks [55]), as well as to better understand 
responses [54, 56]. Regarding the former, focus groups (e.g., studies A6, A11, A12, A20, B2, 
C6, C15, and G1) and interviews (e.g., A8, A26, C1-C3, C7 and G6) have been 
increasingly used to enhance attribute and level selection as well as the lay-out, 
comprehension and design of the DCE questionnaire.  
In the current review, five studies used qualitative approaches to debrief respondents in 
order to strengthen understanding of why people state particular preferences and, in turn, 
how results are to be interpreted (studies C4, C20, C24, C32 and G8). Studies C4 and C20 
collected data about the participant’s understanding of the questionnaire via a follow-up 
telephone interview; a couple of patients in Study C24 completed the survey in a ‘think 
aloud’ exercise, followed by a cognitive debrief interview to identify areas of 
misunderstanding; and studies C32 and G8 examined the free-text comments provided by 
the respondents in order to examine further their experiences of choices.   
 
 
 
2.4 Discussion 
Whilst DCEs were introduced into health economics to value patient experience factors, 
applications today are much broader. The technique has been used to value health 
outcomes, investigate trade-offs between health outcomes and patient experience factors, 
and more recently, to estimate utility weights within the QALY framework. Applications 
have also extended beyond economic evaluation, to investigate labour-market choices 
amongst health care professional, priority setting frameworks at the local/national level 
and preferences regarding clinical decision making. The number of applications has grown 
rapidly and has spread to many different health care systems that had previously not 
applied the technique. 
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Our review of the technical practice of DCE in health economics suggests a number of 
important developments. Although Guttman et al. [11] concluded that the methods and 
design employed are quite similar during the past two decades, we found that the 
importance of the experimental design component of a DCE is being increasingly 
recognised in health economics. The less efficient random pairing method was less 
commonly used, with a move towards D-efficient designs. As a result, the precision of the 
parameter estimates may be increased whereas the biases of the results may be decreased. 
Almost all studies that used statistically efficient designs were conducted in the most 
current period 2006-2008, which is an encouraging development. In these studies SAS 
software was frequently used, probably because it creates choice sets directly and is 
flexible (e.g. possibility of restricted designs and designs taking into account alternative 
specific parameters). Street and Burgess [24] found that design methods available in SAS 
often produce efficient designs, but the effects are not fully independent, resulting in 
some attribute effects with shared covariances. Recent software has been designed 
specifically for stated choice experimental designs (Ngene, http://www.choice-
metrics.com/), allowing for the generation of various stated choice experimental designs. 
We expect this software to gain ground in health economics for designs using prior 
assumptions about parameters. Louviere and Lancsar [13] note that “more research is 
needed to identify general conditions where a priori knowledge of signs and/or true 
parameters will significantly improve design properties.” This is likely to be an important 
area for future research. We would also hope to find less studies published without details 
of the experimental design methods and source. 
The use of richer econometric models for estimation is in its infancy in health economics, 
although there is some evidence exists of a move towards models with greater flexibility. 
Some current studies used NL and LCM models compared to none in the baseline period 
1990-2000. Also the MXL model was used more often. As a result, particularly the 
adjustment for preference heterogeneity increased. Wansbeek et al. [57] has singled 
heterogeneity out as ‘the most salient feature of consumer demand at the micro level’. 
Increasing computational power and increasingly richer data sets, allows models such as 
MXL and LCM, or even heteroscedastic models, to be empirically testable. There seems 
to be policy relevance to move towards richer econometric models, because these models 
can give additional policy relevant information, and may avoid wrong policy conclusions 
due to incorrect assumptions in the choice model. However, there are also problems in 
applying these more advanced models, such as that the researcher needs to make 
additional decisions regarding which coefficients to vary with which distribution, and the 
number of latent classes. The limitations of these advanced modelling methods should be 
recognised by practitioners. Following on from this, we expect MXL models will lose 
ground in health economics, and that in the near future ‘new’ models (such as 
‘generalised’-MNL or ‘scale heterogeneity’-MNL) will be introduced that account for scale 
heterogeneity. 
Thirdly, external validity is still under-researched. The challenge was posed by Ryan and 
Gerard [6] to find imaginative solutions to test this fundamental research question. Hereto, 
 35 
Chapter 2 
stated and actual behaviour have to be compared. At this point we may learn from other 
areas. Studies from other areas (Environmental and Agricultural economics) investigated 
the external validity of DCEs by using controlled laboratory experiments [58-62] (a 
controlled laboratory experiment takes place in a laboratory with subjects knowing they 
are part of an experiment), framed field experiments [63] (a framed field experiment takes 
place in the field context with subjects knowing they are part of an experiment), or natural 
field experiments [62] (a natural field experiment takes place in the field without subjects 
knowing they are part of an experiment), which is the strongest external validity test. In a 
laboratory or framed field experiment, individual’s desire to “do the right thing”, or make 
the “moral” choice [64] may influence behaviour. Laboratory experiments may however 
provide a starting point to test for external validity of DCEs in health or health care. It is 
hoped that imaginative solutions emerge to test the external validity of DCEs in health 
economics. Internal validity tests, on the other hand, are largely incorporated in the DCE 
practice in health economics, which should be continued. Further research is needed to 
find out if transitivity tests or Sen’s contraction property tests are more appropriate to test 
the internal validity of DCE responses than non-satiation tests. Mixed methods may be 
useful to get more insight into the internal validity of DCEs. Qualitative techniques, such 
as the think aloud technique, may show that seemingly ‘irrational’ choice behaviour may 
not be so irrational after all [56]; and thus may provide clues whether deleting ‘irrational’ 
preferences or ‘non-compensatory’ simple tests are valid. Further, even if respondents are 
not trading, and marginal rates of substitution therefore cannot be estimated, these 
preferences are still important from a policy perspective [5]. 
A further issue raised at the time of the 1990-2000 survey was generalisability of results. 
The recent growth of DCE in health economics means that there is now a stock of over 
150 published studies (and growing). It follows that the point has been reached where it is 
viable and timely to consider theoretical, methodological and practical application of 
credible DCE transfers in health economics. It has also been argued that DCE 
methodology may be particularly well suited for transfers because of its conceptually rich 
foundation [65]. Progress in this area would benefit policy makers, such as at the NHS, by 
informing decision-makers and commissioners of research how to best deal with 
situations when it may be more efficient to make use of existing information rather than 
pay for new studies or when information is needed quickly, or new empirical studies 
cannot be afforded.  
Following on from this, one notable feature of our review is the absence of the use of 
DCE output within an economic evaluation decision-making framework. This is clearly 
an important area for future research. Whilst QALYs continue to be the recommended 
measure of value when making recommendations regarding provision of alternative 
health care interventions by bodies such as NICE [66], the importance of the patient 
experience is also being increasingly recognised [67, 68]. Future work should explore the use 
of DCEs within an economic evaluation modelling framework. 
One significant methodological limitation of our study is that we may not be accurately 
representing the state of DCE practice due to publication lags. It could well be that more 
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progress has been attained that we are able to give credit for (i.e., the ‘picture’ is probably 
better than this review implied). This can only come to light at a later time. For example, 
the 11 studies that were found to embrace richer estimations procedures (i.e., studies A16, 
A30, A34, A38, C16, C17, C19, C20, C25, C36, and C37) were also more recently 
published (i.e. 2005-2008).  
In summary, the current systematic review shows that the applications of DCEs today are 
much broader than valuing patient experience factors. Regarding methodological issues, 
recently published DCEs in health economics made more use of foldover methods and 
D-efficient criterion for designing DCEs compared to 1990-2000. Also the use of models 
with greater flexibility such as NL, LCM and MXL slightly increased in time. There has 
been a shift towards use of more statistically efficient designs and richer econometric 
models. However, much progress has still to be made towards external validity. Also 
consideration needs to be given to incorporation of the results of a DCE into a decision-
making framework by policy makers.  
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Appendix 2.A   
 
 
Studies in current review are grouped by study objective. 
 
 
A. Patient or consumer experience factors 
 
Study A1 
van der Pol M, Cairns J. Estimating time preferences for health using discrete choice 
experiments. Soc Sci Med. 2001 May;52(9):1459-70 
 
Study A2 
Longworth L, Ratcliffe J, Boulton M. Investigating women's preferences for intrapartum 
care: home versus hospital births. Health Soc Care Community. 2001 Nov;9(6):404-13. 
 
Ratcliffe J, Longworth L. Investigating the structural reliability of a discrete choice 
experiment within health technology assessment. International Journal of Technology 
Assessment in Health Care. 2002; 18 (1) 139-144. 
 
Study A3 
Hundley V, Ryan M, Graham W. Assessing women's preferences for intrapartum care. 
Birth. 2001 Dec;28(4):254-63. 
 
Hundley V, Ryan M. Are women's expectations and preferences for intrapartum care 
affected by the model of care on offer? BJOG. 2004 Jun;111(6):550-60. 
 
Study A4 
Gyrd-Hansen D, Slothuus U. The citizen's preferences for financing public health care: a 
Danish survey. Int J Health Care Finance Econ. 2002 Mar;2(1):25-36 
 
Study A5 
Moayyedi P, Wardman M, Toner J, Ryan M, Duffett S. Establishing patient preferences 
for gastroenterology clinic reorganization using conjoint analysis. Eur J Gastroenterol 
Hepatol. 2002 Apr;14(4):429-33. 
 
Study A6 
Phillips KA, Maddala T, Johnson FR: Measuring preferences for health care interventions 
using conjoint analysis: an application to HIV testing. Health Serv Res 2002 Dec, 
37(6):1681-1705. 
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Study A7 
Scott A, Watson MS, Ross S. Eliciting preferences of the community for out of hours 
care provided by general practitioners: a stated preference discrete choice experiment. Soc 
Sci Med. 2003 Feb;56(4):803-14. 
 
Study A8 
Taylor S, Armour C: Consumer preference for dinoprostone vaginal gel using stated 
preference discrete choice modelling. Pharmacoeconomics 2003, 21(10):721-735. 
 
Study A9 
Burge P, Devlin N, Appleby J, Rohr C, Grant J. Do patients always prefer quicker 
treatment? : a discrete choice analysis of patients' stated preferences in the London patient 
choice project. Appl Health Econ Health Policy. 2004;3(4):183-94. 
 
Study A10* 
Bishop AJ, Marteau TM, Armstrong D, Chitty LS, Longworth L, Buxton MJ, Berlin C: 
Women and health care professionals' preferences for Down's Syndrome screening tests: 
a conjoint analysis study. Bjog 2004 Aug, 111(8):775-779. 
 
Study A11 
Dwight-Johnson M, Lagomasino IT, Aisenberg E, Hay J: Using conjoint analysis to assess 
depression treatment preferences among low-income Latinos. Psychiatr Serv 2004 Aug, 
55(8):934-936. 
 
Study A12 
Roux L, Ubach C, Donaldson C, Ryan M: Valuing the benefits of weight loss programs: 
an application of the discrete choice experiment. Obes Res 2004 Aug, 12(8):1342-1351. 
 
Study A13 
Gerard K, Lattimer V, Turnbull J, Smith H, George S, Brailsford S, Maslin-Prothero S. 
Reviewing emergency care systems 2: measuring patient preferences using a discrete 
choice experiment. Emerg Med J. 2004 Nov;21(6):692-7 
 
Gerard K, Lattimer V. Preferences of patients for emergency services available during 
usual GP surgery hours: a discrete choice experiment. Fam Pract. 2005 Feb;22(1):28-36. 
 
Study A14 
Salkeld G, Solomon M, Butow P, Short L. Discrete-choice experiment to measure patient 
preferences for the surgical management of colorectal cancer. Br J Surg. 2005 
Jun;92(6):742-7. 
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Study A15 
Hanson K, McPake B, Nakamba P, Archard L. Preferences for hospital quality in Zambia: 
results from a discrete choice experiment. Health Econ. 2005 Jul;14(7):687-701 
 
Study A16 
Ryan M, Major K, Skåtun D. Using discrete choice experiments to go beyond clinical 
outcomes when evaluating clinical practice. J Eval Clin Pract. 2005 Aug;11(4):328-38. 
 
Study A17* 
Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A: Differences 
between patients', physicians' and pharmacists' preferences for treatment products in 
haemophilia: a discrete choice experiment. Haemophilia 2005 Nov, 11(6):589-597. 
 
Study A18 
Ryan M, Diack J, Watson V, Smith N: Rapid prenatal diagnostic testing for Down 
syndrome only or longer wait for full karyotype: the views of pregnant women. Prenat 
Diagn 2005 Dec, 25(13):1206-1211. 
 
Study A19 
Longo MF, Cohen DR, Hood K, Edwards A, Robling M, Elwyn G, Russell IT. Involving 
patients in primary care consultations: assessing preferences using discrete choice 
experiments. Br J Gen Pract. 2006 Jan;56(522):35-42 
 
Study A20 
Kjaer T, Gyrd-Hansen D, Willaing I: Investigating patients' preferences for cardiac 
rehabilitation in Denmark. Int J Technol Assess Health Care 2006 Spring, 22(2):211-218. 
 
Study A21 
Akkazieva B, Gulacsi L, Brandtmuller A, Péntek M, Bridges JF. Patients' preferences for 
healthcare system reforms in Hungary: a conjoint analysis. Appl Health Econ Health 
Policy. 2006;5(3):189-98. 
 
Study A22* 
Lewis SM, Cullinane FM, Carlin JB, Halliday JL: Women's and health professionals' 
preferences for prenatal testing for Down syndrome in Australia. Aust N Z J Obstet 
Gynaecol 2006 Jun, 46(3):205-211 
 
Study A23 
Rubin G, Bate A, George A, Shackley P, Hall N. Preferences for access to the GP: a 
discrete choice experiment. Br J Gen Pract. 2006 Oct;56(531):743-8 
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Study A24 
Peacock S, Apicella C, Andrews L, Tucker K, Bankier A, Daly MB, Hopper JL. A discrete 
choice experiment of preferences for genetic counselling among Jewish women seeking 
cancer genetics services. Br J Cancer. 2006 Nov 20;95(10):1448-53. 
 
Study A25 
Porteous T, Ryan M, Bond CM, Hannaford P. Preferences for self-care or professional 
advice for minor illness: a discrete choice experiment. Br J Gen Pract. 2006 
Dec;56(533):911-7 
 
Study A26 
Seston EM, Elliott RA, Noyce PR, Payne K. Women's preferences for the provision of 
emergency hormonal contraception services. Pharm World Sci. 2007 Feb;29(3):183-9. 
 
Study A27 
Hjelmgren J, Anell A. Population preferences and choice of primary care models: a 
discrete choice experiment in Sweden. Health Policy. 2007 Oct;83(2-3):314-22. 
 
Study A28 
Schwappach DL, Strasmann TJ. Does location matter? A study of the public's preferences 
for surgical care provision. J Eval Clin Pract. 2007 Apr;13(2):259-64.  
 
Study A29 
Turner D, Tarrant C, Windridge K, Bryan S, Boulton M, Freeman G, Baker R. Do 
patients value continuity of care in general practice? An investigation using stated 
preference discrete choice experiments. J Health Serv Res Policy. 2007 Jul;12(3):132-7.  
 
Study A30 
Kjaer T, Gyrd-Hansen D. Preference heterogeneity and choice of cardiac rehabilitation 
program: results from a discrete choice experiment. Health Policy. 2008 Jan;85(1):124-32.  
 
Study A31* 
Gidman W, Elliott R, Payne K, Meakin GH, Moore J. A comparison of parents and 
pediatric anesthesiologists' preferences for attributes of child daycase surgery: a discrete 
choice experiment. Paediatr Anaesth. 2007 Nov;17(11):1043-52.  
 
Study A32 
Pitchforth E, Watson V, Tucker J, Ryan M, van Teijlingen E, Farmer J, Ireland J, 
Thomson E, Kiger A, Bryers H. Models of intrapartum care and women's trade-offs in 
remote and rural Scotland: a mixed-methods study. BJOG. 2008 Apr;115(5):560-9. 
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Study A33 
Fitzpatrick E, Coyle DE, Durieux-Smith A, Graham ID, Angus DE, Gaboury I. Parents' 
preferences for services for children with hearing loss: a conjoint analysis study. Ear Hear. 
2007 Dec;28(6):842-9. 
 
Study A34 
Hole AR. Modelling heterogeneity in patients' preferences for the attributes of a general 
practitioner appointment. J Health Econ. 2008 Jul;27(4):1078-94.  
 
Study A35 
Cheraghi-Sohi S, Hole AR, Mead N, McDonald R, Whalley D, Bower P, Roland M. What 
patients want from primary care consultations: a discrete choice experiment to identify 
patients' priorities. Ann Fam Med. 2008 Mar-Apr;6(2):107-15. 
 
Study A36 
Grutters JP, Joore MA, Kessels AG, Davis AC, Anteunis LJ. Patient preferences for 
direct hearing aid provision by a private dispenser. A discrete choice experiment. Ear 
Hear. 2008 Aug;29(4):557-64. 
 
Study A37 
Gerard K, Salisbury C, Street D, Pope C, Baxter H. Is fast access to general practice all 
that should matter? A discrete choice experiment of patients' preferences. J Health Serv 
Res Policy. 2008 Apr;13 Suppl 2:3-10. 
 
Study A38 
Negrín MA, Pinilla J, León CJ. Willingness to pay for alternative policies for patients with 
Alzheimer's Disease. Health Econ Policy Law. 2008 Jul;3(Pt 3):257-75. 
 
Study A39 
Wellman GS, Vidican C. Pilot study of a hierarchical Bayes method for utility estimation 
in a choice-based conjoint analysis of prescription benefit plans including medication 
therapy management services. Res Social Adm Pharm. 2008 Sep;4(3):218-30. 
 
Study A40 
Clark M, Moro D, Szczepura A. Balancing patient preferences and clinical needs: 
Community versus hospital based care for patients with suspected DVT. Health Policy. 
2009 May;90(2-3):313-9. [Epub 2008 Dec 6]. 
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B. Valuing health outcomes 
 
Study B1 
Osman LM, McKenzie L, Cairns J, Friend JA, Godden DJ, Legge JS, Douglas JG: Patient 
weighting of importance of asthma symptoms. Thorax 2001 Feb, 56(2):138-142. 
 
McKenzie L, Cairns J, Osman L: Symptom-based outcome measures for asthma: the use 
of discrete choice methods to assess patient preferences. Health Policy 2001 Sep, 
57(3):193-204. 
 
Study B2 
Ratcliffe J, Buxton M, McGarry T, Sheldon R, Chancellor J: Patients' preferences for 
characteristics associated with treatments for osteoarthritis. Rheumatology (Oxford) 2004 
Mar, 43(3):337-345. 
 
Study B3* 
Lee A, Gin T, Lau AS, Ng FF: A comparison of patients' and health care professionals' 
preferences for symptoms during immediate postoperative recovery and the management 
of postoperative nausea and vomiting. Anesth Analg 2005 Jan, 100(1):87-93. 
 
Study B4 
Haughney J, Partridge MR, Vogelmeier C, Larsson T, Kessler R, Stahl E, Brice R, Lofdahl 
CG: Exacerbations of COPD: quantifying the patient's perspective using discrete choice 
modelling. Eur Respir J 2005 Oct, 26(4):623-629. 
 
Study B5 
Osoba D, Hsu MA, Copley-Merriman C, Coombs J, Johnson FR, Hauber B, Manjunath 
R, Pyles A: Stated preferences of patients with cancer for health-related quality-of-life 
(HRQOL) domains during treatment. Qual Life Res 2006 Mar, 15(2):273-283. 
 
Study B6 
Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors 
that affect adherence to bipolar disorder treatments: a stated-preference approach. Med 
Care. 2007 Jun;45(6):545-52.  
 
Study B7 
Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug 
treatment: a stated-preference, discrete choice experiment with patients with psoriasis. 
Arch Dermatol. 2007 Sep;143(9):1175-9. 
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Study B8 
Aspinall PA, Johnson ZK, Azuara-Blanco A, Montarzino A, Brice R, Vickers A. 
Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol 
Vis Sci. 2008 May;49(5):1907-15. 
 
 
C. Investigating trade-offs between health outcomes and patient or consumer 
experience factors 
 
Study C1 
Shackley P, Slack R, Michaels J. Vascular patients' preferences for local treatment: an 
application of conjoint analysis. J Health Serv Res Policy. 2001 Jul;6(3):151-7. 
 
Study C2 
Telser H, Zweifel P: Measuring willingness-to-pay for risk reduction: an application of 
conjoint analysis. Health Econ 2002 Mar, 11(2):129-139. 
 
Study C3 
Ratcliffe J, Van Haselen R, Buxton M, Hardy K, Colehan J, Partridge M: Assessing 
patients' preferences for characteristics associated with homeopathic and conventional 
treatment of asthma: a conjoint analysis study. Thorax 2002 Jun, 57(6):503-508. 
 
Study C4 
Hall J, Kenny P, King M, Louviere J, Viney R, Yeoh A: Using stated preference discrete 
choice modelling to evaluate the introduction of varicella vaccination. Health Econ 2002 
Jul, 11(5):457-465. 
 
Study C5 
Aristides M, Chen J, Schulz M, Williamson E, Clarke S, Grant K: Conjoint analysis of a 
new Chemotherapy: willingness to pay and preference for the features of raltitrexed 
versus standard therapy in advanced Colorectal Cancer. Pharmacoeconomics 2002, 
20(11):775-784. 
 
Study C6 
Salkeld G, Solomon M, Short L, Ryan M, Ward JE: Evidence-based consumer choice: a 
case study in colorectal cancer screening. Aust N Z J Public Health 2003, 27(4):449-455. 
 
Study C7 
Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M: Patients' preferences for 
the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 2004 
Feb, 328(7436):382. 
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Study C8 
Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N: Patient preference and 
willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry 
application of a discrete choice experiment. Value Health 2004 Jul-Aug, 7(4):442-454. 
 
Study C9 
Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M: Eliciting preferences 
for drug treatment of lower urinary tract symptoms associated with benign prostatic 
hyperplasia. J Urol 2004 Dec, 172(6 Pt 1):2321-2325. 
 
Study C10 
Weston A, Fitzgerald P: Discrete choice experiment to derive willingness to pay for 
methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell 
carcinoma. Pharmacoeconomics 2004, 22(18):1195-1208. 
 
Study C11* 
Lee A, Gin T, Lau AS, Ng FF: A comparison of patients' and health care professionals' 
preferences for symptoms during immediate postoperative recovery and the management 
of postoperative nausea and vomiting. Anesth Analg 2005 Jan, 100(1):87-93. 
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Abstract 
Introduction  Active case finding for osteoporosis is used to identify patients who may 
benefit from preventive drugs. We aimed to elicit the relative weight that patients place on 
various aspects of preventive drug treatment for osteoporosis. 
Methods We designed a discrete choice experiment, in which women had to choose 
between drug profiles that differed in five treatment attributes: effectiveness, side effects 
(nausea), total treatment duration, route of drug administration, and out-of-pocket costs. 
We included 120 women aged 60 years and older, identified by osteoporosis case finding 
in 34 general practices in the Netherlands. A conditional logit regression model was used 
to analyse the relative importance of treatment attributes, the trade-offs that women were 
willing to make between attributes, and their willingness to pay. 
Results All treatment attributes proved to be important for women’s choices. A 
reduction of the relative 10-year risk of hip fracture by 40% or more by the drug was 
considered to compensate for nausea as a side effect. Women were prepared to pay an 
out-of-pocket contribution for the currently available drug treatment (bisphosphonate) if 
the fracture risk reduction was at least 12%. 
Conclusions Women identified by active osteoporosis case finding stated to be prepared 
to take preventive drugs, even if side effects were expected and some out-of-pocket 
contribution was required. 
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3.1 Introduction 
Osteoporosis constitutes a major public health problem. In the USA, approximately 1.5 
million fractures annually are attributable to osteoporosis, including 700,000 vertebral 
fractures, 250,000 distal forearm (Colles’) fractures, 250,000 hip fractures, and 300,000 
fractures of other limb sites [1]. Osteoporotic fractures have a major economic impact on 
society and on the quality of life of patients [2,3]. Preventive drug treatments, such as 
bisphosphonates (alendronate, etidronate, and risedronate) reduce the risk of osteoporotic 
fractures in women with postmenopausal osteoporosis by stabilising or increasing the 
bone density [4–8]. Various practice guidelines recommend a case-finding approach to 
identify persons with a high risk of osteoporotic fractures [9, 10]. Once identified, women 
are commonly prescribed preventive drug treatments. However, insight into the relative 
importance of attributes of preventive drug treatment (such as a bisphosphonate) is 
limited. Ideally, patients with high fracture risks make an informed decision on taking 
preventive medication, based on deliberative trade-offs between the burden of medication 
(e.g., duration, side effects), individual fracture risk, and treatment efficacy. 
This study investigated patients’ preferences for preventive drug treatment for 
osteoporosis by means of a discrete choice experiment (DCE), where attributes of 
hypothetical drug treatments were systematically varied. DCEs have increasingly been 
used in health care as an approach to elicit patient preferences [11–15]. The DCE was used 
to determine the trade-offs that community-dwelling elderly women make between the 
different treatment attributes, and their willingness to pay for each attribute. We also 
investigated whether high-risk patients (i.e., 10-year risk of a hip fracture greater than 6%) 
had different preferences than low-risk patients. 
 
 
 
3.2 Materials and methods 
 
3.2.1 Study sample and elicitation mode 
We recruited community-dwelling elderly women (aged over 60 years) from 34 general 
practices (in the area of Rotterdam, the Netherlands), who participated in a study on 
osteoporosis case finding. This latter study used a simple risk score to identify women at 
high risk of osteoporotic fractures, based on Dutch guidelines [9, 10]. After completion of 
the risk score, women were asked if they were willing to participate in the current study. 
Women were informed about their lifetime fracture risk (low or high). We aimed to 
administer the DCE questionnaire to 120 women with an overrepresentation of women 
with a high fracture risk (n=60). Earlier studies have shown that this number of 
respondents is sufficiently large for reliable statistical analyses [15–19]. The DCE 
questionnaire was sent by post and a trained medical student collected the answers from 
the respondent by telephone a week later. 
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3.2.2 DCE 
DCEs assume that a given healthcare intervention or treatment can be described by its 
characteristics (attributes) and that any woman’s preferences for an intervention or 
treatment are determined by the levels of the attributes [15]. Attributes should be identified 
beforehand as potentially important for the choice of an intervention or treatment [20]. 
The relative importance of attributes and the trade-offs that women make between them 
can be assessed when women are offered a series of choices between treatment 
alternatives that have different combinations of attribute levels [21].  
 
3.2.3 Attributes and attribute levels 
The choice of attributes and the attribute levels was based on a literature review focusing 
on bisphosphonates, expert interviews (n=5; three GPs, the director of the Dutch 
Osteoporosis Foundation, and a specialist in internal medicine), and personal interviews 
with 15 community-dwelling women aged over 60 years (i.e., the target group) with and 
without osteoporosis (n=10 and n=5, respectively).  
 
Table 3.1  Attributes and levels for osteoporosis drug treatment 
 
Beta coefficients in 
regression analysis 
Tablet once a month (TABLETmonthly)
Tablet once a week (TABLETweekly) β1
Injection by GP every four months (INJECTIONfourmonths) β2
Injection by GP every month (INJECTIONmonthly) β3
β4
5
10
25
50
β5
No (0)
Yes (1)
β6
1
2
5
10
β7 
0
120
240
720
Total treatment duration (years) (TIME)
Total cost to you (€) (COST)
Attributes and levels 
Route of drug administration:
10-year risk reduction of a hip fracture (%) (EFFECTIVENESS):
Nausea (during two hours after intake) (NAUSEA):
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We asked experts and women in the interviews to comment on and complete the list of 
treatment attributes that was created from literature review. We also asked women to rank 
the attributes from most important to less important with respect to their preferences for 
osteoporosis treatment. The number of attributes in a DCE is limited (due to impact on 
the random component variability) [22], and the ranking results allowed us to make an a 
priori selection of the most relevant attributes. These were: effectiveness of treatment, 
side effect of treatment (nausea), total treatment duration, route of drug administration, 
and costs (Table 3.1). Most of the attribute levels of preventive drug treatment for 
osteoporosis in our experiment were directly related to bisphosphonates. We also 
included some hypothetical levels. By including hypothetical levels we can extend the 
assessment of preferences beyond the currently available treatments for osteoporosis to 
treatments that are not yet traded in real markets, but may become available in the future. 
The results are potentially useful to guide the development of new drugs for osteoporosis, 
because we identified what is important for such a drug to be accepted by the target 
group. The interviews helped us to determine the hypothetical attribute levels. For 
example, we determined the levels for the cost-attribute by asking women directly their 
willingness to pay for preventive drug treatment for osteoporosis. 
 
3.2.4 Study design and questionnaire 
The combination of attributes and attribute levels (four attributes with four levels, and 
one attribute with two levels) resulted in 512 hypothetical drug treatment profiles (44 * 21). 
For obvious practical reasons, not all of these could be used in a questionnaire. Therefore, 
we generated a sample of hypothetical drug treatment profiles from all these 512 drug 
profiles for the questionnaire (i.e., we used a fractional factorial design) [23].  
 
 
 
Treatment A Treatment B No treatment 
Route of drug 
administration 
Tablet 
once a week 
Injection by GP 
every 4 months Not applicable 
10-year risk reduction of a 
hip fracture 10% 25% 0% 
Nausea (during 2 hours 
after use) Yes No No 
Total treatment duration 2 years 5 years 0 years 
Total cost to you 
(thus per month) 
€ 0 
(€ 0) 
€ 120 
(€ 2) 
€ 0 
(€ 0) 
Which treatment do you 
prefer?           
□ A             □ B □ None 
 
Figure 3.1  Example of a choice set as presented in the questionnaire 
 63 
Chapter 3 
This sample must be large enough to estimate at least all main effects in a regression 
analysis. In our case, a sample of 16 hypothetical drug treatment profiles was sufficient [22]. 
iles, choice sets were created. Each choice set 
te levels (i.e., 
reatment A and Treatment B always had different attribute levels in each choice set). 
oo much overlap would reduce the information obtained on trade-offs between 
na 6 ch App  
included a dominant choice set in the questionnaire to test for rationality (i.e., a choice set 
rug treatment profil terized era  
uestionnaire star ailed on o
uestionn s available from  request). The 
was pilot tested (n=10) to check for any pro in interpretatio  face 
nalysed by taking oice among hree options rug 
t o drug’ tion) a observation om 
den e dominant question were excluded from further analyses. The 
ression model. Assuming 
 
Based on these 16 drug treatment prof
consisted of two drug treatment profiles and a ‘no drug’ treatment option; see Figure 3.1 
for an example. 
The first drug treatment profile (i.e., Treatment A) of each choice set was always one of 
the 16 hypothetical drug treatment profiles selected for the fractional factorial design. We 
created the second drug treatment profile (i.e., Treatment B) of each choice set by means 
of a specific technique (‘fold-over’) to ensure minimal overlap of attribu
T
T
attribute levels. Our question ire contained 1 oice sets (see endix 3.A). We
including one d
attributes). The q
e charac  by logically pref ble levels on all
f each attribute ted with a det  written descripti
and its levels (the complete q
questionnaire 
aire i  the authors on
blems n and
validity. 
 
 
3.2.5 Analyses 
The DCE was a each ch  the t  (two d
reatment profiles, and a ‘n
ts who failed th
treatment op s an . Data fr
respon
remaining observations were analysed by a conditional logit reg
that all attributes have an independent influence on a woman’s preference, the following 
model was estimated [22]: 
 
V = β0 + β1TABLETweekly + β2INJECTIONfourmonths + β3INJECTIONmonthly +   
       β4EFFECTIVENESS + β5NAUSEA + β6TIME + β7COST  
 
where 
 
–  V represents the utility derived for preventive osteoporosis drug treatment. 
–  β0 is a constant reflecting the respondents’ preference for receiving osteoporosis 
drug treatment relative to no osteoporosis drug treatment. 
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–  β1 to β7 are coefficients that indicate the relative importance of each attribute (Table 
3.1). β1 to β3 are dummy variables of the attribute ‘route of drug administration’, 
with tablet once a month as the base level.  
he absolute value of V has no direct interpretation [22]. The sign of a coefficient reflects 
ibute has a positive or negative effect on utility. The value of a coefficient 
rtance of the corresponding attribute. A statistically significant 
mate of how much longer the respondent is willing to take 
teoporosis drug treatment (in years) to avoid nausea. The value of coefficient β7 is used 
 estimate the willingness to pay (WTP). For example, the WTP to avoid nausea was 
the conditional logit 
ression model to assess whether high-risk patients (i.e., 10-year risk of a hip fracture 
her than 6%) had different preferences than low-risk patients. 
.1
(ove
frac h fracture risk patients did not differ in 
T
whether the attr
indicates the relative impo
coefficient was interpreted as indicating that the respondent considered the attribute 
important. A priori we expected all attributes to be important, and that only the attribute 
‘effectiveness’ would have a positive effect. The utility from the ‘no drug’ treatment 
option was normalized to zero. The trade-offs that the respondents were willing to make 
between the attributes were estimated by the ratios of the coefficients. For example, 
β5/β6 represents an esti
os
to
estimated as β5/−β7, where β7 represents the importance of a 100 euro change in price.  
We conducted a subgroup analysis by using interaction terms in 
reg
hig
 
 
3.3 Results 
 
3.3  Respondents 
Of the 181 women (76 low and 105 high fracture risk patients) invited, 120 responded 
rall response rate 120/181=66%; 60/76 (79%) and 60/105 (57%) for low and high 
ture risk patients, respectively). Low and hig
educational level (χ2 test, p=0.22), but the high fracture risk patients were older, and 
more frequently lived without a partner (Table 3.2). 
 
3.3.2 DCE results 
Most women indicated that they found the DCE questions (very) clear and had no 
difficulty in completing the questionnaire. In total, 117 of 120 women (98%) passed the 
dominant question. All coefficients were significant (Table 3.3).  
All signs were consistent with a priori expectations. The positive constant term suggests 
that respondents preferred drug treatment over ‘no drug’ treatment if all other attributes 
were set to zero. The positive sign of the coefficient ‘effectiveness’ indicates that women 
preferred a drug treatment with a higher risk reduction of 10-year risk of a hip fracture 
over a drug treatment with a lower risk reduction. The negative signs for the other 
coefficients indicate that women preferred a cheaper and shorter drug treatment without 
nausea. A monthly tablet was preferred to other routes of drug administration (i.e., weekly 
tablet or injection).  
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Table 3.2  Respondent characteristics 
 
120 (100.0) 60 (50.0) 60 (50.0)
<0.001 *
60-64 28 (23.3) 21 (35.0) 7 (11.7)
<0.001 *
single 53 (44.2) 17 (28.3) 36 (60.0)
67 (55.8) 43 (71.7) 24 (40.0)
Eductional level 0.215
(13.3)
P-valuea
Group
All patients     
(%)
Low fracture risk 
patients (%)
High fracture risk 
patients (%)
Age (years)
64-69 18 (15.0) 11 (18.3) 7 (11.7)
70-74 20 (16.7) 17 (28.3) 3 (5.0)
75-79 28 (23.3) 10 (16.7) 28 (30.0)
80 and older 26 (21.1) 1 (1.7) 25 (41.7)
Household
with partner
Low 63 (52.5) 31 (51.7) 32 (53.3)
Intermediate 46 (38.3) 26 (43.3) 20 (33.3)
High 11 (9.2) 3 (5.0) 8
a significant difference between low and high fracture risk patient groups
* significant at the 5% level  
 
 
 
Table 3.3  Women’s preferences for preventive osteoporosis drug treatment 
\ 
Beta Attribute
coefficient p Value
Constant (drug treatment) 1.23 <0.001* 0.81 1.66
Drug administration (base level
tablet once a month):
tablet once a week -0,31 <0.001* -0.45 -0.17
injection every four months -0.21 0.027* -0.41 -0.02
injection once a month -0.44 <0.001* -0.64 -0.25
Effectiveness (10% risk reduction) 0.28 <0.001* 0.23 0.34
Side effect nausea -1.10 <0.001* -1.30 -0.89
Treatment duration (1 year) -0.04 <0.001* -0.06 -0.02
Cost (€100) -0.15 <0.001* -0.18 -0.11
* significant at the 5% level
95% CI
Number of observations 5,589 (117 respondents x 16 choices x 3 options per choice, minus 27 missing 
values), Pseudo R2 = 0.1847, log pseudolikelihood = -1668.7
 
 
 
The magnitude of the attribute coefficients corresponds with the relative importance of 
the attributes. For a correct interpretation of the comparison of the coefficients of the 
attributes, we need to pay attention to the different units of measurement. For example, 
the coefficient of 0.28 of ‘effectiveness’ implies the increase in utility per 10% of risk 
 66 
Patients’ preferences for osteoporosis drug treatment 
 
reduction. A risk reduction of 40% is four times larger than 10% risk reduction. Thus, a 
of 40% implies a utility of 1.10 for the attribute ‘effectiveness’ (i.e., four 
multiplied with the coefficient of 0.28 of ‘effectiveness’). A superficial comparison of the 
coefficients in Table 3.3 may easily lead us to the wrong conclusion that nausea as a side 
effect had a larger influence on women’s choices for preventive drug treatment than the 
attribute ‘effectiveness’. As shown in the computation above, a risk reduction of more 
than 40% contributes more to the utility of a preventive drug treatment for osteoporosis 
than absence of nausea. A 40% risk reduction (i.e., utility 1.10) compensates for the 
disutility of minus 1.10 of the attribute ‘nausea’.  
A positive utility value of a specific drug profile indicates a preference for that treatment 
to no treatment. The utility of a currently most frequently used preventive osteoporosis 
drug treatment (bisphosphonate taken as a weekly tablet, approximately 30% fracture risk 
reduction, nausea as a possible side effect, total treatment duration of five years, and no 
out-of-pocket payment) equals 
 
V = 1.23 – 0.31(TABLETweekly) + 3.0 * 0.28(EFFECTIVENESS) – 1.10(NAUSEA) –  
       5 * 0.04(TIME) - 0 * 0.15(COST) = 0.46. 
 
This outcome has a positive sign. Thus, the women in our sample preferred this drug 
eatment over no treatment. 
Based on the expressed preferences, women were prepared to adhere to drug treatment 
an estimated 5.7 years longer to change from an injection every 4 months to a tablet once 
a month, if all other attributes remained constant (Table 3.4). For every 10% additional 
fracture risk reduction, they were prepared to adhere to drug treatment 7.5 years longer. 
Respondents were willing to pay an extra total amount of €752 to avoid nausea as a side 
effect, or €26 for every 1-year decrease in total drug treatment duration.  
For bisphosphonates, we estimated that respondents were willing to pay up to an 
estimated 338 euro out-of-pocket payment to receive treatment compared with no 
treatment (WTP = 847(constant) − 212(weekly tablet) + 3.0*195(risk reduction) – 
752(side effect nausea) – 5*26(treatment duration)). They would thus be willing to pay for 
this treatment if the fracture risk reduction was at least 12 % (see Appendix 3.B). 
 
3.3.4 High versus low fracture risk patients 
The results of conditional logit regression modelling of data from both risk groups ar
presented in Table 3.5. Only the interaction between the effectiveness of treatment and
risk reduction 
tr
 
3.3.3 Trade-offs 
e 
 
risk group was significant (p=0.05). Lower levels of effectiveness of the preventive drug 
treatment for osteoporosis were more acceptable to high-risk patients than to low-risk 
patients. High-risk patients therefore accepted a less effective drug to reduce their fracture 
risk.      
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Table 3.5  Differences between low and high-risk patients’ preferences for preventive osteoporosis 
drug treatment 
 
Attribute Beta coefficient of low risk patients
Beta coefficient of 
high risk patients p-Value
Constant (drug treatment) 1.178 1.316 0.748
Drug administration (base level
tablet once a month):
tablet once a week -0.360 -0.255 0.464
injection every 4 months -0.125 -0.317 0.323
injection once a month -0.445 -0.454 0.966
Effectiveness (1% risk reduction) 0.023 0.034 0.050 *
Side effect nausea -1.046 -1.161 0.582
Treatment duration (1 year) -0.033 -0.045 0.583
Cost (€1) -0.002 -0.001 0.435
*significant at the 5% level
Number of observations 5,589 (117 patients (i.e. 58 low-risk + 59 high-risk patients) x 16 choices x 3 options 
per choice, minus 27 missing values), Pseudo R2 = 0.1895, log pseudolikelihood = -1658.8  
 
 
3.4 Discussion 
Women identified by active case finding for osteoporosis said in this DCE that they were 
prepared to adhere to preventive drug treatment. Treatment effectiveness (hip fracture 
risk reduction), side effects (nausea), total treatment duration, route of drug 
administration, and out-of-pocket costs were all relevant to women’s preferences for drug 
treatment. Nausea as a side effect had a large influence on women’s choices, though a risk 
reduction of 40% or more was sufficient to make nausea as a side effect acceptable. 
Patients with high fracture risk were more prepared to take a less effective drug treatment 
than low fracture risk patients.  
This study illustrated the feasibility of DCE to elicit elderly women’s preferences for 
osteoporosis drug treatment. An acceptable fraction of potential respondents agreed to 
participate in the experiment, and only 3 of 120 failed the dominant question. This study 
therefore adds to the available literature on the usefulness of DCE to investigate 
preferences for drug treatment [15, 24–26].  
In a previous DCE investigating women’s preferences for osteoporosis treatment, early 
postmenopausal women were willing to use a tablet once a week if the drug reduced the 
absolute lifetime risk of fracture by at least 10% [27]. In our study, we considered relative 
reductions in 10-year risk of a hip fracture, which limits the comparability between these 
two DCEs. According to Fraenkel et al., women willing to consider a drug treatment 
strongly preferred taking a tablet once a week rather than having an injection in a doctor’s 
office. We also found that women preferred a tablet once a week to injection once a 
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month, but that an injection in a doctor’s office every 4 months was preferred to having 
to take a tablet once a week. This was in line with findings of another study which showed 
many women preferred annual injections to weekly oral medication [28].  
The women in our study showed a very positive attitude towards preventive drug 
treatment for osteoporosis, and said they were prepared to take preventive drug treatment 
even when the effectiveness of the treatment was zero. This may reflect a kind of placebo 
effect for drug treatment. In practice, a substantial proportion of women discontinue 
treatment with bisphosphonates [29, 30]. Various patient characteristics (e.g., being retired) 
were associated with a high compliance with treatment for osteoporosis [31]. Further 
research is needed to investigate why patients, who are prepared to start with 
bisphosphonates, discontinue treatment.  
The effectiveness of the preventive osteoporosis drug treatment was less important for 
high-risk patients than for low-risk patients. All patients had knowledge of lifetime 
fracture risk (low or high). Patients at high risk were probably more aware of the 
consequences of their fracture risk than low-risk patients, and were therefore more 
prepared to take a less effective drug treatment.  
In our study we used a postal questionnaire and the answers of the respondent wer
llected later by telephone. The use of an interviewer can be regarded as a strength in the 
sign, because this procedure led to data completeness as well as a check of a 
spondent’s understanding. However, this design also had some limitations. First, 
ed nausea as the most relevant gastrointestinal side effect, other 
ects that are also common (e.g., stomach pain, heartburn) were not 
 selected by active case finding, which precludes 
 and how drug treatment attributes influence 
that 
e 
co
de
re
although we includ
gastrointestinal side eff
included in the DCE. More in general, we selected the most relevant attributes in our 
DCE using interviews, but this careful procedure does not guarantee that attributes that 
we did not include are irrelevant to women’s preferences for osteoporosis treatment. 
Second, we studied main effects only, since these generally account for 70% to 90% of 
explained variance in a DCE [22]; specific combinations of attribute levels may have 
specific effects that remained unidentified. Third, the current results could be validated by 
comparison with actual behaviour of women in drug treatment for osteoporosis. Fourth, 
the respondents were women
generalization of the findings to all women. On the other hand, women identified by 
active osteoporosis case finding are those who will have to decide about treatment and 
therefore constitute the most relevant study group.  
Patient-centred and demand-led care is becomingly increasingly important in current 
medical practice. Understanding which
women’s preferences for osteoporosis drug treatment is important to optimize the 
treatment design that patients will follow. The present study showed that the target group 
may well accept the currently available bisphosphonates with sufficient margin 
(satisfactory effectiveness, side effects, and so on); this is an important result for policy 
decision-making on the introduction of active case finding on a large scale, in addition to 
considerations related to cost-effectiveness.  
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In conclusion, this DCE showed that women identified by active osteoporosis case 
finding  showed a positive attitude to preventive drug treatment, even if side effects (such 
as nausea) were expected and some out-of-pocket contribution was required. 
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Appendix 3.A   
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treatmen ablet once a week as a route 
side effe  120 euro out-of-pocket 
ts for
Treatmen
by GP every 4 months as a route of drug administration, 10% risk reduction of a hip 
acture as treatment effectiveness, nausea for up to two hours after intake as a side effect, 
tal treatment duration of 1 year, and 240 euro out-of-pocket costs for the entire 
eatment. Respondents had to choose between this Treatment A, Treatment B, or no 
treatment. 
c
c
b
Overview of the 16 choice sets used in our questionnaire. 
t A of choice set 1 (i.e., code ‘baadb’) represents a hypothetical preventive drug 
t for osteoporosis with the following characteristics: t
of drug administration, 5% risk reduction of a hip fracture as treatment effectiveness, no 
cts (nausea), total treatment duration of 10 years, and
cos  the entire treatment. In the questionnaire this treatment was presented with 
t B of choice set 1 (i.e., code ‘cbbac’) with the following characteristics: injection 
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Treatment A Treatment B Code book:
I
a
Route of drug administration
tablet once a month
b
b
a
d
c
10 years
no nausea
10% risk reduction of a hip fracture
€ 240
tablet once a week 
c
d
injection by GP every 4 months
injection by GP every month
II
a
Effectiveness
5% risk reduction of a hip fracture
c
d
III Side effects (nausea)
25% risk reduction of a hip fracture
50% risk reduction of a hip fracture
b
IV Total treatment duration
nausea for up to two hours after intake
a
b
c
1 year
2 years
5 years
V
a
b
Out-of-pocket costs
€ 0
€ 120
d € 720
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 reduction (%) by means of 
d treatment duration five years) 
d WTP (€). 
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Abstract 
Background  Osteoporotic fractures have a serious economic impact on society and on 
the quality of life of patients. Differences in opinions on the desirability of preventive 
treatment initiation may hamper the process and outcome of shared decision making 
between physician and patient. 
Objective To evaluate and compare preferences of GPs and patients for preventive 
osteoporosis drug treatment. 
Methods  Discrete-choice experiment (DCE) involving 34 general practices in the area of 
Rotterdam, the Netherlands. Participants included 40 GPs and 120 women aged >60 
years who participated in a study on osteoporosis case finding. We included any woman 
aged >60 years, with an over-representation of women with a high fracture risk (n=60). 
Outcomes (i) The relative weights that GPs and patients place on five treatment 
attributes of preventive osteoporosis drug treatment: effectiveness, nausea as an adverse 
effect, total treatment duration, route of drug administration and out-of-pocket costs; and 
(ii) the determinants of any differences in preferences between GPs and patients. 
Results The response rate was 40/59 (68%) for GPs and 120/181 (66%) for patients. All 
treatment attributes proved to be important for preferences of GPs and patients. GPs had 
a significantly less favourable attitude towards preventive osteoporosis drug treatment 
than patients; they placed significantly higher values on effectiveness of preventive drug 
treatment and short total preventive treatment duration than patients. 
Conclusions GPs and patients showed different preferences towards preventive 
osteoporosis drug treatment. Addressing each of these differences may have a positive 
effect on the process and outcomes of shared decision making regarding treatment 
initiation. 
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4.1 Background 
 
Health professionals and patients may or may not share the same preferences related to 
the patient’s treatment. If preferences of health professionals and patients are polarized, 
decision making on patients’ treatment may be more difficult to achieve in a model of 
shared medical decision making [1]. Differences in opinions on the desirability of 
treatment may hamper the process and outcome of shared decision making between 
physician and patient.  
Osteoporosis is a disease characterized by low bone mass, microarchitectural 
deterioration of bone tissue leading to enhanced bone fragility and a consequent increase 
in fracture risk [2]. Osteoporosis is a major public health problem. In the USA, 
approximately 1.5 million fractures annually (including vertebral, distal forearm, hip and 
other limb sites) are attributable to osteoporosis [3]. In the Netherlands, the situation is 
similar, with about 75 000 fractures attributable to osteoporosis annually [4]. Osteoporotic 
fractures have a serious economic impact on society and on the quality of life of patients 
[5, 6]. Preventive osteoporosis drug treatment, such as bisphosphonates, may reduce the 
risk of osteoporotic fractures [7-10]. 
The aim of this study was to evaluate and compare preferences of GPs and patients for 
preventive osteoporosis drug treatment by means of discrete-choice experiments (DCEs), 
and to investigate determinants of the differences found. DCEs are increasingly used in 
healthcare to elicit preferences [11-14]; however, only a few DCEs have directly compared 
preferences of health professionals and patients [15-18]. DCEs assume that a given 
healthcare intervention or treatment can be described by its characteristics (attributes) and 
that any respondent’s preferences for an intervention or treatment are determined by the 
levels of the attributes [14]. Attributes are identified beforehand as potentially important 
for the choice of an intervention or treatment [21]. The relative importance of attributes 
and the trade-offs that respondents make between them can be assessed when 
respondents are offered a series of choices between treatment alternatives that have 
different combinations of attribute levels [22].  
 
 
 
 
4.2 Methods 
 
4.2.1 Study population 
We included GPs and women aged >60 years from 34 general practices (in the area of 
Rotterdam) who participated in a study on osteoporosis case finding. An over-
representation of women with a high fracture risk (n=60), identified using a simple risk 
score, based on (inter)national guidelines [4, 19], was included in the study sample. More 
details of the recruitment of women for the original study were described previously [20]. 
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4.2.2 Study format 
We followed the recommended five stages of undertaking a DCE [12]. First, we identified 
the attributes (characteristics) of osteoporosis drug treatment by means of a literature 
review, expert interviews (Dutch Osteoporosis Foundation, a specialist in internal 
medicine, and three GPs), patient interviews (n=15) and a study in community-dwelling 
women aged ≥60 years (i.e. target group) with and without osteoporosis (n=10 and n=5, 
respectively). Five treatment attributes were selected: effectiveness of treatment 
(reduction of risk of hip fracture), nausea as an adverse effect of treatment, total 
treatment duration, route of drug administration and costs.  
Second, we assigned levels to these attributes, using the same sources of information 
(Table 4.1). In our experiment, most of the attribute levels of preventive drug-treatment 
for osteoporosis were directly related to bisphosphonates. Additional inclusion of 
hypothetical attribute levels enables extension to the assessment of preferences beyond 
the currently available treatments for osteoporosis to treatments that are not yet traded in 
real markets, although may become available in the future. 
 
Table 4.1  Attributes and levels for preventive osteoporosis drug treatment 
 
Beta coefficients in 
regression analysis 
Tablet once a month (TABLETmonthly)
Tablet once a week (TABLETweekly) β1
Injection by GP every four months (INJECTIONfourmonths) β2
Injection by GP every month (INJECTIONmonthly) β3
β4
5
10
25
50
β5
No (0)
Yes (1)
β6
1
2
5
10
β7 
0
120
240
720
Total treatment duration (years) (TIME)
Total cost to you (€) (COST)
Attributes and levels 
Route of drug administration:
10-year risk reduction of a hip fracture (%) (EFFECTIVENESS):
Nausea (during two hours after intake) (NAUSEA):
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Third, hypothetical drug-treatment profiles were selected for the questionnaire. The 
combination of attributes and attribute levels (four attributes with four levels, and one 
attribute with two levels) resulted in 512 hypothetical drug-treatment profiles (44 * 21). 
For obvious practical reasons, not all of these could be used in a questionnaire. Therefore, 
we used a fractional factorial design (i.e. we generated a sample of hypothetical drug 
treatment profiles from all these 512 drug profiles for the questionnaire) [23]. This sample 
must be large enough to estimate at least all main effects in a regression analysis. Our 
fractional factorial design included a sample of 16 hypothetical drug treatment profiles, to 
allow for estimation of all main effects [24, 25]. These drug-treatment profiles fulfilled the 
demands of level balance (i.e. all attribute levels occurred with equal frequency) and 
orthogonality (i.e. levels were independent of each other). 
Fourth, choice sets were created. Each choice set consisted of two drug-treatment 
profiles and a ‘no drug’ treatment option (see Figure 4.1). The first drug-treatment profile 
(i.e. treatment A) of each choice set was always one of the 16 hypothetical drug-treatment 
profiles of the fractional factorial design. We created the second drug-treatment profile 
(i.e. treatment B) of each choice set by means of cycle ‘fold-over’ technique to ensure 
minimal overlap of attribute levels (i.e. treatment A and treatment B always had different 
attribute levels in each choice set). Too much overlap would reduce the information 
obtained on trade-offs between attribute levels. According to the results of an analysis 
using the software of Street and Burgess (Department of Mathematical Sciences, 
University of Technology, Sydney, NSW, Australia)[30] our choice set design had an 
efficiency of 95% compared with an optimal choice set design. All main effects were 
uncorrelated. 
      .                                                        
 
 
Treatment A Treatment B No treatment 
Route of drug 
administration 
Tablet 
once a week 
Injection by GP 
every 4 months Not applicable 
10-year risk reduction of 
a hip fracture 10% 25% 0% 
Nausea (during 2 hours 
after use) Yes No No 
Total treatment duration 2 years 5 years 0 years 
Total cost to you 
(thus per month) 
€ 0 
(€ 0) 
€ 120 
(€ 2) 
€ 0 
(€ 0) 
Which treatment do you 
prefer?           
□ A             □ B □ None 
 
Figure 4.1  Example of a choice set as presented in the questionnaire 
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Our design used a series of choice sets fulfilling the demands of level balance, 
orthogonality and minimal overlap (i.e. repeated occurrence of an attribute level in a 
choice set was kept at minimum). We included a dominant choice set in the questionnaire 
to test for rationality (i.e. a choice set including one drug-treatment profile characterized 
by logically preferable levels on all attributes). The dominant choice set was an extra 
choice set (i.e. 17 choice sets were created).  
The questionnaire started with a detailed written description of each attribute and its 
levels. In particular, the attribute ‘effectiveness’ was explained with examples, because it is 
known from the literature that respondents may have difficulties understanding numerical 
risks. The questionnaire was pilot tested on GPs and patients (n=2 and n=8, respectively) 
to check for any problems in interpretation and face validity. None of the respondents 
raised any problems with understanding the questionnaire, so the pilot test did not result 
in any changes to the questionnaire. The questionnaire was sent to all respondents by 
post. GPs and patients received the same choice sets. Patients were asked to express their 
preferences as if it was their own treatment; GPs expressed in each choice set which 
treatment option they preferred for a female patient aged >60 years with a high fracture 
risk (10-year risk of a hip fracture higher than 6%) from their viewpoint as a physician.  
A trained medical student collected the answers from the patient by telephone 1 week 
later. The GPs returned the self-completed questionnaire by post. 
 
 
4.2.3 Analyses 
We analysed the DCE by taking each choice (excluding the dominant choice set) among 
the three possibilities (two drug-treatment profiles and a ‘no drug’ treatment option) as an 
observation. Data from respondents who failed the dominant question were excluded 
from further analyses. Conditional logit regression models (i.e. multinomial models) were 
used to investigate the effects of the treatment attributes on GPs’ and patients’ 
acceptance of preventive osteoporosis drug treatment. These models were implemented 
in STATA software (Version 8.0, College Station, TX, USA). Assuming that all attributes 
have an independent influence on a GP’s or woman’s preference, the following model 
was estimated (equation 1): 
 
V =   β0 + β1TABLETweekly + β2INJECTIONfour months + β3INJECTIONmonthly 
+ β4EFFECTIVENESS + β5NAUSEA + β6TIME + β7COST 
(Eq. 1) 
 
where V represents the utility derived for preventive osteoporosis drug treatment, as 
derived from the observed choice behaviour; β0 is a constant reflecting the respondents’ 
preference for receiving osteoporosis drug treatment relative to no osteoporosis drug 
treatment; β1 to β7 are coefficients that indicate the relative importance of each attribute 
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(Table 4.1). β1 to β3 are variables of the attribute ‘route of drug administration’, with 
‘Tablet once a month’ as the base level (Table 4.1).  
The sign of a coefficient reflects whether the attribute has a positive or negative effect on 
utility. The absolute value of these utility scores has a relative interpretation: the higher 
the utility score, the stronger the respondent’s preference for a particular preventive 
osteoporosis drug-treatment profile. The value of a coefficient indicates the relative 
importance of the corresponding attribute. Preferences (sign, significance of coefficient) 
towards a single attribute need to be interpreted under the condition of ‘ceteris paribus’, 
i.e. by keeping everything else equal. The results of the patients’ preferences were 
described previously [20]. 
The differences between GPs’ and patients’ preferences were estimated by including 
statistical interaction terms in the model.  
Using the coefficients, we generated the ranks and total utility scores assigned by GPs and 
patients to the 16 hypothetical drug-treatment profiles for preventive osteoporosis 
treatment. 
 
 
 
4.3 Results 
Between October 2006 and June 2007, we invited 59 GPs and 181 patients to take part in 
the study. The response rate was 40/59 (68%) for GPs and 120/181 (66%) for patients. 
GPs and patients differed in age, sex and educational level (p≤0.001; Table 4.2). 
 
 
Table 4.2  Respondents characteristics 
 
GPs               
(n = 40)
Patients       
(n = 120) p-value
a
Age, yr (mean ± sd) 49.3 ± 7.9 71.8 ± 7.9 <0.001
Sex (%) <0.001
male 80 0
female 20 100
Household
single NA 53
with partner NA 67
Eductional level (%) <0.001
low 0 53
intermediate 0 38
high 100 9
a difference between general practitioners and patients 
NA = not available
Characteristics
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4.3.1 Discrete choice experiment results 
 
Of 40 GPs, 39 (98%) passed the dominant question. All treatment attribute coefficients 
had p-values <0.05 (Table 4.3), i.e. all attributes were significant determinants of GPs’ 
choices. However, with respect to the route of drug administration, the attribute levels 
‘tablet once a week’ and ‘injection once every 4 months’ did not differ from the attribute 
level ‘tablet once a month’. Thus, GPs valued the routes of drug administration equally, 
with the exception of ‘an injection once a month’, which was less preferred than a ‘tablet 
once a month’. The negative constant term suggests that GPs preferred ‘no drug’ 
treatment for the patient over drug treatment if all other attributes were set to zero (i.e. 
10-year risk reduction of a hip fracture of 0%, tablet once a month, no nausea as an 
adverse effect, very short treatment duration and no out-of-pocket payment). According 
to the positive sign of the coefficient for the attribute ‘effectiveness’, GPs preferred a 
more effective treatment than a less effective treatment as would be expected. According 
to the negative signs of the coefficients, GPs preferred a cheaper and shorter drug 
treatment without nausea as an adverse effect over a more expensive and longer drug 
treatment with nausea as an adverse effect. 
Of 120 patients, 117 (98%) passed the dominant question. All coefficients were 
significant at the 5% level (Table 4.3). Patients preferred drug treatment over ‘no drug’ 
treatment if all other attributes were set to zero (positive sign of the constant term). The 
positive sign of the coefficient ‘effectiveness’ indicates that, as expected, patients 
preferred a drug treatment with a higher risk reduction of 10-year risk of a hip fracture 
over a drug treatment with a lower risk reduction. The negative signs for the other 
coefficients indicate that patients preferred a cheaper and shorter drug treatment without 
nausea over a more expensive and longer drug treatment with nausea as an adverse effect. 
A monthly tablet was preferred to other routes of drug administration (i.e. weekly tablet 
or injection).  
The opposite signs of the constant terms indicate that GPs and patients had opposite 
preferences for preventive osteoporosis drug treatment. The distinction between the 
more reserved (rather negative) attitude towards preventive osteoporosis drug treatment 
of GPs and the more positive attitude of patients is further corroborated by the results 
shown in Table 4.3. GPs had a higher coefficient value for ‘effectiveness’ of drug 
treatment and a more negative value for ‘treatment duration’, suggesting that GPs 
demand a higher effectiveness and a shorter treatment duration than patients for a 
treatment to become acceptable. GPs did not prefer a monthly tablet to a weekly tablet as 
a route of drug administration, but patients did. 
Ranking of the 16 hypothetical preventive treatment scenarios by their relative utilities as 
derived from the choice experiment showed that GPs preferred only five of them to ‘no 
drug’ treatment (i.e. positive utility score; Table 4.4), whereas patients preferred 12 of 16 
hypothetical treatments over ‘no drug’ treatment.  
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Preferences of GPs and patients for preventive osteoporosis drug treatment 
The rank orders of the groups were significantly correlated (Spearman’s rank correlation 
coefficient, r=0.78). For both groups, the optimum hypothetical treatment was a weekly 
tablet with a 50% relative risk reduction of hip fracture, a total treatment duration of 5 
years, that was not associated with the adverse effect of nausea, and relative low out-of-
pocket costs (€240 for the total treatment of 5 years; thus, €4 per month). The four 
hypothetical preventive osteoporosis drug treatment scenarios that were most preferred 
by the GPs for osteoporosis patients had optimal levels of effectiveness, but some of 
them were associated with nausea as an adverse effect. The four hypothetical preventive 
osteoporosis drug treatment scenarios that were most preferred by the patients were not 
associated with nausea as an adverse effect, but the effectiveness of the treatment was not 
always optimal. Holding the route of drug administration constant, GPs preferred a more 
effective and shorter duration of the drug treatment for a patient, and accepted that it 
could cause nausea and required some out-of-pocket costs (drug profile 15) over one that 
was less effective and had a longer treatment duration (drug profile 4), whereas patients 
showed the reverse pattern (similarly, drug profile 12 compared with drug profile 1). This 
means that patients accepted a less effective and longer duration of the drug treatment if 
the drug treatment did not cause nausea (for up to 2 hours after intake) and did not 
require out-of-pocket costs. 
 
 
 
4.4 Discussion 
This study shows that the participating GPs had a much less favourable attitude towards 
preventive osteoporosis drug treatment than the patients. Treatment effectiveness (hip 
fracture risk reduction), adverse effects (nausea), total treatment duration, route of drug 
administration and out-of-pocket costs were all relevant to GPs’ and patients’ preferences 
for drug treatment; however, GPs placed higher relative values on effectiveness of drug 
treatment and shorter total treatment duration than patients.  
There are no previous DCEs directly comparing preferences of health professionals and 
patients for preventive osteoporosis drug treatment. A DCE showed that health 
professionals were less focused on the process attributes of haemophilia care (e.g. 
infusion frequency) than patients [16]; this suggested that aspects of the treatment process 
was more relevant for patients than for health professionals. This is in line with our study, 
which showed that GPs did not prefer ‘a monthly tablet’ over ‘a weekly tablet’ or over ‘an 
injection every 4 months’ as a route of drug administration, whereas patients did. Two 
other preference studies, using other methods than formal DCE, also showed that health 
professionals had a less positive attitude towards treatment than patients (chemotherapy 
for solid tumours [26], and antibacterial treatment for acute respiratory illness [27]).  
Our study illustrated the willingness of GPs and patients to participate in the relatively 
complex exercise of a DCE to weigh up the advantages and disadvantages of various 
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hypothetical preventive osteoporosis drug treatments. It provides further evidence that 
the DCE approach can be applied successfully in healthcare to directly compare (the 
determinants of the) preferences from health professionals and patients [15-18].  
The inclusion of a ‘no drug’ treatment option in each choice set was warranted in the 
context of this study. GPs may prefer not to prescribe preventive osteoporosis drug 
treatment because Dutch treatment guidelines do not currently recommend preventive 
osteoporosis drug treatment for women who did not yet have an osteoporotic fracture or 
an abnormal low bone mass. For patients, the decision to start such treatment should be 
based on autonomous choice. Forcing GPs and patients to choose only between active 
treatments was likely to inflate any estimates obtained. However, including a ‘no drug’ 
treatment option raises issues about how non-participation is accounted for when 
analysing the data [28]. The conditional logit regression model (i.e. a multinomial model, 
MNL) is a relatively simple model. It assumes that errors are independent and identically 
distributed, that observed choices are independent, and that preferences are homogenous. 
A mixed logit model represents the most advanced and flexible discrete model to date, 
because it relaxes the assumptions embodied in MNL models. However, the MNL model 
was the best option for analysis of our dataset because of the relatively small number of 
GPs.  
This study had some limitations. First, we used a main-effects only design, assuming that 
all attributes were valued independently of each other (i.e. all interactions between 
attributes were zero); this may be reasonable since main effects typically account for 70–
90% of explained variance in DCE [24]. Second, this study used a postal questionnaire 
whereby the answers of the GPs and patients were collected by post and by telephone, 
respectively; this could result in bias in data collection. Third, the sample of GPs was 
selective, because they had already participated in a study on osteoporosis case finding; 
however, it is not known whether this has (largely) influenced the results. Fourth, the 
results of this study may not be applicable in healthcare systems in which patients never 
pay any out-of-pocket costs for drug treatment. Finally, the current results could gain 
importance if it were possible to validate the stated preferences by revealed preferences 
from actual behaviour, i.e. testing for external validity [29]. 
 
 
 
4.5 Conclusions 
Our study found that GPs placed more importance on greater effectiveness and shorter 
treatment duration of preventive osteoporosis treatment than patients did.  
The GPs had a much less favourable attitude towards preventive osteoporosis drug 
treatment than patients. This finding is consistent with other studies that show that health 
professionals generally have a less positive attitude towards curative treatment than 
patients, although our study is the first one to show this for preventive treatment. 
Essentially, the benefits of preventive treatment are uncertain in the individual patient 
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case. The decision to initiate preventive treatment should ideally be taken in a process of 
shared decision making in which both the patient and health professional are actively 
involved. Awareness and explicit address of differences in personal values regarding 
preventive treatment in general may have a positive effect on the process and outcomes 
of shared decision making on treatment initiation in individual patients. 
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Abstract 
Study Design  Discrete choice experiment 
Objective  To investigate the reduction in the risk of surgery that scoliosis patients would 
require in order to consider brace treatment as acceptable, and to elicit the trade-offs 
individuals make between characteristics of brace treatment.  
Summary of Background Data  The effectiveness of brace treatment in idiopathic 
scoliosis patients has not been established in randomized controlled trials (RCTs). 
Treatment with a brace can be quite bothersome. Patients’ preferences for brace 
treatment are unknown. Insight into patients’ preferences for (characteristics of) brace 
treatment will be useful for future trials and for the development of braces that may 
optimize compliance with brace treatment. 
Methods  A total of 197 patients who had completed treatment (brace and/or surgery) 
for scoliosis were approached for the study, of which 135 gave informed consent. A 
discrete choice experiment was designed in which patients had to choose between 
hypothetical brace treatment profiles that differed in four treatment attributes: 
effectiveness, visibility, discomfort, and treatment duration. A multinomial logit model 
was used to analyze the relative importance of these attributes. Subgroup analyses were 
conducted for brace-only, brace-surgery, and surgery-only patients.  
Results  The response rate was 86% (116/135). All treatment attributes proved to be 
important for patients’ choices. All subgroups were prepared to initiate treatment with a 
Boston brace if the brace would reduce the need for surgery by 53%. Risk reductions 
from 32-74% were required for acceptance of a treatment duration of 3 years.  
Conclusions  Scoliosis patients stated to be prepared to undergo brace treatment only if 
it provides sizeable reduction of the risk of surgery. Effectiveness and discomfort in 
wearing a brace were the most important determinants of the choices. These results are 
important if RCTs would conclusively establish that bracing is effective, and show 
directions for the further technical development of braces to increase the compliance with 
brace treatment. 
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5.1 Introduction 
 
Idiopathic scoliosis (IS) is defined as a lateral curvature of the spine with a minimal Cobb 
angle of 10º of unknown origin. The Cobb angle is the angle between the upper most 
inclined vertebra and the lower most inclined vertebra. Besides a lateral curvature of the 
spine, there is a fixed rotation of one or more vertebrae, and a rotational deformation of 
that vertebra [1]. About 0.3% of all children aged between 10 and 16 years have IS that 
progresses to curvatures with Cobb angles over 20-25 degrees [2]. In this situation, the 
chance is small that the curvature will disappear spontaneously, and brace treatment is 
usually applied. Brace treatment is supposed to prevent further progression of the 
curvature and thereby the need for surgery, which is indicated when a patient has a Cobb 
angle of more than about 45-50 degrees [1]. Therefore, the ’effectiveness of brace 
treatment’ is commonly defined as the reduction of the risk of surgical intervention [3-5]. 
The effectiveness of brace treatment has not yet been convincingly established in RCTs.  
In both the US and the Netherlands, an RCT on (Boston) bracing IS patients was 
designed; in the US the trial is currently running (BrAIST) [6]. The Dutch trial was halted 
recently because of insurmountable problems with patient inclusion. 
Treatment with a brace can be rather bothersome [7, 8]. Patients (usually aged 10-16 years) 
have to wear the brace for 18-23 hours a day, during several years of puberty [1] , the brace 
is often visible, and can be uncomfortable to wear. In conclusion, brace treatment has 
serious disadvantages and uncertain benefit.  
The present study had two aims. First, we investigated the size of the reduction of the risk 
of surgery required by scoliosis patients to consider brace treatment, with its drawbacks, 
as acceptable. Second, we elicited the trade-offs individuals make between characteristics 
of brace treatment. The results of the study are potentially important for trials that will 
investigate the effectiveness of brace treatment. A trial may show that the effectiveness of 
a brace treatment is in fact  below the threshold for acceptance required by scoliosis 
patients. Furthermore, the results may provide directions for the further technical 
development of braces, and thereby for optimising compliance with brace treatment. If 
brace treatment appears to be effective, but not sufficiently effective for scoliosis patients 
to be preferred over observation, improving brace characteristics (e.g. comfort or 
visibility of the brace) may decrease the required risk reduction of surgery so that brace 
treatment will be preferred over observation.  
A discrete choice experiment (DCE) was used. DCEs have increasingly been used in 
health care as an approach to elicit patient preferences [9-13]. We hypothesised that patients 
will value brace treatments more highly once they have experienced them, and that 
patients, irrespective of their type of experienced treatment, will ‘defend’ their own 
treatment. These phenomena are known as "status quo bias" and "cognitive discordance", 
respectively, and can bias results. To offset these potential biases, and attempt to capture 
the full range of preferential attitudes towards brace treatments, we elicited preferences 
from brace-only, brace-surgery, and surgery-only patients. We used the most conservative 
estimates for the risk reduction required by patients to accept brace treatment. 
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5.2 Materials and methods 
 
The study was conducted according to the principles of the Declaration of Helsinki. 
Under Dutch law, observational health surveys are exempted from approval from a 
Medical Ethics Committee.  
 
5.2.1 Study sample 
The 197 patients who gave consent for participation in the former NESCIO (Netherlands 
Evaluation Study on Screening for scoliosis) study [14], were approached again for their 
consent to send them a new questionnaire. These patients had completed treatment with 
a brace, surgery, or with a brace followed by surgery, and were recruited in 12 Dutch 
hospitals. For the braced patients, Boston braces had been used. Four weeks after the first 
mailing, a reminder was sent. A total of 135 patients gave informed consent regarding the 
questionnaire; for seven patients we had the incorrect address, one had moved to another 
country, and two did not give consent. The non-response rate at this stage of the study 
was 26.4%.  
 
5.2.2 Variables 
The following data concerning patient characteristics were collected: age at filling out the 
questionnaire, highest current or completed education, Cobb angle at diagnosis, Cobb 
angle after treatment, type(s) of treatment and, if applicable, total bracing period. Data on 
age and education were collected to assure that differences between groups could not be 
explained by differences in age and/or education. Data on post-treatment attitudes about 
choosing/not choosing brace treatment were collected to test for convergent validity of 
the DCE results. 
 
5.2.3 Discrete Choice Experiment 
DCEs assume that a given healthcare intervention can be described by its characteristics 
(attributes) and that any subject’s preferences for an intervention are determined by the 
levels of the attributes [15]. Attributes should be identified beforehand as potentially 
important for the choice of an intervention [16]. The relative importance of attributes and 
the trade-offs patients make between these can be assessed when patients are offered a 
series of choices between brace treatment alternatives that have different combinations of 
attribute levels [17]. 
We identified four attributes of brace treatment, with specific focus on the attributes of 
the Boston brace. The attributes and the attribute levels were chosen based on literature, 
expert interview (specialist in orthopaedics), and personal interviews with patients who 
had experienced brace treatment and/or surgery for scoliosis (i.e., the target group). The 
attributes were: effectiveness of brace treatment, brace comfort, total treatment duration, 
and visibility of the brace (Table 5.1).  
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Table 5.1  Attributes and attribute levels for brace treatment 
 
Coefficients in 
regression analysis 
β1
12.5
25
50
75
β2
No (0)
Yes (1)
β3
2
4
6
8
β4 
No (0)
Yes (1)
Total treatment duration (years) (TIME)
Brace is uncomfortable (DISCOMFORT)
Attributes and attribute levels 
Risk reduction of an operation (%) (EFFECTIVENESS):
Brace is visible (VISIBLE):
 
 
 
The combination of attributes and attribute levels (2 attributes with 4 levels, and 2 
attributes with 2 levels) resulted in 64 hypothetical brace treatment profiles (42 * 22). For 
practical reasons, not all of these could be used in a questionnaire. Therefore, we 
generated a sample of hypothetical brace treatment profiles from all these 64 brace 
treatment profiles for the questionnaire (i.e., we used a fractional factorial design) [18]. A 
sample of 16 hypothetical brace treatment profiles was sufficient to estimate at least all 
main effects in a regression analysis [19]. Based on these 16 profiles, choice sets were 
created. Each choice set consisted of two brace treatment profiles between which the 
patients could choose. If the patients considered both brace treatments as not acceptable, 
the patient could opt-out. Figure 5.1 shows an example. The first brace treatment profile 
(i.e. Brace treatment A) of each choice set was always one of the 16 hypothetical brace 
treatment profiles selected for the fractional factorial design. We created the second brace 
treatment profile (i.e. Brace treatment B) of each choice set by means of a specific 
technique (cycle ‘fold-over’) to ensure minimal overlap of attribute levels (i.e., Brace 
treatment A and Brace treatment B always had different attribute levels in each choice set) 
[20]. Too much overlap would reduce the information obtained on trade-offs between 
attribute levels.  
Before participants started with the 16 choice sets of the DCE in the questionnaire, they 
were  asked  to rank the  four  attributes of a hypothetical brace treatment (total treatment  
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Brace treatment 
A
Brace treatment 
B
No brace 
treatment
Total treatment duration 4 years 6 years 0 years
Brace is visible to wear Yes No Not applicable
Risk of surgery
Reduces from 
40% to 20%
Reduces from 
40% to 10% Remains 40%
Brace is uncomfortable        
to wear
No Yes Not applicable
Which brace treatment      do 
you prefer? □ A □ B □ None
 
 
Figure 5.1  Example of a choice set as presented in questionnaire 
 
 
duration of two years, 30% risk reduction of surgery, brace is comfortable to wear, and 
invisible under clothing) from most important to least important. The questionnaire 
included a detailed written description of each attribute and its levels. While answering the 
choice sets of the DCE, the patients had to imagine that they were an 11-year-old patient 
with scoliosis that is eligible for brace treatment. A dominant choice set was included in 
the questionnaire to test for rationality (i.e. a choice set including one brace treatment 
profile characterized by logically preferable levels on all attributes). Finally, patients who 
had been treated with a brace (whether or not before surgery) were asked if they would 
choose for brace treatment again if they would face the same situation. The questionnaire 
was pilot tested to check for any problems in interpretation and face validity (n=10).  
 
5.2.4 Analyses 
Because some data were skewed and for some variables there were less than 30 patients in 
a subgroup, non-parametric tests (Mann Whitney U-test) were used to determine 
significant differences in age, education, Cobb angle, and brace duration between the 
different subgroups. 
Data from respondents who failed the dominant question in the DCE were excluded 
from further analyses. The DCE was analyzed by taking each choice among the three 
options (two brace treatment alternatives, and a no brace treatment option) as an 
observation. The observations were analyzed by a multinomial logit regression model. 
Assuming that all attributes have an independent influence on a patient’s preference, the 
following model was estimated: 
 
V = β0 + β1TIME + β2 EFFECTIVENESS + β3VISIBLE + β4DISCOMFORT 
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Where: 
 
- V represents the observed preference score for a (hypothetical) brace treatment 
as derived from the respondents’ choice behaviour; 
 
- β0 is an alternative specific constant reflecting the respondents’ preference for 
receiving brace treatment relative to no brace treatment;  
 
- β1 to β4 are coefficients that indicate the relative importance of each attribute 
(Table 5.1).  
 
The values of V have a relative interpretation, i.e., an observed preference score for a 
brace treatment profile with a higher value of V is preferred over a brace treatment profile 
with a lower value of V. A positive preference score value of a specific brace profile 
indicates a preference for that treatment over no brace treatment (i.e., the preference 
score from the no brace treatment option was normalized to zero). The statistical 
significance of a coefficient indicates that the respondents considered the attribute 
important in their choices. A priori, we expected all attributes to be significant. The sign 
of a coefficient reflects whether the attribute has a positive or negative effect on 
preference score. We expected that only the attribute ‘effectiveness’ would have a positive 
effect (i.e., a positive sign) 
The value of a coefficient indicates the relative contribution of the corresponding attribute 
to total preference score. For a correct interpretation of the comparison of the 
coefficients of the attributes, we need to consider the different units of measurement. For 
instance, a change in effectiveness of brace treatment of 1 percent may not be as 
important as a marginal change in any other three attributes. Assuming a linear benefit 
function, the change in benefit resulting from a 20 percent change in effectiveness of 
brace treatment is 20 times larger than a 1 percent change in effectiveness of brace 
treatment, which may outweighs the benefit of a marginal change in other three attributes.  
Subgroup analyses were conducted by using interaction terms in the multinomial logit 
regression model to assess whether brace-only, brace-surgery, and surgery-only patients 
had different preferences for each brace treatment attribute.  
 
 
 
5.3 Results 
 
 
5.3.1 Respondents 
The response rate was 116/135 (86%). In total, 113 of 116 patients (97%) passed the 
dominant question. Of these 113 respondents, 41 had been treated with a brace only 
(brace-only group), 41 had been treated with a brace followed by surgery (brace-surgery 
group), and 31 had been treated surgically only (surgery-only group). The respondents of 
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each subgroup had a mean age of about 20 years at the time of completion of the DCE 
questionnaire (Table 5.2). There were no significant differences between the subgroups, 
except, as expected, the Cobb angle at diagnosis. Results of direct ranking showed that 
effectiveness and discomfort of the brace were considered the most important attributes 
of brace treatment (Table 5.3). 
 
 
Table 5.2  Characteristics of the study population 
 
Brace-only Brace-surgery Surgery-only
(n=41) (n=41) (n=31)
n (%) n (%) n (%)
Girls        36   (87.8)        37  (90.2)        27  (87.1)
Lower education level          4    (9.8)          7  (17.5)          2   (6.5)
Intermediate education level        18   (43.9)        21  (52.5)        19  (61.3)
Higher education level        19   (46.3)        12  (30.0)        10  (32.3)
Mean (SD) Mean (SD) Mean (SD)
Age at survey (years)       20.2   (1.6)       19.5   (2.5)       19.7   (2.4)
Cobb angle at diagnosis (°)a       27.0  (10.3)1,2       34.0  (13.8)1,3       50.0  (15.5)2,3
Cobb angle after treatment (°)a       31.0  (10.2)       30.0  (13.3)       34.0  (10.1)
Total bracing period (years)b         2.7   (1.8)         2.1   (1.7) NA  
 
1,3 p < 0.05; 2 p < 0.01; a on average, 73.5% of the Cobb angles were available; b for five 
brace-only patients and five brace-surgery patients data on total bracing period were 
missing 
 
 
Table 5.3  Direct ranking of the attributes from most important to least important 
 
Effectiveness Discomfort Visible Time
% % % %
Brace-only (n=39) 53.8 23.1 20.5 2.6
Brace-surgery (n=40) 35.0 40.0 22.5 2.5
Surgery-only (n=31) 51.6 25.8 9.7 12.9
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5.3.2 DCE results for total group 
Most patients found the DCE questions (very) clear and had no difficulties in completing 
the questionnaire. All coefficients were significant (Table 5.4, column 3); thus, all 
attributes were important for patients’ choices. All signs were consistent with a priori 
expectations. The positive constant term (0.79) suggests a positive attitude towards brace 
treatment.  
Patients weighted uncomfortable wearing of a brace about 1.4 times more important than 
visibility of wearing of a brace (Table 5.4, column 2; 1.16/0.82=1.4). As an example based 
on these results, the change in preference score in moving from ‘no brace treatment’ to a 
hypothetical brace treatment profile characterized by a total treatment duration of 5 years, 
50% reduction in the risk of undergoing surgery,  comfortable  wearing, and invisibility 
under clothing; can be estimated as:  
 
 
V = 0.79 + 5*-0.35(TIME) + 0*-0.82(VISIBLE) + 5*0.40(EFFECTIVENESS) +                 
0*-1.16(DISCOMFORT) = 1.04;  
 
 
To this end, we used the coefficients of Table 5.4, column 2. A treatment duration of 5 
years contributes negatively to V by -1.75 (5*-0.35). In contrast to visible wearing, 
invisible wearing of the brace under clothing does not have a negative relative 
contribution to V (i.e., value is zero). An effectiveness of brace treatment of 50% 
contributes positively to V by 5 * 0.40 per 10% risk reduction of surgery (i.e. value 
+2.00). And finally, in contrast to uncomfortable wearing, comfortable wearing of the 
brace does not contribute negatively to V (the value zero). The resulting estimate of V 
(0.79 + (5*-0.35) + (0*-0.82) + (5*0.40) + (0*-1.16)) results in a positive preference score 
of 1.04, suggesting that the participants would accept this particular brace treatment 
profile. 
 
 
5.3.3 Subgroup analyses 
Table 5.4 shows the results of multinomial logit regression modelling of data from the 
three subgroups and between the three subgroups (columns 4-12). The constant term was 
only significant for the brace-only group (Table 5.4, columns 4-5); thus, only the brace-
only patients had an unconditionally positive attitude towards brace treatment. If the 
effectiveness of the brace treatment was 30% (as in the hypothetical brace treatment in 
the direct ranking exercise) the brace-only group and the surgery-only group considered 
the effectiveness of brace treatment to be the most important attribute (coefficients 1.68 
(3*0.56) and 1.20 (3*0.40), respectively) followed by discomfort of the brace (coefficients 
1.29 and 1.05, respectively) (Table 5.4, columns 4 and 8). In contrast, the brace-surgery 
patients considered comfort of the brace as the most important attribute (coefficient 1.20) 
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followed by effectiveness of the brace treatment (coefficient 1.05 (3*0.35)) (Table 5.4, 
column 6). 
There were no significantly different preferences for attributes of brace treatment 
between brace-surgery patients and surgery-only patients (Table 5.4, columns 11-12). 
Brace-only patients were significantly less prepared to undergo long treatment duration 
compared to brace-surgery patients and surgery-only patients, but were more prepared to 
wear a less effective brace.  
Brace-only patients chose significantly more often for brace treatment again if they would 
be in the same situation, than did patients who were treated with a brace followed by 
surgery (70.0% vs. 24.4%, respectively). 
Figure 5.2 shows the relationship between effectiveness (%) of a Boston brace (assuming 
this brace is visible and uncomfortable to wear) and acceptance of maximal treatment 
duration (years) of bracing for brace-only, brace-surgery, and surgery-only patients. If the 
brace would reduce the relative risk of surgical intervention by 53%, then all sub-groups 
were prepared to initiate brace treatment (treatment duration of 0 years). However, brace-
only, brace-surgery, and surgery-only patients were only prepared to accept a Boston 
brace for 3 years if the brace would reduce the relative risk of surgical intervention by 
32%, 69% and 74%, respectively. 
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Figure 5.2  Regression lines showing the relationship between effectiveness (%) and acceptation of 
maximal treatment duration (years) of bracing for brace-only, brace-surgery, and surgery-only 
patients 
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5.4  Discussion 
 
The present study shows that scoliosis patients, including patients who underwent 
surgery, reported that they would be prepared to undergo brace treatment only if it is 
associated with sizeable reduction of the risk of surgery. Effectiveness and comfortable 
wearing of a brace played the most important role in the patients’ choices. The risk 
reduction required by these patients for acceptance of a Boston was in the range of 32-
74%.  
There are no previous DCEs investigating how large the risk reduction on surgery must 
be for scoliosis patients to consider brace treatment as acceptable, or eliciting the trade-
offs individuals make between characteristics of brace treatment with which to compare 
our data. However, Dolan et al. [21] investigated the required risk reduction (number of 
surgeries avoided by the use of a brace before the participant would favour bracing over 
observation, given their understanding of the side-effects) desired by parents of scoliosis 
patients and parents of a surrogate group. They found a median desired risk reduction of 
50% (from 60% reduced to 30%), which is quite similar to our study results. In an 
orthopaedic context Snoek et al. [22] used a DCE to study the effects of health outcomes 
and non-health outcomes on the decision for reconstructive interventions for the upper 
extremities in subjects with tetraplegia. They showed that process effects, which relate to 
the intensity of treatment, were equally important or even more important than functional 
outcome in the decision for reconstructive upper extremities surgery in subjects with 
tetraplegia. This is in line with our study, which also showed that besides health outcome 
(i.e., effectiveness of brace treatment) other characteristics (treatment duration, comfort 
and visibility) proved to be important for patients’ choices. 
The ‘real’ risk of progression and the need for surgery in case of no brace treatment is not 
well established. Surgical rates of 0-38% have been reported, with higher rates in not 
braced patients than in braced patients; however, these studies were not based on 
randomized controlled trials [23-25]. By including hypothetical levels of effectiveness we 
could extend the relative importance of the effectiveness of brace treatment in 
comparison with other attributes of brace treatment. 
This study has illustrated the feasibility of DCE to investigate whether a given attribute is 
important for patients’ choices for brace treatment; the relative importance of these 
various attributes; and the trade-offs individuals are made between these attributes. A 
reasonable proportion of potential respondents agreed to participate in the investigation, 
and only 3 of 116 failed the dominant question. This study therefore adds to the available 
literature on the usefulness of DCE to investigate preferences for treatment [28-30]. 
Comparing our DCE results with the results of the direct ranking exercise in our 
questionnaire, the brace-only group and the surgery-only group considered the 
effectiveness of brace treatment to be the most important attribute followed by comfort 
of the brace in both methods, whereas the brace-surgery patients considered comfort of 
the brace as the most important attribute followed by effectiveness of the brace 
treatment. These results support convergent validity of the DCE results. Prior rank-
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ordering of the attributes was included to familiarize respondents with the attributes, but 
some (expectedly small) effects on the eventual results due to anchoring-and-adjustment 
bias cannot be excluded.  
This study had various limitations. First, we used a main effects only design, assuming 
that all attributes were value-independent of each other (i.e., all interactions between 
attributes were zero). This may, however, be reasonable since main effects typically 
account for 70-90% of the explained variance in DCE [19]. Second, this DCE used 
attributes of the Boston brace only, because that is the most commonly used brace in the 
Netherlands at present. It is conceivable that other brace types, like SpineCor braces® or 
TriaC® may be preferred differently, because these are less rigid than the Boston brace. 
Third, all patients in our study population had experienced treatment for scoliosis and 
therefore knew what they were choosing for in this DCE. This strength is, however, also 
a limitation. These patients may have ‘defended’ their own treatment (i.e., cognitive 
discordance), and this may have biased the results. For example, brace-only patients had 
no experience of surgery and may have been more afraid of surgery than the surgery 
patients and may, therefore, have expressed more willingness to wear a brace. Brace-
surgery patients have experienced both forms of treatments, but this group may have 
been disappointed in brace treatment because eventually they had to undergo surgery. 
Surgery patients might be too positive towards surgery, because their surgery had been 
successful. The differences in the preferences we found were in the expected directions, 
i.e., the surgery-only patients expressed the least positive preferences for brace treatment. 
Therefore, we may conclude that the general attitude for brace treatment was positive. 
Regardless of the variations in preferences between the patient groups in this study, new 
IS patients who have to decide about brace treatment might have other preferences. The 
current results could gain importance if it were possible to ask new IS patients what 
preferences they state and then compare their stated preference with their actual 
behaviour later on.  
In conclusion, our study shows that scoliosis patients, including patients who underwent 
surgery, reported that they would be prepared to undergo brace treatment only if it is 
associated with sizeable reduction of the risk of surgery. Effectiveness and comfortable 
wearing of a brace played the most important role in the patients’ choices. The risk 
reduction required by these patients for acceptance of a Boston brace was in the range of 
32-74%. These results are important, because they give more insight into minimal clinical 
important differences, which are important for trials that will investigate the effectiveness 
of brace treatment. 
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Abstract 
Background  Patients’ preferences are important determinants in the decision for a 
specific type of breast reconstruction (BR). Understanding patients’ motivational factors 
in the decision for a specific type of BR can contribute to further improve patient 
information and to develop demand-led healthcare. We explored patients’ preferences for 
three BR modalities. 
Methods  We approached 386 patients who previously underwent a therapeutic or 
prophylactic mastectomy, of whom 247 had also undergone a BR. A discrete choice 
experiment (DCE) was designed. BRs were characterized by six treatment attributes. 
Relative importance of attributes and trade-offs patients were willing to make between 
them were analyzed using a multinomial logit regression model.  
Results  Overall response rate was 71%. All treatment characteristics proved important 
for patients’ choices, with material and aesthetic result being most important. Patients 
who had not undergone a BR had a stronger preference for BR with autologous tissue. 
Genetically predisposed patients expressed more negative consequences (disutility) from 
long-term complications than those without an increased risk for breast cancer. A unique 
model was developed to estimate utilities derived from different types of BR. Autologous 
free flap BR fitted in best with patients’ preferences. 
Conclusions  Material and aesthetic result are the most important determinants for 
patients’ choice for a specific type of BR after mastectomy. Our study provides insight 
into the relative weight patients place on various aspects of BR and the trade-offs they 
make between BR characteristics. Patients’ preferences need to be taken seriously in the 
development of demand-led healthcare for breast cancer patients.  
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6.1  Introduction 
Breast reconstruction (BR) is aimed at restoring patients’ quality of life and body image 
after mastectomy, and increasingly becomes an integral part of breast cancer (BC) 
treatment. Multiple techniques are available, differing in characteristics such as material 
used, duration of the operation(s), recovery period, complication rates, and aesthetic 
result. Each technique has (dis)advantages and therefore its own place in current practice 
[1]. 
Multiple factors have to be considered to determine the optimal treatment modality for 
individual patients. Procedural characteristics have to be regarded in the context of 
patient-related factors (e.g., age, medical history, body habitus) and surgeon-related 
factors (e.g., expertise, experience) to assess which methods are technically feasible and 
which risks acceptable. Adjuvant radiation therapy, for example, is a relative contra-
indication for implant BR due to increased complication rates, while sufficient excess 
abdominal tissue is a prerequisite for autologous BR using abdominal tissue [2, 3]. 
Complementary to the medical analysis performed by the plastic surgeon regarding which 
BR type individual patients could undergo, patients’ preferences for the procedure they 
would opt for are also important determinants of the treatment choice. Understanding 
women’s motivational factors and personal views can contribute to further improve 
patient-centered and demand-led healthcare.  
The aim of this study was to explore patients’ preferences for different BR modalities 
after (prophylactic) mastectomy using a discrete choice experiment (DCE). We also 
evaluated whether preferences differed between patients who had or had not undergone a 
BR and between women with or without a genetic predisposition to develop BC. 
 
 
 
 
6.2  Patients and methods 
 
6.2.1  Breast reconstruction 
There are essentially three types of BR after mastectomy, using implant material, 
autologous tissue, or a combination of both [1]. At our institution, the most frequently 
performed methods per category are: 1) breast implants preceded by tissue expansion, 2) 
free Deep Inferior Epigastric Artery Perforator (DIEP) flap, and 3) pedicled Latissimus 
Dorsi (LD) flap with an implant, respectively. BR can be performed directly after 
mastectomy (primary BR) or at a later stage (delayed or secondary BR). The Daniel den 
Hoed Cancer Center specifically attracts patients with a genetic predisposition to develop 
BC, who frequently opt for prophylactic bilateral mastectomy. In the Netherlands, BR is 
covered by basic health insurance and no out-of-pocket expenses are required from 
patients. 
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6.2.2  Discrete choice experiment 
DCEs are a rather novel approach to elicit patient preferences, with their origin in 
mathematical psychology. They assume that healthcare interventions can be described by 
their characteristics (attributes) and that patients’ preferences are determined by attribute 
levels [4]. Relative importance of attributes and trade-offs that respondents make between 
them can be assessed by offering a series of choices between treatment alternatives with 
different combinations of attribute levels [5]. Concept and definitions are illustrated in 
Figure 6.1. A DCE was designed to determine trade-offs that women who underwent a 
prophylactic or therapeutic mastectomy make when they are offered a choice between 
different BR types. 
 
 
6.2.3  Attributes and attribute levels 
Choice of attributes and their levels was based on data from literature and interviews with 
specialists and with women having had a mastectomy or BR [2, 3, 6-9]. Six attributes were 
selected: 1) material used for reconstruction; 2) number and duration of operations; 3) 
short- and 4) long-term complication rate; 5) aesthetic result; 6) waiting time. 
Three levels were determined per attribute. Some hypothetical levels were included to 
allow assessment of preferences to be extended beyond currently available treatments and 
to potentially guide the development of new techniques (Table 6.1). 
 
 
Reconstruction  
A 
Reconstruction  
B 
Reconstruction  
C 
Characteristics of BR 
 
Material used for BR 
Autologous 
tissue from 
abdomen 
Implant;         
no extra scar n.a. 
Number and duration of 
operations 
2 x 1 hour 1 x 3 hours n.a. 
Short-term complication 
rate 
10% 1% n.a. 
Long-term complication 
rate 
10% 30% n.a. 
Aesthetic result Good Excellent n.a. 
Waiting time 0 months 6 months n.a. 
 
      Attribute        Choice set          BR alternative            Attribute level 
 
Figure 6.1  Concept of DCEs illustrated using a choice set as presented in questionnaire – Which 
type of breast reconstruction would you choose? 
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Table 6.1  Six attributes with three levels each used for Discrete Choice Experiment to assess 
women’s preferences for three different types of BR 
 
Coefficient in regression analysis 
Implant β1
Autologous tissue from abdomen β2
Autologous tissue from back with implant
1 x 3 hours
2 x 1 hour β3
1 x 7 hours β4
β5
1 percent
5 percent
10 percent
β6
0 percent
10 percent
30 percent
Moderate
Good β7 
Excellent β8 
β9 
0 months
6 months
12 months
Long-term complication rate
Aesthetic result
Waiting time
Attributes and levels 
Material used for reconstruction
Number and duration of operation(s)
Short-term complication rate
 
 
 
6.2.4  Study design and questionnaire 
The combination of attributes and attribute levels (6 attributes with 3 levels each) resulted 
in 729 (36) hypothetical BR alternatives. Eighteen BR alternatives proved sufficient to 
estimate all main effects in a regression analysis, while guaranteeing orthogonality 
(attributes being independent of each other) and level balance (levels occurring with equal 
frequency) [10, 11]. Choice sets were designed using the ´fold-over´ technique to ensure 
minimal overlap of attribute levels between BR alternatives and optimal efficiency [12]. All 
main effects were uncorrelated [13]. Choice sets consisted of two BR alternatives and a ‘no 
reconstruction’ option to allow patients to ‘opt out’ (Figure 6.1); BR is elective surgery 
and patients should not be forced to choose BR.  
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Previous studies demonstrated that more than 16 choice sets per respondent are 
associated with lower response rate and/or response reliability [14, 15]. Therefore, 18 choice 
sets were divided over two questionnaires containing nine choice sets each (i.e., two 
questionnaires constituted one full dataset) by using a blocked design [16].  
Each questionnaire started with a detailed description of attributes and their levels. 
Pictures were included to demonstrate ‘moderate’ and ‘excellent’ aesthetic results. Short-
term complications (e.g., infection, haematoma, or flap failure) were defined as arising 
within 6 weeks after BR, while long-term complications (e.g. capsular contracture, 
abdominal herniation) were stated to arise between 6 weeks and 5 years after BR. A 
dominant choice set (i.e., a choice set in which both alternatives used implant material, 
but one was characterized by logically preferable levels on all other attributes) was 
included to test for rationality.  
The main part of each questionnaire comprised of nine choice sets. Patients were asked to 
consider all three options as realistic alternatives and to choose the option that appealed 
most to them. Furthermore, eight questions covered medical history, satisfaction with 
previous BR, whether or not patients would opt for (the same type of) BR again, marital 
status, and level of education.  
The questionnaire was pilot tested (n=10) to check for problems in interpretation and 
face validity. As none of the respondents raised any problems, no alterations were made.  
 
 
6.2.5  Study sample 
We randomly approached 386 women from a total group of 820 who had undergone a 
mastectomy with (n=247) or without (n=139) BR between 2002 and 2006. The vast 
majority of patients had been diagnosed with sporadic BC. Seventy-nine patients were 
genetically predisposed to develop BC due to a BRCA 1/2 mutation and chose to 
undergo a contralateral or bilateral prophylactic mastectomy. None of the respondents 
had signs of BC recurrence at the time of the study. Women over 70 years of age were 
not eligible.  
The number of respondents, choices per respondent, attributes, and attribute levels 
determine the power of a DCE. A formal power analysis is not feasible, however, as 
patients’ preferences are hard to predict. Earlier studies have shown that the sample size 
of our study is sufficient for reliable statistical analyses [4, 17].  
 
6.2.6  Procedure  
The questionnaire and a prepaid return envelope were mailed to 386 patients. After 4 
weeks non-responders were sent a reminder and after two months remaining non-
responders were contacted by telephone. Written informed consent was obtained from all 
patients. The study was approved by the medical ethical review committee (MEC-2007-
406). 
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6.2.7  Statistical analyses 
Differences in age were analyzed using Student’s t-tests for independent samples, while 
differences in categorical variables were analyzed using Pearson chi-square tests.  
The DCE was analysed taking each choice among the three options as an observation. 
Data from respondents who failed the dominant question were excluded from further 
analysis. Remaining observations were analyzed by a multinomial logit regression model 
to determine the relative importance of treatment attributes. This model was 
implemented in SAS software (Version 9.1, SAS Institute Inc., Cary, NC, USA). 
Assuming that all attributes have an independent influence on women’s preferences, the 
following model was estimated [11]:  
 
V = 0 + (1 * implant) + (2 * autologous tissue from abdomen) + (3 * (2x1 hour 
……. operations)) + (4 * (1x7 hour operation)) + (5 * short term complications) + (6 
………  * long term complications) + (7 * good aesthetic result) + (8 * excellent aesthetic 
…….. result) + (9 * waiting time) 
 
Where: 
- V represents total relative utility or relative positive consequences derived from a 
certain type of BR, which can be viewed as the preference for that particular health 
state [18].  
- 0 is a constant reflecting respondents’ preference for receiving BR relative to ‘no 
BR’; 
- 1 to 9 are coefficients indicating the relative importance of each attribute or 
attribute level; β1 to β4, β7 and β8 are dummy variables of ‘material used’, ‘duration 
of operation(s)’, and ‘aesthetic result’, with ‘autologous tissue from the back with 
implant’, ‘1x3 hour operation’, and ‘moderate aesthetic result’ as respective base 
levels; 
- short- and long-term complication rates are scored as a fraction of 10%; 
- waiting time is scored in months. 
 
Using these coefficients, relative utility scores of BR profiles can be generated and 
subsequently ranked. The higher a relative utility score, the stronger the preference for 
that particular BR alternative. Relative values allow comparison of strengths of 
preferences for specific BR types. Absolute values of V, however, have no direct 
interpretation [11]. The sign of a coefficient reflects whether the attribute has a positive or 
a negative effect on utility, and the value indicates the relative importance of the 
corresponding attribute to total relative utility. A statistically significant coefficient is 
interpreted to indicate that respondents considered the attribute important. A priori all 
attributes were expected to be important, and material and aesthetic result were expected 
to have a positive effect. Trade-offs that respondents were willing to make between 
attributes were estimated by the ratios of the coefficients. For example, β2/β9 estimates 
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how much longer respondents are willing to wait (in months) to undergo autologous BR 
instead of BR with autologous tissue and an implant. 
Subgroup analyses were conducted using interaction terms in the multinomial logit 
regression model to assess whether patients who previously underwent BR had different 
preferences than patients who had not. We also compared patients who had undergone 
BR after sporadic BC to genetically predisposed patients who had undergone BR. 
 
 
6.3  Results 
 
6.3.1  Respondents 
Of 386 invited patients, 320 responded and 272 agreed to participate (overall response 
rate: 71%). Patients who had undergone a BR (n=186; 69%) were significantly younger 
(p<0.01) and more frequently had an increased risk of BC (p<0.001) than patients who 
had not undergone a BR. Of all respondents who underwent BR, mutation carriers were 
also younger than patients not being at increased risk of hereditary BC (p<0.01), and 
more frequently lived with a partner (p=0.04; Table 6.2). Table 6.3 gives an overview of 
the experiences of respondents who underwent BR.  
 
 
6.3.2  DCE results 
In total, 270 of 272 patients (99%) passed the dominant question. All treatment attribute 
coefficients were significant and all signs were in keeping with a priori expectations (Table 
6.4). The positive constant term suggests that respondents generally had a positive 
attitude towards BR. Respondents preferred autologous tissue over implants, while 
autologous tissue combined with an implant was least popular. A short operation was 
preferred over a long operation and patients would rather undergo two short operations 
than one long one. Patients were less likely to choose options with increasing 
complication rates, both short- and long-term, but short-term complications were more 
important than long-term complications (higher regression coefficient for short-term 
complications). An ‘excellent’ aesthetic result was preferred over ‘good’ or ‘moderate’.  
Noteworthy, the magnitude of attribute coefficients corresponds with their relative 
importance. For example, the coefficient of -0.30 for long-term complication rate implies 
the decrease in utility per 10% rise. A risk reduction of 30% therefore corresponds with a 
utility increase of 0.90.  
Nearly 75% of respondents who underwent BR were willing to make a trade-off with 
regard to material used for BR (data not shown). Only 27% consistently chose their 
preferred material, which in over 90% of these cases matched their own BR type.  
The results of subgroup analyses are presented in Table 6.5. Patients with a BR had a 
significantly more positive attitude towards BR than women without a previous BR. 
Except  for  women  without BR having a significantly stronger preference for autologous  
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tissue, there were no differences between both groups. Mutation carriers who had 
undergone BR experienced more negative consequences (disutility) from long-term 
complications than those without a genetic predisposition.  
The relative importance of attributes was subsequently used to estimate and compare the 
relative utility derived from different BR profiles (Table 6.6). In contrast to (relatively) 
fixed levels for material and duration of operation, levels for complication rates and 
aesthetic result are more variable and prone to discussion. The isolated effect of material 
and number and duration of operations on utility was therefore evaluated first by 
assuming equal complication rates (5%), aesthetic results (good), and waiting time (0 
months) (Table 6, top lines). Under these assumptions, utility derived by DIEP flap BR 
was higher than utilities derived by implants preceded by TE and LD transpositions 
(relative utility of 0.93 compared to 0.78 and 0.66, respectively). The effect of changes in 
attribute levels on relative utilities and the subsequent ranking of different treatment 
scenarios are also presented. 
 
 
Table 6.4  Women’s preferences for breast reconstruction 
 
Attribute
Coefficient in 
regression analysis
n=270
Constant (breast reconstruction) 0.20 0.05
Material used for reconstruction (base level:
     autologous tissue from back with implant)
Implant 0.33 <0.01
Autologous tissue from abdomen 0.76 <0.01
Number and duration of operation(s) (base level:
      1 x 3 hours)
2 x 1 hour -0.21 <0.01
1 x 7 hours -0.49 <0.01
Short-term complication rate (per 10 %) -0.43 <0.01
Long-term complication rate (per 10 %) -0.30 <0.01
Aesthetic result (base level: moderate)
Good 0.82 <0.01
Excellent 1.18 <0.01
Waiting time (per month) -0.01 0.05
p-value
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6.4  Discussion 
This discrete choice experiment showed that autologous material and an excellent 
aesthetic result were the most important determinants in women’s choices for (a specific 
type of) BR.  
Patients’ motivation for and satisfaction with BR have been previously assessed, mostly 
focusing on general determinants of patients’ preferences for BR and its timing [19-22]. 
These studies, however, did not distinguish between different types of BR, nor did they 
evaluate the impact of specific procedural characteristics on patients’ choices. Specific 
comparative data are therefore not available.  
DCEs are increasingly being used in healthcare to explore trade-offs women make 
between different treatment modalities [4, 23, 24]. With a high participation rate and only 2 
of 272 respondents failing the dominant question, this DCE demonstrated its feasibility 
to elicit (determinants of) women’s preferences for BR as well as patients’ willingness to 
participate in a relatively complex study to weigh up pros and cons of various BR 
treatments. 
Characteristics of subgroups with regard to age, genetic predisposition, complication 
rates, and patient satisfaction were in line with other publications. Patients who undergo a 
BR tend to be younger than patients who refrain from BR [25, 26]. In addition, a BRCA 
mutation is generally recognized at a younger age than the mean age at which BC 
develops in the population, and women who opt for prophylactic mastectomy tend to 
request BR as well. Short-term complications are more frequent in autologous BR, while 
long-term complications (e.g., capsular contracture) are typical for implant 
reconstructions [7]. Patient satisfaction after BR is generally high, but several studies 
reported higher satisfaction rates after autologous reconstructions [19, 27]. This unequal 
division of complication and satisfaction rates could potentially affect our results: 
preference for autologous tissue may be overrated due to higher satisfaction levels in 
women who previously underwent an autologous BR compared to women who 
experienced other types of BR. It was technically not possible to fully adjust for this. 
Patients’ backgrounds should therefore be kept in mind when analyzing our results.  
Respondents having undergone a LD transposition were least likely to choose the same 
type of BR again. DCE results showed that both implant material and autologous tissue 
were preferred over the combination of autologous tissue with an implant. These findings 
are in line with each other and demonstrate our study’s (internal) validity. 
Genetically predisposed women having undergone mastectomy and BR reported more 
expected disutility from long-term complications than those not being at increased risk of 
hereditary BC. A generally younger age combined with a prophylactic rather than a 
therapeutic mastectomy might explain why the former group considers long-term 
complications more cumbersome than older women with a history of BC who are more 
preoccupied with survival and short-term results of BR. 
In estimating the relative utilities for existing BR techniques (Table 6.6), long-term 
complication rates of 5% and 10% were firstly used. In reality, however, long-term 
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complication rates after implant reconstructions have been reported to be as high as 40% 
[7]. Similarly, we based our estimates on ‘good’ aesthetic results while autologous 
reconstructions are frequently said to yield superior aesthetic results [19]. In our own 
experience, DIEP flap surgery can frequently be performed in less than five hours. Such 
changes in attribute levels have a major impact, and would drastically increase the 
differences between autologous and implant BR. In contrast, waiting time hardly affected 
utility levels. In our opinion, this finding is remarkable as waiting time for autologous BR 
has recently been a big issue in the Dutch media. We had therefore expected a more 
substantial effect for this variable.  
All patients in our study population had experienced mastectomy and a majority of 
patients had also undergone BR. Respondents could therefore identify themselves with 
the presented choices, which is one of the prerequisites for a successful DCE. This 
design, however, may simultaneously bias the results, as patients who previously 
underwent BR are likely to incorporate their experiences in their answers and ‘defend’ 
their own choice and treatment (cognitive dissonance) [28]. This mechanism could explain 
why patients who had not undergone a BR had an even stronger preference for 
autologous material than women with a BR. Respondents who previously had a positive 
experience with implant BR (nearly 60% of all respondents with a BR) are less likely to 
demonstrate a strong preference for autologous tissue, regardless of their original 
preferences. Nevertheless, only 27% of respondents who had experienced BR were not 
willing to make a trade-off with regard to material used and consistently chose their 
preferred material.  
The choices our respondents had to make were realistic, yet in real life decisions had 
already been made. It is possible, therefore, that preferences presented here differ from 
those of patients facing a forthcoming mastectomy. The current study design does not 
allow stated preferences to be validated by revealed preferences from actual behavior (i.e., 
testing for external validity) [29]. This interesting comparison would be possible if the 
study was repeated prospectively in women who are about to undergo mastectomy and 
are currently deciding on BR. A prospective design would also prevent previous 
experience from interfering with patients’ choices. Further research could shine a light on 
this.  
Given cross-national differences in health care organization and financing, it may not be 
possible to completely generalize these results to other countries, such as the US. 
In conclusion, this DCE showed that patients’ choices for BR after (prophylactic) 
mastectomy are influenced by all investigated BR attributes, with material and aesthetic 
result being the most important ones. Autologous free flap BR (e.g., DIEP flap) seemed 
to fit in best with patients’ preferences. More insight into the relative weight patients 
place on various aspects of BR and the trade-offs they make between BR attributes could 
enable healthcare workers to improve counseling and may have a positive effect on the 
process and outcomes of shared decision-making of BC treatment. 
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Abstract 
Objectives To determine the influence of different screening tests and their 
characteristics on individual preferences for colorectal cancer (CRC) screening. 
Design  A discrete choice experiment (DCE). 
Setting  Region Rotterdam in the Southwest of the Netherlands. 
Participants  The DCE questionnaire was sent to a population based random sample 
(n=1,498) of the screening naïve population (50-74 years old) and to a random sample 
(n=769) of previously screened subjects of a CRC screening pilot programme using faecal 
occult blood test (FOBT, n=512) or flexible sigmoidoscopy (FS, n=257). 
Main outcome measures  Preferences and expected uptake for and trade-offs between 
different screening strategies FOBT, FS and total colonoscopy (TC), screening intervals 
and risk reduction of CRC related mortality. 
Results  In total 489/1,498 (33%) screening-naïve (52% male; mean age±SD 61±7yrs) 
and 545/769 (71%) screened subjects (52% male; mean age±SD 61±6yrs) returned the 
questionnaire. Type of screening test, screening interval, and risk reduction of CRC 
related mortality influenced subjects’ preferences for CRC screening (all p<0.05). 
Screening-naïve and screened subjects equally preferred five-yearly FS and ten-yearly TC 
screening (p=0.24; p=0.11). They preferred both endoscopic screening options to FOBT 
screening if, based on the literature, realistic risk reduction of CRC related mortality was 
applied (all p-values <0.001). Both screening naïve and screened subjects were willing to 
undergo a ten-yearly TC instead of a five-yearly FS to obtain an additional risk reduction 
of CRC mortality of 25% (p<0.001). 
Conclusions  Assuming realistic test characteristics, subjects in the target population 
preferred endoscopic screening to FOBT screening primarily due to the more favourable 
risk reduction of CRC related mortality. Increasing knowledge on risk reduction by 
different screening strategies is therefore warranted to prevent unrealistic expectations 
and to optimise informed choice. 
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7.1 Introduction 
 
Colorectal cancer (CRC) is the second cause of cancer-related death in the Western world. 
Screening can reduce CRC related mortality by removal of adenomas and early detection 
of CRC [1-5]. There is compelling evidence to support screening of average-risk individuals 
over 50 years of age [3-7]. Guidelines underline the role of individual preferences in the 
selection of a screening test [8-10], since insufficient evidence is available to recommend 
one screening test to another. Individual preferences for a certain screening test have 
been found to influence uptake in a CRC screening programme [11]. Uptake is a key factor 
determining the effectiveness of such a screening programme. However, uptake levels are 
fairly low in many countries (<60%) [3, 4, 12-14]. Several countries, including The 
Netherlands, are considering introduction of a nation-wide CRC screening programme. It 
is therefore essential to obtain insight into individual preferences for available screening 
strategies prior to the implementation of a nation-wide screening programme.  
Previous surveys demonstrated a broad variation in preferences for CRC screening tests, 
since tests differ in benefit (CRC mortality reduction) on the one hand and potential 
harms on the other hand (perceived burden, complications). Subjects who valued 
effectiveness most highly chose for colonoscopy screening, whereas others preferred 
faecal occult blood testing (FOBT) because of the less invasive character [11, 15-17]. These 
studies however did not provide data on the relative importance of test characteristics on 
preferences, for example, how much potential health gain does a subject require to 
undergo invasive endoscopic screening? 
Discrete choice experiments (DCEs) are becoming more widely used in health care 
research [18-22]. A DCE is capable of establishing preferences and to predict uptake in 
controlled experimental conditions, through responses to realistic and hypothetical 
scenarios. DCEs may be valuable for patient centred evaluations of health technologies 
[23].  
This study was conducted to determine individuals' preferences and to predict uptake for 
CRC screening programmes with various screening tests, and the relative importance of 
different test characteristics for these preferences in an average risk population. 
Furthermore, we aimed to identify differences in preference structures between 
subgroups in the population. 
 
7.2  Methods 
7.2.1 Data sources 
A total of 1,498 screening-naïve individuals aged 50-74 years old were randomly selected 
from municipal registries of the Rotterdam region in the Southwest of the Netherlands. 
We also invited a random sample 769 screened subjects of a CRC screening trial 
comparing guaiac-based FOBT (gFOBT), faecal immunochemical test (FIT) and flexible 
sigmoidoscopy (FS) (Figure 7.1). This screening trial was carried out in the same target 
population as mentioned above [24]. 
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Screening naive Participants
1498 were invited
400 (82%) analysable
1009 did not respond
489 (33%) responded
769 were invited
496 (91%) analysable
545 (71%) responded
89 failed the 
rationality test  
224 did not respond 
49 failed the 
rationality test 
257 FS 
participants
256 gFOBT 
participants 
256 FIT 
participants
 
Figure 7.1   Study profile 
 
 
 
7.2.2 Discrete choice experiments  
DCEs can measure individuals’ preferences for health care interventions. DCEs are based 
on the assumptions that a healthcare intervention can be described by its characteristics 
(attributes) (e.g. frequency of undergoing the intervention) and that the individual 
valuation of the intervention is determined by pre-defined levels (e.g. monthly, yearly) of 
those attributes. The health care intervention (e.g., screening test) as well as its test 
characteristics have to be specified before generating an experimental design. In a DCE 
individuals choose between several realistic and hypothetical scenarios. Preference 
estimates can be obtained from the choice data and describe the relative preference for 
characteristics of the health care intervention. 
 
7.2.3 Attributes and levels 
FOBT, FS and total colonoscopy (TC) are most widely used as CRC screening test and 
therefore incorporated in this study design. The characteristics and their levels were 
derived from the literature, expert opinions (n=3) and interviews with potential screenees 
(n=40). Experts were asked to comment on a list of characteristics derived from literature 
review. Potential screenees could also comment on the list of characteristics and rank 
them in order of importance. Based on these data we selected the two most important 
characteristics as identified by both groups: risk reduction of CRC related mortality (RR) 
and screening interval. Noteworthy, characteristics that are directly related to the test (e.g. 
oral bowel cleansing solution is not required for FOBT and always for TC) were already 
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captured by the specific screening test (FOBT, FS and TC). All subjects were informed 
about the incorporated test characteristics of the three screening tests (Appendix 7.A). 
The specific values (levels; e.g. amount of risk reduction, or length of screening interval) 
for each test characteristic incorporated the range of possible test outcomes of a specific 
screening test (FOBT, FS and TC) based on the current literature (Table 7.1). The levels 
were test specific to create realistic scenarios (Table 7.1).  
 
 
7.2.4 Study design and questionnaire   
The design contained three tests (FOBT, FS and TC) and two characteristics (risk 
reduction of CRC related mortality and screening interval) with three levels each (Table 
7.1). The test specific levels (e.g. screening interval of FOBT between four months and 
triennial) were required to select realistic combinations. Furthermore, unrealistic 
combinations of the characteristics' levels were blocked (i.e. a combination of the lowest 
RR with the shortest screening interval as well as the highest RR combined with the 
longest screening interval). The combination of the characteristics and levels resulted in 
21 (i.e. 7*3) possible test scenarios, and thus 343 (i.e. 73) possible combinations of the 
scenarios (i.e. full factorial design). It is not feasible to present a single individual with all 
these combinations. We therefore reduced the design in such away that two-way 
interactions could be estimated (i.e. we created a fractional factorial design). We therefore 
used SAS software (Version 9.1, SAS Institute Inc., Cary, NC, USA), which is capable of 
generating designs that are highly efficient (i.e. maximizing D-efficiency or minimizing D-
error) in such circumstances [25]. We chose a design with 84 choice sets divided over 7 
versions of the questionnaire (D-error 0.573). Each choice set included two CRC 
screening tests and an option not to be screened (opt-out) (Appendix 7.B).  
A rationality test was included in the questionnaire to determine the understanding of the 
questionnaire by each subject. This test was a choice set of which one screening option 
was logically preferable to the other option given the levels of each test characteristic 
…… 
 
Table 7.1  Alternatives, attributes and the alternative specific levels based on the literature 
 
 
Alternatives Alternative specific levels Literature References
Screening interval (yr)
     FOBT 1/4 - 1 - 3 1 - 2
     Sigmoidoscopy 1 - 5 - 10 5 - 10 [8, 28, 29]
     Colonoscopy 2 - 5 - 10 5 - 10
Risk reduction (%)
     FOBT 10 - 25 - 40 13 - 33 [3-5]
     Sigmoidoscopy 40 - 50 - 70 49 - 62 [1, 2, 28, 30]
     Colonoscopy 75 - 85 - 95 80 - 84 [28, 31, 32]
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(biennial FS screening resulting in 40% RR against biennial FS screening resulting in 70% 
RR). It is common practice to exclude irrational responses from the analysis [26-28], and 
that was why this approach was adopted here. However, some recent discussions in the 
literature suggest that these responses could be included [29, 30]. Further sensitivity analyses 
were conducted. Inclusion of irrational responses led to similar results.  
Subjects' social economic status (SES), previous endoscopy experience and experience 
with CRC in family and close friends were determined. Furthermore, the generic health 
status (EQ-5D summary score) was assessed. This is a validated classification of subject’s 
own health [31].  
We conducted a pilot study (n=20) to ascertain subjects could manage the length of the 
questionnaire and to examine the intelligibility, acceptability and validity. The 
questionnaire was mailed to all subjects. Background information on the three screening 
tests (Appendix 7.A) was printed on the first page of the questionnaire. A reminder was 
sent to non-responders four weeks later. 
 
 
7.2.5 Data Analysis  
Each choice between two tests and the opt-out was considered as a specific observation. 
The DCE was analysed using multinomial logit regression models with test specific 
parameters. The model was implemented in SAS software (Version 9.1, SAS Institute 
Inc., Cary, NC, USA). A priori we expected the test as well as the two characteristics to be 
important for subjects’ choices and that a higher risk reduction would have a positive 
effect on preferences and lengthening of ‘screening interval' a negative effect.  
We assumed that there was no linear relationship between the different levels of the 
characteristics. On this basis, we estimated the following models for the DCE:  
 
Uno test  =  0 
UFOBT  =   β0 + β1Interval1yr + β2Interval3yr + β3RR25 + β4RR40 + εFOBT 
FS 
 
UFS      = β5 + β6Interval5yr + β7Interval10yr + β8RR50 + β9RR70 + ε
UTC      = β10 + β11Interval5yr + β12Interval10yr+ β13RR85 + β14RR95 + εTC
 
Utility (U) represents the preference score for a (hypothetical) CRC screening programme 
consisting of the deterministic and observable component (V) and the random 
component (ε) to the analysis, accounting for unobserved or unobservable components 
of choice. The constant terms (screening test; β0, β5, β10) are alternative specific constants 
that indicate the general attitude of subjects towards screening with a specific screening 
test compared to no screening. β1,2, β6,7, β11,12  are coefficients of the levels of the test 
characteristic ‘screening interval’ and β3,4, β8,9, β13,14  are coefficients of the levels of the 
test characteristic ‘risk reduction of CRC related mortality’; each coefficient indicates the 
relative weight individuals place on that test specific level compared with the reference 
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level for that test specific test characteristic (for the reference levels see Table 7.3). A two-
sided p-value smaller than 0.05 was considered statistically significant.  
Generic health status was dichotomized to an EQ-5D summary score of ‘1’, representing 
full health, versus an EQ-5D summary score ‘<1’, indicating sub-optimal health. 
Aggregate data on socio-economic status (SES) were available at the level of the area 
postal code (www.cbs.nl) of the subject, weighted by population size and classified into 
three groups (high, intermediate, low).  
Chi-square and Student t-tests were used to assess the differences in the value of 
characteristics between screening naïve and screened subjects as well as between 
subgroups (age, gender, SES, EQ-5D, prior endoscopy experience, or knowing someone 
affected by CRC) within the screening-naïve population. 
To examine the predicted uptake of CRC screening based on our results, we applied 
previously proposed models to our data [32, 33]. We also investigated the effect of changing 
the characteristics, as identified by the results of our multinomial logit model, on the 
expected uptake of CRC screening.  
 
 
7.2.6 Ethical approval 
The study was approved by the Institutional Review Board of the Erasmus MC, 
University Medical Centre (MEC-2007-224). 
 
 
Table 7.2  Subjects’ characteristics 
 
Screening naïve Screened subjects p-value
Invited subjects (n) 1,498 769
Sex (male; n-%) 209 (52) 260 (52) 0.96
Age (mean-SD) 60.7 (6.6) 61.1 (6.4) 0.36
EQ5D score (mean-SD) 0.94 (0.11) 0.93 (0.10) 0.76
Social economic status (n-%) <0.01
High 195 (49) 196 (40)
Intermediate 77 (19) 96 (19)
Low 128 (32) 204 (41)
Endoscopy experience (n-%) <0.01
Yes 92 (23) 242 (49)
No 307 (76) 251 (50)
Unknown 1 (1) 3 (1)
Related to CRC patient (n-%) 0.78
Yes 53 (13) 67 (13)
No 285 (71) 381 (77)
Unknown 62 (16) 48 (10)
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7.3 Results 
 
A total of 489/1,498 (33%) screening-naïve and 545/769 (71%) screened subjects 
returned the questionnaire. Screening-naïve subjects were of higher SES than screened 
subjects (p<0.001, Table 7.2). A higher proportion of screened subjects previously 
underwent an endoscopy compared to screening-naïve subjects (49% vs. 23%; p<0.001). 
Among the subjects that participated in the CRC screening trial 22% (70/324) of the 
screenees that performed a FOBT previously underwent an endoscopy and obviously all 
(172/172) FS screenees.   
 
7.3.1 DCE  
A significantly higher proportion of the screened subjects (91%) passed the rationality test 
compared to the screening-naïve subjects (82%; p<0.001).  
Screening-naïve subjects did not prefer FOBT to no screening. They expressed a positive 
attitude towards FS and TC (positive and statistically significant sign, Table 7.3, Figure 
7.2). A high RR was preferred to intermediate and low RR for all screening tests (p-values 
<0.01). Screening-naïve subjects expressed a more positive attitude towards an 
intermediate (FOBT: annually; FS: five-yearly; TC: five-yearly) compared to a short 
screening interval (FOBT: three monthly; FS: annual; TC: biennial). Further lengthening 
of the screening interval (FOBT: triennial; FS: ten-yearly; TC: ten-yearly) had only a small 
positive effect on subjects’ preferences for FOBT (p=0.02) and FS (p=0.02), and no 
effect on subjects’ preferences for TC screening. 
Screened subjects had a positive attitude towards all screening tests (p<0.001). A high RR 
was preferred to intermediate and low RR for all screening tests, and an intermediate 
screening interval was preferred to a short screening interval (Table 7.3, Figure 7.2). 
Screened subjects did not prefer an intermediate to a long interval for all screening tests 
(FOBT p=0.67; FS p=0.99; TC p=0.10).  
 
7.3.2 Screening-naïve versus screened subjects 
Screened subjects had a more positive attitude towards all screening tests than screening-
naïve subjects (Table 7.3, p<0.001). The differences in preferences regarding RR and 
screening interval between screening-naïve and screened subjects were statistically not 
significant, except for preferences regarding five- and ten-yearly FS screening. The more 
positive attitude of screening-naïve subjects towards longer screening intervals (Five-
yearly p<0.001; ten-yearly p<0.001) indicated that screening naïve-subjects valued 
infrequent screening more positively than screened subjects.  
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Table 7.3  Coefficients of the different tests and test characteristics 
 
Screening test (ref level 'no screening')
   FOBT -0.18 (-0.44-0.08) 0.38 (0.15-0.62)* <0.001
   Sigmoidoscopy 0.30 (0.06-0.54)* 0.94 (0.72-1.16)* <0.001
   Colonoscopy 0.33 (0.08-0.57)* 1.05 (0.84-1.27)* <0.001
Risk reduction of CRC related mortality
   FOBT
       3% to 2.7% (RR 10%) (ref level)
       3% to 2.4% (RR 25%) 0.19 (-0.01-0.38) 0.17 (-0.01-0.34) 0.45
       3% to 1.8% (RR 40%) 0.78 (0.54-1.02)* 0.65 (0.44-0.87)* 0.88
   Sigmoidoscopy
       3.0 to 1.8% (RR 40%) (ref level)
       3.0 to 1.5% (RR 50%) 0.10 (-0.09-0.29) 0.33 (0.16-0.50)* 0.97
       3.0 to 0.9% (RR 70%) 0.65 (0.42-0.89)* 0.65 (0.44-0.86)* 0.08
   Colonoscopy 
       3.0 to 0.8% (RR 75%) (ref level)
       3.0 to 0.5% (RR 85%) 0.16 (-0.03-0.35) 0.19 (0.02-0.36)* 0.95
       3.0 to 0.1% (RR 95%) 0.40 (0.17-0.62)* 0.41 (0.20-0.61)* 0.79
Screening interval
   FOBT
       Four-monthly (ref level)
       Annual 0.73 (0.52-0.93)* 0.64 (0.44-0.83)* 0.50
       Triennial 0.96 (0.72-1.20)* 0.67 (0.46-0.89)* 0.07
   Sigmoidoscopy
       Annual (ref level)
       Five-yearly 0.92 (0.74-1.11)* 0.55 (0.39-0.72)* <0.001
       Ten-yearly 1.14 (0.91-1.37)* 0.56 (0.36-0.75)* <0.001
   Colonoscopy
       Biennial (ref level)
       Five-yearly 0.71 (0.52-0.90)* 0.56 (0.39-0.73)* 0.22
       Ten-yearly 0.72 (0.48-0.95)* 0.42 (0.21-0.63)* 0.06
Screened subjects
Coeff    (95%CI) p-valueAttribute levels
Screening naïve
Coeff     (95%CI)
 
 
 
7.3.3 Differences in preferences between subgroups  
No differences in preferences were found between men and women, apart from a more 
positive attitude towards FS and TC among men (FS p=0.06; TC p=0.02). Men, in 
contrast to women, did prefer FS and TC to no screening (men: FS p<0.001; TC 
p<0.001; women FS p=0.07; TC p=0.84). Respondents’ age, SES and EQ-5D summary 
score did not influence the attitude towards a screening test, interval or RR. Subjects who 
 131 
Chapter 7 
reported to have a close friend or family member with CRC expressed a more positive 
attitude towards TC screening than subjects without (p=0.01). Experience with FS or TC 
was positively associated with the willingness to undergo a TC (p<0.001). Subjects that 
underwent FS screening had a more positive attitude towards FS and TC screening than 
subjects who performed a FOBT (p<0.001). 
 
 
 
 
 
Figure 7.2  Preferences for the different screening strategies at a long (--), intermediate (…) and 
short (__) screening interval and different levels of mortality risk reduction for screening-naïve and 
screened subjects. 
*Preferences for long and intermediate screening interval were similar 
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7.3.4 Trade-offs 
Screening-naïve subjects were, when assuming the same interval (annual) and RR (40%), 
more willing to undergo FOBT than FS screening (preferences: FOBT=1.32; FS=0.30; 
p<0.001). Preferences were similar for a five-yearly FS and an annual FOBT if both tests 
would generate a RR of 40% (preferences: FOBT=1.32; FS=1.23; p=0.40). A five-yearly 
FS was preferred to annual FOBT if FOBT was associated with a less favourable RR than 
FS screening (preferences: FOBT 25%RR = 0.73; FS 40%RR = 1.23; p<0.001).  
A five-yearly FS was preferred to a ten-yearly TC if the difference in RR was 25% in 
favour of TC (e.g. FS = RR 50%; TC =RR 75%; p<0.001). The preferences for a five-
yearly FS and a ten-yearly TC were similar if TC would achieve an additional 35% RR 
(p=0.24), while more than 45% difference in RR was associated with a preference for 10-
yearly TC (p<0.001).  
Screening-naïve subjects equally preferred FS and TC screening, but did prefer both 
endoscopic screening options to FOBT screening if, based on the literature, the most 
realistic screening intervals and mortality reduction were applied (preferences: annual 
FOBT RR 25% = 0.77; five-yearly FS RR 50% = 1.33; ten-yearly colonoscopy RR 85% = 
1.22 ; FS vs. FOBT p<0.001, TC vs. FOBT p<0.001; TC vs. FS p=0.24). 
Screened subjects made similar trade-offs between the screening test, interval and RR as 
screening-naïve subjects. 
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Figure 7.3  Effects of changing the screening programme characteristics on the average 
probability of uptake for respectively FOBT (45%), FS (58%) and TC (58%) in screening-naïve 
subjects. 
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7.3.5 Predicted uptake 
Predicted uptake of screening naïve subjects for FOBT, FS and TC screening was 45%, 
58% and 58% respectively, assuming screening with the reference level for RR and 
screening interval. Based on realistic screening intervals and mortality reduction from the 
literature, these numbers were 68% for FOBT, 79% for FS, and 81% for TC. The 
screening programme characteristics had substantial impact on the expected uptake 
among screening naïve subjects (Figure 7.3).  
 
 
7.4 Discussion 
 
7.4.1 Principle findings 
In this population-based study we found that the type of screening test, screening interval, 
and risk reduction of CRC related mortality significantly influenced individual preferences 
among screening naïve and screening experienced subjects in the target population (aged 
50-74 years old). Both screened and screening-naïve subjects preferred FS and TC to 
FOBT screening if, based on the literature [3-7, 9, 34, 35], the most realistic screening interval 
and risk reduction on CRC related mortality were applied (annual FOBT with 25% RR; 
five-yearly FS with 50% RR, ten-yearly colonoscopy with 85% RR). This underlines the 
importance of adequate information on those aspects of CRC screening to achieve 
informed decision-making by potential screenees. 
Five studies investigated preferences in CRC screening using a DCE [18, 19, 36-38], with two 
studies investigating preferences among available screening tests [19, 36]. This is the first 
DCE including both a screening naïve and screening experienced population. In 
agreement with previous DCE studies, we found that RR dominated preferences for a 
screening test. Both FS and TC screening were therefore preferred to FOBT screening 
when associated with sufficient RR [19, 36].  
The literature on preferences for the optimal screening interval per test is limited. One 
study reported a preference for five or ten-yearly to annual screening irrespective of the 
screening test [36]. However, deciding on screening interval without information on the 
screening test leads to unrealistic choices, since an annual FOBT is less burdensome than 
an annual TC. We therefore used test specific screening intervals, which add to the 
validity of our results. In our study, screened subjects equally preferred intermediate and 
long screening interval for all tests. Reassurance may be a reason for preferring frequent 
screening [39]. However, both intermediate and long interval of all three screening tests 
were preferred to a short interval, suggesting that subjects trade-off between reassurance 
and frequency of undergoing a screening test. 
Men had a more positive attitude towards FS and colonoscopy screening than women. 
This finding is in accordance with FS screening programmes which described a lower 
uptake among women than among men [12, 13, 24]. Known barriers for women to 
participate in endoscopy screening are male endoscopists [40], and anxiety prior to 
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screening [41]. A different approach to inform both sexes on screening or sex-specific 
screening strategies might be considered in a nation-wide screening programme to 
improve acceptance. 
The results of this study may be relevant to predict population preferences for newer 
screening tests with a similar profile or an improved version of a screening test. For 
example, recently randomised trials demonstrated more favourable detection rates for 
FIT than gFOBT [14, 24, 42] suggesting a larger reduction of CRC related mortality. 
According to our data, informing people in the target population about a more favourable 
effect on CRC related mortality of FIT would lead to a higher acceptance of FIT 
screening and most likely a higher uptake.  
Predicted uptake of FS or TC screening based on our model was significantly higher than 
uptake of FOBT screening, given realistic levels. This finding is in contrast to the 
observed higher uptake of FOBT than FS screening in the randomised screening trial 
performed in the same population as this DCE. Screenees in this trial were however not 
specifically informed on test efficacy. This suggests that increasing awareness on the 
efficacy of a screening test may enhance uptake. It is therefore of paramount importance 
to improve the level of awareness on achievable risk reduction of CRC related mortality 
to obtain a higher uptake, especially for the more effective endoscopic screening tests. 
This is further underlined by two European studies. A Swiss study [43], in which the 
majority (75%) of all screenees chose to undergo a TC, and only a small proportion (25%) 
preferred FOBT or FS screening after they were informed about the efficacy of the three 
screening tests. A large population-based Italian study found simialar participation rates 
for FS and FOBT when subjects were offered a choice between both strategies [44]. 
 
 
7.4.2 Strengths and weaknesses of this study 
In contrast to previous DCE studies we used a labelled instead of an unlabelled DCE 
design. In a labelled design the specific screening test is mentioned in each choice option 
(FOBT, FS, TC; Appendix 7.B), while in an unlabelled design the screening test is 
presented as ‘screening test A’, 'B’ or 'C' and is further described by certain characteristics 
that are presented in the choice set. CRC screening tests may evoke individual feelings, 
which can not be described in a questionnaire (e.g. anxiety for an endoscopy). It is 
therefore difficult to adequately convey the essential differences from a subject’s 
perspective between FOBT and endoscopic tests in terms of, for example, ‘more 
burdensome’ or ‘less burdensome’. Using a labelled design, the scenarios are more 
realistic, which adds to the validity of the results. Furthermore, we assessed preferences 
among screening-naïve and screened subjects within the target population (aged 50-74 yrs 
old) including all social economic classes, which adds to the generalisability of the results. 
Experienced subjects stated a more positive attitude towards all screening tests than 
screening-naïve subjects. A selection bias may explain this difference in attitude, as 
experienced subjects have already demonstrated interest in screening and therefore 
express a more positive attitude towards screening. There is however also an experience 
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effect, i.e. anticipated discomfort and pain might be higher than actually experienced. This 
experience might reduce anticipated pain and discomfort for successive screening round. 
Additionally, there may also be an expose effect, i.e. people tend to develop a preference 
merely because they are familiar with it. Our results suggest that subjects who underwent 
screening are willing to return for a successive screening round, which is of vital 
importance for efficacy of a screening programme. Costs of screening were not included 
as a test characteristic in this study. All CRC screening programmes in Europe including 
the Netherlands do not require out-of-pocket costs. Including cost would therefore 
influence the results in an unrealistic manner. A limitation of this study is the significantly 
lower response rate in screening-naïve than in screened subjects. This may have led to 
selection bias and therefore a more positive attitude towards screening in the latter group.  
 
 
7.4.3 Conclusions 
Both screening-naïve and screened subjects stated a more positive attitude towards both 
endoscopic screening strategies than FOBT if, based on the literature, the most realistic 
screening interval and risk reduction on CRC related mortality were applied. Risk 
reduction of CRC related mortality mainly determined the preference for endoscopic 
screening tests. This underlines the importance of awareness on achievable risk reduction 
of CRC related mortality of the different screening test to enhance uptake particularly for 
endoscopic screening tests and to optimise informed choice. 
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Appendix 7.A   
 
 Faecal occult blood 
test 
Sigmoidoscopy Colonoscopy 
Preparation None. - One or two enemas (bowel 
  preparation). 
- No fasting. 
- You have to drink 4 litres of special 
  cleansing solution the day before  
  the procedure.   
- You have to fast for 12 hours prior 
  to the procedure.   
- You cannot work the afternoon 
  prior to and the day of the  
  procedure. 
The procedure 
 
 
 
 
 
How do I carry out the 
test? 
At home, several (1-3) 
samples of stool are 
collected by using the 
test set. The test can be 
returned by mail to the 
laboratory.  
 
What does the test 
measure? 
The test measures if 
there are (in)visible 
traces of blood present 
in the stools.  
 
What happens if the 
test results are 
abnormal?  
You will be advised to 
undergo a colonoscopy. 
 
       
The procedure 
The last 60 cm of the large bowel is 
examined by using a flexible tube with 
a small camera on the tip. This tube is 
inserted through the anus.  
During the procedure the large bowel 
will be filled with air in order to 
carefully examine the bowel. 
 
What do I feel of the investigation? 
Because of the air put into your 
bowel you may feel abdominal 
cramps. 
 
What happens if abnormalities are 
found? 
Precursors of colon carcinoma 
(polyps) are removed during the 
procedure (this is painless). You will 
be advised to undergo a colonoscopy 
to see if there are other abnormalities 
in the remainder large bowel.  
The procedure 
You will be given conscious sedation 
(‘short narcosis’). Therefore, you may 
fall into a light sleep. The entire large 
bowel (100-120 cm) is examined by 
using a flexible tube with a small 
camera on the tip. This tube is 
inserted through the anus.  
During the procedure the large bowel 
will be filled with air in order to 
carefully examine the bowel.  
 
What do I feel of the investigation? 
Due to the air and tube in your bowel 
you may feel abdominal pressure and 
cramps. 
 
What happens if abnormalities are 
found? 
Precursors of colon carcinoma 
(polyps) are removed during the 
procedure (this is painless). 
 
After the 
procedure 
- You can return to your 
daily  
  activities immediately.  
- You may eat and drink again 
  immediately and go home.  
- You may eat and drink again and 
  go home after one hour. 
- You cannot drive a car, ride a 
  motorcycle or bicycle. 
Perceived burden  Low. High. High. 
Results - You will receive the 
result by 
  mail within two weeks. 
- Directly after the procedure. 
- When tissue has been removed, 
  you will receive the pathology 
  results by mail within two weeks. 
- Directly after the procedure. 
- When tissue has been removed, 
  you will receive the pathology 
  results by mail within two weeks. 
Test at home or 
in the hospital 
At home. Hospital. Hospital. 
Total duration of 
the procedure 
30 minutes. 15 minutes. 1 hour and 45 minutes. 
Complications Never. In 1 in 10.000 individuals: severe 
blood loss or a perforation or a tear 
through the bowel wall.   
In 1 in 1.000 individuals: severe blood 
loss or a perforation or a tear through 
the bowel wall.    
    Background information on all screening test as applied to all subjects.
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Choice set 
 
 
 
 
 
 
 
 
 
 
Suppose screening for colon cancer is introduced. Which situation do you prefer?  
(fill in: A, B or C)       □ 
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Chapter 8 
Abstract 
Introduction  In many countries uptake of colorectal cancer (CRC) screening remains 
low.  
Aim  To assess how procedural characteristics of CRC screening programmes determine 
preferences for participation and how individuals weigh these against the perceived 
benefits from participation in CRC screening. 
Methods  A discrete choice experiment was conducted among subjects in the age-group 
of 50 – 75 years, including both screening-naïve subjects as well as participants of a CRC 
screening programme. Subjects were asked on their on preferences for aspects of CRC 
screening programmes using scenarios based on: pain, risk of complications, screening 
location, preparation, duration of procedure, screening interval and risk reduction of CRC 
related death.  
Results  The response was 31% (156/500) for screening-naïve and 57% (124/210) for 
CRC screening participants. All aspects proved to significantly influence the respondents’ 
preferences. For both groups combined, respondents required an additional relative risk 
reduction of CRC related death by a screening programme of 1% for every additional 10 
minutes of duration, 5% in order to expose themselves to a small risk of complications, 
10% to accept mild pain, 10% to undergo preparation with an enema, 12% to use 0.75 
litres of oral preparation combined with 12 hours fasting and 32% to use an extensive 
bowel preparation. Of note, screening intervals shorter than 10 years were significantly 
preferred to a 10-year screening interval. 
Conclusions  This study shows that especially type of bowel preparation, risk reduction 
and length of screening interval influence CRC screening preferences, improving 
awareness on CRC mortality reduction by screening may increase CRC screening uptake.  
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8.1  Introduction 
Colorectal carcinoma (CRC) is the second most frequently occurring malignancy in the 
European Union, and the second leading cause of cancer related death in the Western 
world [1]. A recent study demonstrates that for many European countries CRC mortality 
rates are decreasing while incidence is rising, suggesting an increasing CRC prevalence [2]. 
CRC screening is effective in reducing CRC mortality [3-11]. Screening can reduce CRC 
mortality by early detection of CRC and endoscopic removal of premalignant precursors 
of CRC (adenomas) [5, 11, 12]. There are several methods available for CRC screening. The 
various types of faecal occult blood tests (FOBTs) primarily aim at the early detection of 
CRC, whereas endoscopic and radiologic screening tests (flexible sigmoidoscopy (FS), 
colonoscopy) are effective at both early detection and removal of premalignant lesions [12]. 
Different screening methods are expected to have a different impact on CRC mortality 
reduction due to these differences in preventive potential. CRC screening methods also 
differ with respect to procedural characteristics, which determine the subject’s burden of 
a screening method. CRC screening methods perceived as the most burdensome (FS, 
colonoscopy) also have the largest potential for prevention of CRC [12]. Currently, 
insufficient evidence is available to recommend one screening method over another.  
Attendance is an important determinant of the effectiveness of CRC screening 
programmes. Uptake of CRC screening in a pilot screening programme in the 
Netherlands has remained lower than uptake of breast and cervical cancer screening [13-15]. 
In many countries, uptake of CRC screening, as well as continuing adherence to CRC 
screening, has also remained suboptimal [3, 4, 13, 16-18]. It has been established that increasing 
colorectal cancer screening uptake, in comparison with other targets, has a large potential 
for reducing CRC related mortality [19]. Attendance rates depend on the willingness of 
individuals to undergo a certain screening test. This willingness may be influenced by 
perceived advantages and drawbacks of CRC screening tests and furthermore, by 
knowledge and awareness of CRC, CRC risk and CRC screening [18, 20, 21]. Individuals may 
be willing to undergo a screening test despite several drawbacks in order to maximize 
health benefit or vice versa (to accept a lower health benefit in order to avoid several 
burdensome test characteristics). To optimise a CRC screening programme it is of 
paramount importance to gain insight in factors that influence population preferences for 
CRC screening programmes and the trade-offs individuals are willing to make between 
benefits and drawbacks of a CRC screening programme. Research has shown that patient 
preferences can have a major impact on their willingness to use services and furthermore, 
there is an increasing emphasis on involvement of patients in health care decisions [22].   
This study therefore investigated preferences for CRC screening using a discrete choice 
experiment (DCE). DCE is a survey methodology with its origin in market research. 
DCEs are widely used for the assessment of preferences in transport and environmental 
economics and marketing research [23]. They are increasingly used for health care purposes 
[24, 25]. 
It  has been  demonstrated that awareness of CRC and CRC screening in the Netherlands 
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has remained low [21]. There is currently no organised CRC screening programme in the 
Netherlands, except for hereditary or familial CRC. A similar situation is encountered in 
many countries in the EU, in fact, only approximately 50% of the target population is 
offered any type of screening for CRC. It is of particular importance to study preferences 
in a screening naïve population, since they may guide the introduction and adjustment of 
new CRC screening programmes in these countries.  
The aim of our study was to determine how procedural characteristics of various CRC 
screening methods determine preferences for participation, and how individuals weigh 
these against the expected health benefits from CRC screening. We compared the relative 
importance of aspects of the three most commonly used CRC screening tests: FOBT, FS 
and colonoscopy.  
 
 
 
8.2  Materials and methods 
 
8.2.1 Study population 
We conducted the study in two groups. The first group included a total of 500 screening-
naïve individuals aged 50-74 years old who were randomly selected from the population 
registry of the region Rijnmond in the Southwest of the Netherlands. The region includes 
Rotterdam and surrounding suburbs and harbours 338,000 inhabitants in the target age 
groups. The second group included 210 participants of a randomised screening trial for 
CRC in the Netherlands from the same target population as mentioned above. This 
screening trial invited average risk individuals to participate in a CRC screening 
programme with guiac-based FOBT (gFOBT), faecal immunochemical test (FIT) or FS 
[26]. 
 
8.2.2 Invitation of subjects 
Subjects were contacted by mail. They received a questionnaire and an information 
brochure with general and background information about CRC and CRC screening. 
Individuals could return the questionnaire in a postage-paid self-addressed envelope that 
was included in the mailing package. A reminder was sent four weeks later in case of non-
response.  
 
8.2.3 DCE 
DCE is a formal technique to assess preferences, assuming that a healthcare intervention 
(e.g. a screening programme) can be described by its characteristics (attributes; e.g. test 
duration) [27].  Those attributes are further specified by variants of that attribute (levels; 
for test duration: 10, 20, 30 minutes). The DCE assumes that the individual preference 
for a test is determined by the levels of those attributes [27]. Individuals are presented with 
144 
What determines individuals’ preferences for colorectal cancer screening programmes? 
a number of choice sets containing several scenarios (screening programmes). Those 
programmes are described by several attributes with varying levels (Figure 8.1). The 
results of a DCE provide information on the relative importance of the attributes and the 
trade-offs individuals are willing to make between these attributes. The DCE design will 
be explained in more detail further on. 
 
 
8.2.4 Attributes and attribute levels 
The attributes and attribute levels of the DCE were derived from literature review, expert 
opinions, interviews with screening naïve (n=10) and screened (n=10) individuals of the 
target population. In the interviews we asked individuals to point out which of these 
attributes they expected to be important or had been important in their decision to 
participate in a CRC screening programme. The attributes identified as most relevant 
were: pain, risk of complications, location of the screening test, preparation for the 
procedure, duration of the procedure, screening interval and risk reduction of CRC 
related death (Table 8.1). Attribute levels were derived from the literature. The levels for 
each attribute incorporated the range of characteristics or possible test outcomes of all 
different screening methods (FOBT, FS and colonoscopy). The attribute ‘interval’ was 
related to a CRC screening programme, the other attributes were test-related. 
 
 
 
Choice options: Screening A Screening B No screening
Preparation: Enema, no fasting
Drinking 0.75l of 
fluid, 12 hours 
fasting
None 
Location: At home Hospital None 
Pain: None Mild pain None 
Risk of complications: None Small None
The chance of dying from 
colon cancer decreases from:
3%    to   1.8% 3%    to    1.2% remains 3%
In the following 10 years you 
will undergo the test:
5x 2x 0x
Duration: 30 min 60 min None 
Which screening programme     
do you prefer?
□ A □ B □ None
 
 
Figure 8.1 Choice set example 
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Table 8.1  Attributes and levels for CRC screening 
 
 Coefficient in regression analysis 
No pain (reference level)
Mild pain β1
Risk of complications
None (reference level)
Small β2
Location 
At home (reference level)
Hospital β3
Preparation
None (reference level)
Enema, no fasting β4
Drinking of 0.75l of fluid, 12h fasting β5
Drinking of 4l of fluid, 18h fasting β6
Duration β7 
10 min
30 min
60 min
90 min
Interval
1x in 10 years (reference level)
2x in 10 years β8 
5x in 10 years
10x in 10 years β10 
Risk reduction of death from CRC β11 
3% to 2.7% (10% relative risk reduction)
3% to 1.8% (40% relative risk reduction)
3% to 1.2% (60% relative risk reduction)
3% to 0.3% (90% relative risk reduction)
Attributes and levels 
Pain
 
 
 
8.2.5 Study design and questionnaire 
The design contained three attributes with two levels and four attributes with four levels. 
The combination of those attributes and levels resulted in 2048 (i.e. 23 * 44) possible test 
scenarios. Since it is not feasible to present a single individual with all these scenarios, we 
reduced the model to 16 scenarios (a fractional factorial design) by means of a website, 
containing a library of orthogonal arrays [28]. These 16 scenarios were used to create 16 
choice sets. Each choice set contained two screening programmes and an opt-out (the 
option to choose ‘no screening’, see Figure 8.1). A special technique (fold-over [29]) was 
used to create the second programme of each choice set. As a result, our design was an 
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efficient orthogonal design; there was no correlation between any pairs of attributes 
(orthogonality), all levels of each attribute were represented in the same frequency (level 
balance), and similar levels of an attribute did not occur within the same choice set 
(minimal overlap). A rationality test was included in the DCE to investigate the 
understanding of the questionnaire. This was a choice set of which one screening 
programme was logically preferable over the other given the attribute levels. 
The questionnaire further contained questions on background variables (e.g. generic 
health status (EQ-5D [30])) and a question assessing experienced difficulty of the 
questionnaire (5-point scale). A written description of the attributes and levels was given 
at the beginning. We conducted a pilot study (n=20) to ascertain respondents could 
manage the length of the questionnaire and to examine the intelligibility, acceptability and 
validity of the questionnaire.  
The study was approved by the Medical Ethical Committee of the Erasmus MC (MEC, 
MEC-2007-224). 
 
 
8.2.6 Analyses 
Each choice between three options (two screening programmes and the opt-out) was 
considered as a specific observation. A multinomial logit model was used to analyse the 
data. Individuals who failed the rationality test were not excluded from analyses.  
We assumed that there was no linear relationship between the different levels of the 
attributes ‘preparation’ and ‘screening interval’ and that all attributes had independent 
effects on preferences. On this basis, we estimated the following model for the DCE:  
 
 
U = V + ε  = β0 + β1 pain + β2 complications + β3 location + β4 enema + β5 0,75lfluid 
+ β6 4lfluid + β7 duration + β8 interval2+ β9 interval5 + β10 interval10 + 
β11 mortalityreduction + ε 
 
U represents the preference for a (hypothetical) CRC screening programme. V (β0.….β11 
mortalityreduction) is the observable utility that is composed of the preference scores for 
the individual β-coefficients of the model. The constant term (screening programme; β0) 
is an ‘alternative specific constant’ and indicates the relative weight individuals place on 
screening programmes compared to no screening. β1-β11 are coefficients of the attributes 
indicating the relative weight individuals place on a certain attribute(level). ε is the random 
component to the analysis, accounting for unobserved or unobservable components of 
choice. The value of each coefficient represents the importance respondents assign to a 
certain level. However, different attributes utilise different units of measurement. For 
example, the coefficient for ‘risk reduction of death from CRC’ represents the importance 
per relative 10% risk reduction. When looking at a screening programme that generates a 
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50% risk reduction, the coefficient should be multiplied five times in order to enable 
comparison to the coefficients of other levels. An attribute with a two sided p-value 
smaller than 0.05 was considered to be important in the decision to participate in a certain 
screening programme. 
Given the current controversy in the literature on whether to include individuals who 
failed the rationality test or not, the impact of removing respondents who failed the 
rationality test was explored by removing such individuals from the sample and rerunning 
the analysis. The results of the model indicated that removing irrational respondents had 
no major impact on the size or relative importance of the attributes, except for the 
attitudes of CRC screening participants towards preparation with ‘0.75 litres of fluid’. We 
therefore included individuals who failed the rationality tests as currently advised in the 
DCE literature [31, 32]. 
The trade-offs respondents were willing to make between the attributes were calculated 
by the ratios of the coefficients of the different attributes with risk reduction as the 
denominator. For example, β1/β11 indicates how much additional relative risk reduction 
respondents think a test should generate in order to undergo a test that causes mild pain 
instead of a test that causes no pain.  
To examine the expected uptake of CRC screening based on our results, we applied the 
model as presented by Gerard and colleagues and Hall and colleagues to our data [33, 34].  
 
 
                               1 
                                                              (1 + e ^ -V) P = participation 
 
 
 
The model assumes that a preference score of 0 indicates that individuals have an equal 
preference for either participation or non-participation, hence the expected participation 
rate equals 50%. Additionally we investigated the effect of changing the most important 
CRC screening programme characteristics, as identified by the results or our multinomial 
logit model, on the expected uptake of CRC screening. 
Aggregate data on socio-economic status (SES) were available at the level of the 
respondents’ area zip code, weighted by the number of inhabitants per postal code and 
classified into three groups (high, average, low).  
Characteristics of the different groups were compared using parametric and non-
parametric tests. For categorical data, we used Chi-square and Fisher Exact Test to test 
for differences between screening naïve individuals and CRC screening participants. For 
continuous variables, we used the independent Samples T-test. To assess whether there 
were differences in preferences among participants of the FOBT (either gFOBT or FIT) 
and FS screening programme and those with and without endoscopy experience, we 
performed subgroup analyses.  
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Table 8.2  Respondent characteristics 
 
Characteristics Screening naïve Participants Difference
Respons (n respondents/n invited - %) 156/500 (31.0) 124/210 (59.0) p<0.01
Analyzable questionnaires (n - %) 152 (97.4) 120 (96.8) p=0.74
Age (mean - SD) 59.9 (5.7) 62.2 (6.4) p<0.01
Gender (male; n - %) 74 (48.7) 59 (49.2) p=0.94
Socio economic status (n - %)
        High 78 (51.3) 53 (44.2)
        Intermediate 21 (13.8) 20 (16.7)
        Low 53 (34.9) 47 (39.2)
Endoscopy experience (n - %)
        Yes 33 (21.7) 64 (53.3)
        No 117 (77.0) 54 (45.0)
        Unknown 2 (1.3) 2 (1.5)
Knowing someone affected by CRC (n - 
%)
        Yes 19 (12.5) 18 (15.0)
        No 115 (75.7) 88 (73.3)
        Unknown 18 (11.8) 14 (11.6)
EQ-5D summary score (mean - SD) 0.92 (0.11) 0.93 (0.12) p=0.48
p=0.49
p<0.01
p=0.84
 
 
 
 
8.3  Results 
 
8.3.1 Respondents 
The response rate was higher among CRC screening participants (59%; 124/210) 
compared to screening naïve individuals (31%; 155/500) (Table 8.2). The characteristics 
of the respondents are shown in Table 8.2. Among the screening naïve group, 22% had 
undergone an endoscopy in the past. Within the group of CRC screening participants, 
53% had previous endoscopy experience including 23% (16/70) of FOBT screenees and 
logically all FS screening subjects (48/48).  
149  
Chapter 8 
8.3.2 DCE results 
Forty-three percent of the screening-naïve individuals and 50% of the CRC screening 
participants rated the questionnaire as ‘ easy’ (p=0.24).  
The signs of all coefficients of the attributes were consistent with our initial hypotheses 
(see Table 8.3). The positive sign given to the coefficient ‘risk reduction of death from 
CRC’ indicated that respondents preferred a test generating a higher risk reduction over a 
test that generates a lower risk reduction. The positive sign of the coefficients for shorter 
screening intervals indicated that individuals preferred those screening intervals over 
screening once every 10 years. The negative signs for all other attributes indicate that 
individuals preferred a screening test of shorter duration, with no preparation, no pain, 
and no risk of complications.  
 
Table 8.3  Preferences of the screening naïve individuals and CRC screening participants  
 
β-coeff 95% CI β -coeff 95% CI
0.25 (-0.00 to 0.50) 0.62 (0.35 to 0.90)*
No pain (ref)
Mild pain -0.31 (-0.42 to -0.20)* -0.23 (-0.34 to -0.11)*
None (ref)
Small -0.16 (-0.28 to -0.05)* -0.13 (-0.25 to -0.01)*
At home (ref)
Hospital -0.09 (-0.20 to 0.02) -0.01 (-0.13 to 0.10)*
-0.37 (-0.57 to -0.16)* -0.23 (-0.45 to -0.02)*
-0.51 (-0.72 to -0.29)* -0.22 (-0.45 to 0.01)  
-0.98 (-1.18 to -0.77)* -0.88 (-1.10 to -0.67)*
-0.03 (-0.05 to -0.01)* -0.03 (-0.06 to -0.01)*
1x in 10 years (ref)
0.28 (0.11 to 0.45)* 0.24 (0.06 to 0.42)*
0.4 (0.21 to 0.59)* 0.33 (0.13 to 0.53)*
0.33 (0.18 to 0.49)* 0.27 (0.10 to 0.44)*
0.32 (0.29 to 0.35)* 0.26 (0.24 to 0.29)*
* significant at the 5% level; (ref) = reference level; β-coeff = β-coefficient; CI = confidence interval
     2x in 10 years
     5x in 10 years
     10x in 10 years
Risk reduction of death from CRC 
(per relative 10% risk reduction)
     Drinking 0.75l fluid.12h fasting
     Drinking 4l fluid. 18 h fasting   
Duration (per 10 min)
Interval
Risk of complications
Location
Preparation
     Enema. no fasting
Screening naïve Participants
Pain
Constant (screening)
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The non-significant coefficient of the constant term in the screening-naïve group 
indicated that these subjects had, if assuming a screening programme with the reference 
level for all the attributes, no preference for either screening or no screening, whereas the 
group of CRC screening participants expressed a positive attitude towards screening 
compared to no screening (positive significant coefficient). All screening attributes proved 
to be important determinants of the preferences in each of the respondent groups, except 
for location of the screening test, which only significantly influenced preferences of CRC 
screening participants and not those of the screening naïve individuals and a preparation 
with ‘0.75 litres of fluid and 12 hours fasting’, that did not influence preferences of CRC 
screening participants. 
The differences in preferences between screening naïve-individuals and participants of a 
CRC screening programme statistically not significant, except for preferences regarding 
risk reduction of CRC related death. Screening naïve individuals demanded more 
effectiveness from a CRC screening programme compared to participants (p<0.01). We 
performed subgroup analyses, analysing FOBT and FS screenees separately, which 
showed that participants of FOBT and FS screening did differ in preferences: FS 
screenees expressed a positive attitude, while FOBT screenees expressed a negative 
attitude towards a test in the hospital (p<0.001). Furthermore, FS screenees attached 
more importance to a 5-yearly screening interval (p=0.01) and to the effectiveness of a 
screening test (p<0.001) than FOBT screenees.  
When comparing those with previous endoscopy experience to those without endoscopy 
experience, it could be seen that pain had a significant greater influence on preferences 
for those without previous endoscopy experience (p=0.02). The location hospital was 
negatively associated with preferences for those without endosocpy experience, but it had 
a positive affect on preferences for those who had undergo a previous endoscopy 
(difference: p<0.01). Individuals without endoscopy experience also demanded more 
effectiveness from a screening test (p<0.01). 
Screening naïve individuals and CRC screening participants significantly preferred no 
preparation to all other preparations (p-values <0.03). Both groups significantly preferred 
preparation with an ‘enema’  or ‘0.75 litres of fluid’ instead of a preparation with ‘4 litres 
of fluid’ (p-values <0.001). Preparation with an ‘enema’ and ‘0.75 litres of fluid’ were 
valued equally by both groups (p-values > 0.09). 
 
 
8.3.3 Trade-offs 
It can be seen in Table 8.4, that based on the expressed preferences, screening-naïve 
individuals required an additional relative risk reduction of 30% (95% confidence interval 
(CI) 24-37%) for participation in a screening programme with a test requiring a 
preparation with ‘4 litres of fluid and 18 hours fasting’ instead of a test that required ‘no 
preparation’. Respondents preferred shorter screening intervals and they were willing to 
give  up a 12% (CI 7-18%)  relative risk reduction if  the  screening  interval  was  shortened  
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from once every 10 years to a 2-yearly screening interval. Participants of a CRC screening 
programme made trade-offs that were comparable to those of the screening naïve 
individuals.  
 
 
8.3.4 Expected uptake of CRC screening 
The average expected uptake of CRC screening was 56% (CI 50-62%) for screening naïve 
individuals. If we calculate the expected uptake for a screening programme without taking 
into account risk reduction of CRC related death and screening interval it would be 55% 
for the FOBT, 31% for FS and 17% for colonoscopy. This corresponds well to the 
participation rates as observed in the Dutch pilot screening programme (gFOBT 49.5% 
(CI 48.1-50.9%); FIT 61.5% (CI 60.1-62.9%); FS 32.4% (CI 31.1-33.7%) [13]. Assuming 
that all screening tests would generate a 10% risk reduction of CRC related death, uptake 
would increase to 72% for biennial FOBT screening , 46% for 5-yearly FS screening and 
22% for 10-yearly colonoscopy screening. We would expect that, if individuals are aware 
of the achievable risk reduction as currently known from the literature, the uptake would 
increase to 75% for biennial FOBT screening, 80% for five-yearly FS screening and 71% 
for 10-yearly colonoscopy screening (risk reduction of CRC related death respectively 
16% [35], 59% [5] and 74.5% [36]. The effects of changing the CRC screening programme 
characteristics on average expected uptake of CRC screening are shown in Figure 8.2. 
 
 
 
8.4 Discussion 
Our study demonstrates the importance of several procedural characteristics of CRC 
screening programmes for the preferences of potential and actual screenees: risk 
reduction of CRC-related death, preparation for the procedure, procedure related pain 
and complications and screening interval. To optimise a screening program, the 
attendance rate should be high. A high attendance rate is only possible when the utilised 
screening strategy and the information given connect with the preferences of the target 
population. The results of this DCE in the first place indicate targets for improvement of 
CRC screening programmes. Secondly they stress the importance of several aspects of 
screening programmes regarding the information provided to screening invitees. To our 
knowledge, this is the first study assessing preferences for CRC screening among both 
screening-naïve subjects and CRC screening participants.  
In our DCE, especially mortality reduction had an important positive influence on 
preferences for CRC screening methods. A few other studies have investigated 
preferences for CRC screening using a DCE [37-42]. Our finding that individuals attach 
much importance to CRC mortality reduction by a screening method is consistent with 
the results of previous studies [37, 42, 43]. The finding that individuals are prepared to 
undergo  more  burdensome  screening  tests  if  this  results  in  sufficient  additional risk 
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reduction of CRC related mortality demonstrates that they trade benefits and harms of a 
screening test.  
The burden of the required preparation was considered the main drawback of undergoing 
CRC screening. A preparation commonly used for colonoscopy (i.e. drinking 4 litres of 
fluid and 18 hours fasting) would only be chosen when an additional relative risk 
reduction of, on average, 33% would be achieved. In line with our results, Canadian 
investigators found that preparation was ranked as the most important process related 
attribute. In contrast, American investigators found that preparation was rated as the least 
important attribute [38]. The levels that were chosen for the attributes may explain those 
differences. The results of our DCE are of utmost importance when for example starting 
a colonoscopy screening programme with a burdensome preparation. Emphasis should 
be laid on adequate information that should be provided to the target population about 
the burden and benefits including expected CRC mortality reduction by colonoscopy 
screening, since this may compensate for a burdensome preparation. 
Interestingly, we found that respondents significantly preferred shorter screening intervals 
to a 10-year screening interval irrespective of health benefit. This finding is consistent 
with a previous study suggesting that women preferred shorter (annual and biennial) over 
longer (3-, 4- or 5-year) screening intervals for cervical cancer screening [44]. One study 
among Danish individuals and another among both American and Canadian individuals 
could not confirm preferences for shorter CRC screening intervals [37, 41]. A second 
American study could not determine if individuals preferred shorter or longer screening 
intervals [38]. Several studies have showed that reassurance may be a motivation for 
and/or a result of undergoing cancer screening [45, 46]. The preference for shorter 
screening intervals found in our study may be associated with expected reassurance. This 
again stresses the importance of adequate information provided to potential screenees. It 
emphasises the need to adequately inform individuals that longer screening intervals for 
CRC screening do not imply lower reductions in mortality, but that specific CRC 
screening tests with longer screening intervals have more potential for CRC prevention 
and therefore require less frequent testing. 
There were some differences in preferences between FOBT and FS screenees. 
Assessment of preference variations across subgroups is advisory because of status quo 
bias; in other words the tendency of people to value services higher once they have 
experienced them [47]. We conducted the study among both screening-naïve individuals 
and individuals who had prior experience with CRC screening tests, so that we were able 
to investigate if status quo bias was present. The preferences of screening-naïve subjects 
and participants of a CRC screening programme were not significantly different. The fact 
that FOBT screenees expressed a negative attitude towards a test in the hospital, while FS 
screenees expressed a positive attitude towards a test in the hospital may be explained by 
the phenomenon of status quo bias. However, it may also be a result of selection bias; 
that those subjects with a preference for the location ‘home’ do not participate in FS 
screening and vice versa. Interestingly, the same significant difference regarding the 
influence of screening location on preferences was observed when comparing those with 
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endoscopy experience to those without. A possible explanation might be that individuals 
on beforehand have a negative association with the location hospital, but develop a 
positive attitude towards a hospital-based examination once they have experienced it.   
Research has consistently shown that expected pain is one of the most important reasons 
for declining the endoscopic screening offer [18, 48, 49]. The results from our study confirm 
that finding and furthermore they demonstrate that pain has significant less influence on 
preferences of those with endoscopy experience, suggesting that pain actually experienced 
during endoscopic screening is not as severe as expected on beforehand.  
This study revealed uptake levels of the FOBT, FS and TC based on the characteristics in 
our model. We found that mainly risk reduction of CRC related death highly influenced 
the participation that could be expected for the different screening tests. If we took into 
account the fact that individuals in the randomised screening trial were not informed on 
achievable risk reduction or required frequency of testing, the uptake as calculated by the 
model corresponded to the results found in the screening trial [13]. However, participation 
rates based on our model increased if risk reduction of CRC related death increased, 
suggesting that increasing awareness on efficacy of the screening tests might enhance 
uptake.  
Given the low levels of awareness of CRC screening in the Netherlands, it may be of vital 
importance to raise knowledge on achievable risk reduction of CRC related death in order 
to increase screening uptake especially for the more effective endoscopic screening tests. 
The importance of awareness on efficacy of the available screening tests is further 
underlined by data of a Swiss study, in which 75% of all screenees chose to undergo a TC 
and only 25% preferred FOBT or FS screening after they were informed about the 
efficacy of all screening methods [50]. This study involved testimonies from patients with 
CRC in their campaign in order to raise CRC awareness. This strategy has also been used 
in various other campaigns throughout the European Union, among others in the United 
Kingdom, Germany and the Netherlands. CRC patients and their relatives may be 
important advocates for raising awareness, and possibly also for increasing public 
familiarity with endoscopic screening which has been demonstrated to influence CRC 
screening preferences in our study. 
There are some limitations to our study. The way we framed the information on risk 
reduction may have influenced our results.  
Furthermore, there was a significant difference in response rate between screening-naïve 
individuals and CRC screening participants. This may have given a selection bias and 
thereby be a limitation regarding the interpretation of our results.  
In conclusion, individuals are willing to trade-off benefits and harms of CRC screening 
programmes. Especially type of bowel preparation, length of screening interval and 
mortality reduction influenced individuals’ trade-offs. The results provide insight in the 
decision-making process regarding the decision to participate in a CRC screening 
programme. This information can be used to improve information provided to CRC 
screening invitees, and identify targets for increasing participation rates.  
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Chapter 9 
Abstract 
Objectives Discrete choice experiments (DCE) in health economics commonly present 
choice sets in an unlabelled form. Labelled choice sets are less abstract and may increase the 
validity of the results. We empirically compared the feasibility, respondents’ trading 
behaviour, and convergent validity between a labelled and an unlabelled DCE for 
colorectal cancer (CRC) screening programs in the Netherlands. 
Methods A labelled DCE version presented CRC screening test alternatives as ‘fecal 
occult blood test’, ‘sigmoidoscopy’, and ‘colonoscopy’, whereas the unlabelled DCE 
version presented them as ‘screening test A’ and ‘screening test B’. Questionnaires were 
sent to participants and non-participants in CRC screening. 
Results Total response rate was 276/712 (39%) and 1,033/2,262 (46%) for unlabelled 
and labelled DCEs respectively (p<0.001). The labels played a significant role in 
individual choices; approximately 22% of subjects had dominant preferences for 
screening test labels. The convergent validity was modest to low (participants in CRC 
screening: r=0.54; p=0.01; non-participants: r=0.17; p=0.45), largely due to different 
preferences for screening frequency. 
Conclusions This study provides important insights in the feasibility and difference in 
results from labelled and unlabelled DCEs. The inclusion of labels appeared to play a 
significant role in individual choices, but reduced the attention respondents give to the 
attributes. As a result, unlabelled DCEs may be more suitable to investigate trade-offs 
between attributes and for respondents who do not have familiarity with the alternative 
labels, whereas labelled DCEs may be more suitable to explain real life choices such as 
uptake of cancer screening.  
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9.1 Introduction 
Estimates of public and patients’ preferences are of great importance to inform policy 
decision making and improve adherence with public health care interventions or 
programs [1]. Discrete choice experiments (DCEs) have become a commonly used 
technique in health economics to elicit preferences. The DCE is an attribute-based survey 
method for measuring benefits (utility) [2]. In a DCE, subjects are presented with a 
sequence of (hypothetical) scenarios (choice sets) and are asked to choose between two or 
more competing alternatives that vary along several characteristics or attributes of interest 
[2]. DCEs assume that subjects’ preferences (as summarized by their utility function) are 
revealed through their choices [2]. (For further details see Bliemer and Rose [3]; Hensher et 
al. [4]; Louviere et al. [5]; and Ryan et al. [2]). 
A fundamental question that arises in the application of DCE is whether to present the 
choice sets in a labelled or unlabelled form. The unlabelled form involves assigning 
unlabelled alternatives in the choice set, such as ‘alternative A’, ‘alternative B’ and so on. 
The labelled form involves assigning labels that communicate information regarding the 
alternative. In marketing applications, labels tend to consist of brand names and logos, 
which consumers have learnt to associate with different product characteristics and 
feelings. In the context of health economics, labels tend to consist of generic or brand-
name medications, specific screening tests (e.g. colonoscopy, sigmoidoscopy), specific 
treatments (surgery vs conservative), or other descriptors. An advantage of assigning 
labels is that alternatives will be more realistic and the choice task less abstract for the 
subject, which add to the validity of the results. Hence, the results may be better suitable 
to support decision-making at policy level. However, by far most commonly applied 
DCEs in health economics used unlabelled alternatives.  
The aim of our study was to empirically compare the feasibility, respondents’ trading 
behaviour, and convergent validity between a labelled and an unlabelled DCE. All of 
these aspects were explored in the context of a DCE study directed at investigating 
population preferences for colorectal cancer (CRC) screening programs in the 
Netherlands. We were convinced that specific aspects of endoscopy (sigmoidoscopy, 
colonoscopy) or fecal occult blood test (FOBT) that determine its burden could not be 
totally captured by presenting an unlabelled ‘screening test A’ variant to patients [6]. For 
that very reason, we expected differences between an unlabelled and a labelled DCE. 
The paper is structured as follows. The theoretical basis of labelled and unlabelled DCEs 
is briefly reviewed in Section 9.2. The methods including the case study are then 
presented in Section 9.3, and the results are presented in Section 9.4. Finally, a discussion 
and conclusions are drawn. 
 
 
9.2 Theoretical basis of labelled and unlabelled DCEs 
The aim of discrete choice modeling is to estimate the weights that respondents place on 
attributes of alternatives. An individual acting rationally is expected to evaluate the set of 
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available alternatives and will choose that alternative which gives the greatest relative 
utility [4]. Thus, an individual will choose alternative A over B, if U (XA, Z) > U (XB, Z), 
where U represents the individual’s indirect utility function from certain alternatives, XA 
the attributes of alternative A, XB the attributes of alternative B, and Z socioeconomic 
and other characteristics of the individual that influence his/her utility. Choices made in 
DCEs are analyzed using random utility theory (i.e. an error term is included in the utility 
function to reflect the unobservable factors in the individual’s utility function) [4]. Thus, an 
individual will choose alternative A over B, if V (XA, Z) + εA > V (XB, Z) + εB, where V 
is the measurable component of utility estimated empirically, and εA and εB reflect the 
unobservable factors in the individual’s utility function of alternative A and B respectively 
(XA, XB and Z defined as above).  
There are two general types of DCEs: 1) unlabelled and 2) labelled DCEs [5]. Unlabelled 
DCEs use generic titles for the alternatives (e.g. radio-imaging ‘A’ or ‘B’). Labelled DCEs 
use alternative-specific titles for the alternatives (e.g. ‘computer tomography’ or ‘MRI-
scan’). The number of alternatives (irrespective labelled or unlabelled) in a choice set is 
unrestricted from a theoretical point of view [4]. The decision as to whether to use labelled 
or unlabelled DCEs is an important one [4]. The labelled alternative itself conveys 
information to respondents. This matters in choice and other decision tasks, because (a) 
respondents may use labelled alternatives to infer information that they perceive as 
missing, and (b) these inferences may be (and usually are) correlated with the random 
component [5]. Although we may not exactly know what respondents find relevant in the 
label, for forecasting uptake of, for example, a health care intervention it may be 
worthwhile to find out if respondents prefer one alternative label to another. A labelled 
DCE can take effects into account, which respondents may have learnt to associate with 
different health care intervention characteristics and feelings, and as a result may be more 
suitable to predict [6]. Unlabelled and labelled DCEs both have their merits. If each of the 
labelled options has A attributes with L levels and the choice sets are of size M then there 
are L^MA possible choice sets assuming that all labels are presented in a choice set and 
that the same label does not appear more than once in a choice set. If the options are 
unlabelled then there are L^A possible items that can be included in each position of each 
choice set. If the choice sets are of size M and we are not going to allow the same item to 
appear more than once in a choice set then there are "L^A choose M" possible choice 
sets of size M Therefore the designs of an unlabelled DCE can be much smaller. For 
example, two alternatives with 4 attributes and 3 levels yields 6561 (i.e. 3(2*4) = 38) possible 
alternative combinations for a labelled DCE compared with ‘just’ 81 (i.e. 34) possible 
alternative combinations for an unlabelled design. Other merits of unlabelled DCEs 
include that they 1) do not require the identification and use of all alternatives within the 
universal set of alternatives; namely, the attribute levels are sufficiently broad to represent 
all alternatives; and 2) might be more robust in terms of not violating IID-assumption (i.e. 
error terms are independent and identically distributed), because the alternatives may be 
less correlated with the attributes as in labelled DCEs  [4]; and 3) encourage respondents 
to choose an alternative by trading-off attribute levels, which may be desirable from a 
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non-market valuation perspective [7]. On the other hand, merits of using labelled DCEs 
include that they 1) will be more realistic and less abstract, so that responses may better 
reflect the real preference structure; and 2) can study the main effect of the labels.  
 
 
9.3  Methods 
 
9.3.1 Case study 
Colorectal carcinoma (CRC) is the most frequently occurring malignancy within the 
European Union, and the second leading cause of cancer related death in the Western 
world [8, 9]. Various countries have implemented a national screening program for CRC 
screening to detect CRC in an early stage or are investigating prerequisites for 
implementation [10, 11]. There are several screening tests eligible for use as a population-
based screening program such as fecal occult blood tests (FOBTs), sigmoidoscopy, or 
colonoscopy. The DCE study aimed at investigating individual preferences for CRC 
screening.  
 
9.3.2 Discrete choice experiment design 
The questionnaire design phase involved extensive background research, expert opinions 
and interviews with screened individuals. Experts (n=3) were asked to comment on a list 
of test characteristics derived from our extensive literature review. Potential screenees 
(n=40), both participants of a CRC screening program (n=20) and screening naïve 
individuals (n=20), could also comment on the list of test characteristics and rank them in 
order of importance. Based on these data we selected the most important test 
characteristics. The levels for each test characteristic incorporated the range of possible 
test outcomes based on the current literature (for more detail how the qualitative data was 
used to select the final test labels, attributes and levels see Hol et al. [12]; and Van Dam et 
al. [13]). Table 9.1 lists the labels, attributes, and attribute levels chosen. The labelled CRC 
screening tests (‘FOBT’, ‘sigmoidoscopy’, and ‘colonoscopy’) may evoke individual 
feelings, which may not be captured in the unlabelled CRC screening tests (‘CRC 
screening test A’ and ‘CRC screening test B’). Notably, the invasiveness of the alternative 
test was (indirectly) described by the levels of five attributes: ‘side effects of the test’, 
‘complication risk of the test’, ‘preparation for the patient’, ‘location of screening’, and 
‘the duration of screening’. Giving directly the information ‘how a sample is taken’ is in 
our case totally equal to the screening test label: ‘taking a sample from your motion’ is 
equal to FOBT, and ‘tube into your back passage throughout your colon’ is equal to 
colonoscopy. If the unlabelled DCE would include directly this information about ‘how 
the sample is taken’ (thus actually naming the test), then the unlabelled DCE will be a 
labelled DCE as well; the attribute ‘how the sample is taken’ will have an interaction with 
all other attributes and a restricted design is needed to avoid implausible combinations of 
attribute levels (i.e. the attribute levels are alternative specific, and thus a labelled DCE).  
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Table 9.1 Attribute and levels for unlabelled and labelled discrete choice experiment between three 
alternatives A, B, and C. 
 
Attribute
0.3%, 1.2%, 1.8%, 2.7% 1.8%, 2.3%, 2.7%
 0.9%, 1.5%, 1.8%
from 3.0% to 3.0% 
 0.1%, 0.5%, 0.8%
 from 3.0% to 3.0%
Frequency of screening 
per 10 years
Complication risk
Location of screening
Screening duration
Preparation for patient
enema, no fasting
drinking 4l + fasting
Side effects of screening FOBT: none
Sigmoidoscopy: mild pain
Colonoscopy: mild pain
No test: none
FOBT: none
Sigmoidoscopy: 
Colonoscopy: 
No test: none
FOBT: 30min
Sigmoidoscopy: 15min
Colonoscopy: 105min
No test: 0min
Option C: none
Sigmoidoscopy: small
Option C: none Colonoscopy: small
No test: none
Option C: 0 min
FOBT: at home
Sigmoidoscopy: hospital
Colonoscopy: hospital
No test: none
Options A and B: 10, 30, 60, 90 min
Options A and B: 
Options A and B: none, mild pain
none, enema no fasting, drinking 
0.75l + fasting, drinking 4l + fasting
Option C: none
No test: 0
Options A and B: none, small
Options A and B: at home, hospital
Option C: none
Levels in unlabelled model
Option C (no test): 
Levels in labelled model
FOBT: from 3.0% to 
Sigmoidoscopy: from 3.0% to
Reduction in mortality
FOBT: 3, 10, 30
Colonoscopy: 1, 2, 5
FOBT: none
Sigmoidoscopy: 1, 2, 10
Option C: 0
Colonoscopy: from 3.0% to
No test (Option C; base):
Options A and B: 1, 2, 5, 10
Options A and B: from 3.0% to 
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Another point of notice is that the unlabelled experiment had for some attributes a 
smaller level range than the feasible options in the labelled experiment. As a result, we 
avoided some extreme combinations of 30 times a screening test resulting in a reduction 
in mortality from 3.0% to 2.7% in the unlabelled DCE, which added to utility balance. 
The combination of the attributes and attribute levels of the unlabelled design resulted in 
2048 CRC screening test alternatives (44*23). A fractional factorial design was used based 
on a web-site, which contained a library of over 200 orthogonal arrays [14], to reduce the 
number of alternatives to a manageable level of 16 alternatives in which orthogonality and 
level balance were fulfilled. These 16 alternatives were paired up with another orthogonal 
array by using the fold-over technique (i.e. cyclic design), which caused minimal overlap 
between attribute levels [15]. Each choice set (i.e. a set of available alternatives) contained 
two screening test alternatives and an opt-out (see Table 9.2a for an example). The 
unlabelled design had an efficiency of 95% compared with an optimal choice set design, 
and all main effects were uncorrelated according to the results of an analysis using the 
software of Street and Burgess [16].  
Attribute levels in the labelled DCE were alternative-specific. In other words, different 
CRC screening test labels (FOBT, sigmoidoscopy, colonoscopy) were associated with 
different sets of outcomes. Implausible combinations of attribute levels and labels were 
minimized as a result. Furthermore, the implausible combinations of the attribute levels 
longest screening interval with simultaneous highest risk reduction as well as shortest 
screening interval with lowest risk reduction were blocked. Optimal designs for labelled 
DCEs,  which require a design with two-way interactions, are not available for the general  
 
 
 
Table 9.2a  An example of an unlabelled choice set 
 Screening test A 
 
(A) 
Screening test B 
 
(B) 
No screening test 
 
(C) 
Preparation: None Enema, no fasting None 
Location: At home Hospital None 
Pain: None Mild pain None 
Complication risk: None Small None 
Mortality risk of 
colorectal cancer 
decrease: 
from 3%  to 2.7% 
 
 
from 3% to 1.8% remain 3% 
Frequency of 
screening test in the 
next 10 years 
10x 5x 0x 
Time duration 10 minutes 30 minutes 0 minutes 
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case. Fortunately, SAS software is capable of generating designs that are highly efficient 
[15] in such circumstances. Hence, for the labelled DCE a D-efficient design was generated 
with SAS software (Version 9.1, SAS Institute Inc., Cary, NC, USA), which resulted in 84 
choice sets divided over 7 versions of the questionnaire (D-error 0.573). Each choice set 
contained two CRC screening test alternatives and an opt-out (see Table 9.2b for an 
example).  
The unlabelled as well as the labelled DCE contained a dominant choice set (i.e. a choice 
set in which one screening test alternative is logically preferable) to assess the 
understanding of the questionnaire (i.e. rationality test). Testing for internal validity 
should not automatically lead to deleting responses based on ‘irrational’ preferences, 
although it may be ‘common’ practice (e.g. [17-21]). Deleting ‘ irrational responses’ may lead 
to removal of valid preferences, induce sample selection bias, and reduce the statistical 
efficiency and power of the estimated choice models [22]. Therefore further sensitivity 
analyses were conducted to quantify the effect of including and excluding ‘irrational’ 
responses.  
All respondents received the same prior information to the questionnaire: an information 
brochure explaining different current CRC screening tests (FOBT, sigmoidoscopy, and 
colonoscopy; i.e. how the sample could be obtained) and their characteristics (advantages 
and disadvantages). Both DCEs were pilot tested to make sure that respondents could 
manage the length of the questionnaires, and to check for any problems in interpretation 
and face validity. None of the respondents raised any problems with understanding the 
questionnaires, so that the pilot test did not result in any changes to the questionnaires. 
 
 
 
Table 9.2b  An example of labelled choice set 
 Sigmoidoscopy 
 
(A) 
FOBT 
 
(B) 
No screening test 
 
(C) 
Preparation: Enema, no fasting None None 
Location: Hospital At home None 
Pain: Mild pain None None 
Complication risk: Small None None 
Mortality risk of 
colorectal cancer 
decrease: 
from 3%  to 0.9% 
 
 
from 3%  to 2.3% remain 3% 
Frequency of 
screening test in the 
next 10 years 
2x 10x 0x 
Time duration 15 minutes 30 minutes 0 minutes 
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9.3.3 Study sample and elicitation mode 
The questionnaires were sent by mail to subjects who had recently participated in a 
regional call-recall CRC screening program (unlabelled n=212; labelled n=769) and to 
randomly selected screening naïve subjects of the same region (Groot-Rijnmond) 
(unlabelled n=500; labelled n=1,498). It was not possible to directly calculate the 
statistical power to inform the sample size for a choice experiment. Other studies showed 
that a sample size of 42-208 respondents was sufficient to answer 16 unlabelled choice 
sets [23-25]. Because the fractional factorial design of the labelled approach was much larger 
than the unlabelled DCE and more coefficients had to be estimated due to alternative 
specific parameters, we sent out more labelled than unlabelled DCEs to strive for precise 
estimation of the parameters. All respondents were between 50-74 years of age. Besides 
the choice sets, the questionnaires also included background variables of respondents 
such as age, gender, endoscopy (i.e. sigmoidoscopy or colonoscopy) experience, 
familiarity with CRC because of cases in family or friends, and included standardized 
questions (EQ-5D) to measure self-reported health state. A reminder was sent to non-
responders four weeks later. 
 
9.3.4 Analyses 
Chi-square and Student t-tests were used to assess the differences between the 
characteristics of respondents of the unlabelled and labelled DCE (for participants in 
CRC screening and for screening naïve respondents separately).  
To assess feasibility we determined the response rate, rationality test outcome, missing 
values, and the self-rated ease of the task. We used Chi-square tests to compare 
differences in these aspects of feasibility.  
Both DCEs were analyzed by using multinomial logit regression models, in which the 
unlabelled DCE had generic parameters and the labelled DCE had alternative specific 
parameters. These models were implemented in SAS software (Version 9.1, SAS Institute 
Inc., Cary, NC, USA). A priori we expected all attributes to be important, and that all 
attributes would have a negative effect on utility except for ‘mortality reduction’.  
To assess the degree of trading behaviour, we tested for dominant preferences (i.e. if 
respondents based their responses entirely on one specific attribute or label (one specific 
CRC screening test)). Chi-square tests were used to assess differences between both 
DCEs for participants in CRC screening and for screening naïve respondents separately. 
Finally, relative utility values for different screening test profiles were determined based 
on the weights that respondents placed on the attributes of alternatives. The total utility 
value of a screening test profile was equal to the sum of the coefficient weights of its 
attribute levels [26-29]. The agreement between the labelled and unlabelled DCE outcomes 
depends strongly on the scale of both DCEs. In DCEs the scale is not identified and 
everything that depends on the scale is not reliable. Only measures based on correlation 
are really informative. Therefore, convergent validity between both variants was assessed 
 171 
Chapter 9 
by determining the degree of agreement by means of Pearson correlations (r). 
Noteworthy, perfect agreement only exists if the relative utility outcomes between 
unlabelled and labelled DCE lie along the line of equality, whereas perfect correlation (i.e. 
strength of a relation between the two approaches) exists if the relative utility outcomes 
lie along any straight line [30].  
 
 
9.4 Results 
The total response rate was 276/712 (39%) and 1,033/2,262 (46%) for unlabelled and 
labelled DCE respectively (p<0.001). In total, 4 of 276 respondents (1%) and 30 of 1033 
respondents (3%), who missed responses to three or more DCE questions, were excluded 
for further analyses. Forty-four percent of the respondents to the unlabelled DCE came 
from the CRC screening group and 56% from the screening naïve group; this was 53% 
and 47% for the labelled DCE. To correct for this imbalance all further analyses were 
focused on the CRC screening group and screening naïve group separately. Respondents 
did not differ with respect to mean age, gender, and endoscopy experience (p>0.13) for 
unlabelled and labelled variants respectively (Table 9.3). 
 
Table 9.3  An example of labelled choice set 
Unlabelled 
DCE         
(n=272)
Labelled 
DCE       
(n=1003)
Unlabelled vs 
labelled DCE    
(p-value)
Group (n-%) 0.01
CRC screening respondents 120    (44.1) 529   (52.7)
Screening naïve respondents 152    (55.9) 474   (47.3)
Age (mean-SD)
CRC screening respondents 62.2      (6.3) 61.0     (7.0) 0.13
Screening naïve respondents 59.9      (5.7) 60.9     (6.6) 0.29
Gender (male; n-%)
CRC screening respondents 59    (49.2) 277   (52.4) 0.53
Screening naïve respondents 74    (48.7) 238   (50.2) 0.74
Endoscopy experience (n-%)
CRC screening respondents 0.26
   Yes 64    (53.3) 255   (48.2)
   No 54    (45.0) 271   (51.2)
   Unknown 2      (1.7) 3     (0.6)
Screening naïve respondents 0.43
   Yes 33    (21.7) 119   (25.1)
   No 117    (77.0) 353   (74.5)
   Unknown 2      (1.3) 2     (0.4)
Variable
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9.4.1 Feasibility 
The response rate was higher for the labelled DCE then for the unlabelled DCE (Table 
9.4). The labelled DCE especially led to a higher response rate for the CRC screening 
group (71% vs 57%; p<0.001, 33% vs 31% for screening naïve group; p=0.51). An equal 
proportion of respondents of the CRC screening group passed the rationality test 
irrespective of DCE approach (91% vs 91%; p=0.96). However, more respondents failed 
the rationality test with the labelled design in the screening naïve group (18% vs 5% for 
unlabelled design; p<0.001). There was an equal proportion missing values of 1% for 
both DCEs irrespective of the response group. Most respondents indicated that they had 
no difficulties in completing the DCE task, and the groups did not perceive the task 
differently (p=0.28 and p=0.61 for CRC screening group and screening naïve group 
respectively) (Table 9.4). 
 
9.4.2 DCE results 
The effects (i.e. positive or negative direction) of the coefficients of both DCEs were 
consistent with a priori expectations (and showed therefore theoretical validity), except 
for the attribute ‘frequency of screening’ in the unlabelled approach (details in the 
Appendix 9.A). The positive coefficient of this attribute in the unlabelled DCE suggests 
that respondents preferred a higher frequency of screening over a lower frequency of 
screening per 10 years.  
Regarding the unlabelled DCE, all attributes except the attribute ‘location of screening’ 
proved to be important for preferences of both groups for CRC screening tests (see 
Appendix 9.A). The positive constant term suggests that respondents from the CRC 
screening group preferred ‘CRC screening test’ over ‘no CRC screening test’ if all other 
attributes were set to zero.  
Regarding the labelled DCE, all attributes proved to be important for preferences of both 
groups for CRC screening tests (see Appendix 9.B; note that, five out of seven attributes 
(i.e. location of screening, preparation for the patient, side effects of screening, 
complication risk, and screening duration) were attributes that had one alternative specific 
level; as a result their coefficients were catch up in the coefficient of the alternative label). 
The positive and significant alternative specific constants suggest that the CRC screening 
group had a positive attitude towards ‘CRC screening test’ over ‘no CRC screening test’ 
irrespective the utilized screening test (i.e. FOBT, sigmoidoscopy, or colonoscopy). This 
phenomenon was also seen in the screening naïve group, although the alternative specific 
constant of FOBT did not significantly differ from the base level ‘no CRC screening test’.   
The outcomes of the sensitivity analyses, which excluded the respondents who failed the 
rationality test, were quite similar whether or not these irrational responses were retained 
(data not shown). To avoid removal of valid preferences, induction of sample selection 
bias, and unnecessary  reduction of the statistical efficiency and power of the estimated 
choice models, we included the responses of respondents who failed the rationality test in 
all our further analyses. 
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9
 
.4.3 Respondents trading behaviour 
The labelled DCE led to more dominant preferences (i.e. responses entirely based on one 
specific attribute or label) (Table 9.5). This difference was significant for both the CRC 
screening group (41% vs 21% for unlabelled DCE; p<0.001) and the screening naïve 
group (39% vs 24% for unlabelled DCE; p=0.001). This difference was caused by the test 
labels; 24% and 21% of the CRC screening and screening naïve respondents, respectively, 
had dominant preferences for screening test labels. Table 9.5 also shows that the 
attributes of both DCEs did not make the difference in the proportion of dominant 
preferences (0.07<p<0.77). 
 
 
9.4.4 Convergent validity 
Based on the coefficients of the multinomial logit regression models of the unlabelled and 
labelled DCE (Appendices 9.A and 9.B), Figures 9.1a and 9.1b plot the difference in 
relative utility values for different realistic CRC screening programs for CRC screening 
naïve and  CRC  screening  respondents respectively  (see Table 9.6 for more details about  
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Figure 9.1a Correlation between the relative utility values of screening naïve subjeccts for different 
screening tests based on the labelled and unlabelled DCE (Pearson correlation 0.17; p=0.45) 
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the total relative utility scores). Using Pearson correlations the convergent validity 
f screening’), the strength of the relation between both 
pproaches was reasonable good for screening naïve respondents (r=0.71; p=0.03; and 
d high frequency levels respectively), and very good for 
between unlabelled and labelled DCEs was low for screening naïve respondents (r=0.17; 
p=0.45), but modest for respondents with screening experience (r=0.54; p=0.01). The 
regression comparison between unlabelled (independent variable) and labelled DCEs 
(dependent variable) showed a scaling as well as a shift phenomenon. The intercept was 
0.99 (p<0.01) and 0.90 (p<0.01) and the scaling factor was 0.19 (p=0.45) and 0.51 
(p=0.01) for screening naïve respondents and respondents with screening experience 
respectively. Respondents reacted about 0.19 or half as strong to the labelled attributes. 
Taking the attribute levels of frequency into account (i.e. ignoring the relative utility values 
f the attribute ‘frequency oo
a
r=0.53; p=0.07 for low an
respondents with screening experience (r=0.93; p<0.001; and r=0.95; p<0.001 for low 
and high frequency levels respectively). 
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Figure 9.1b Correlation between the relative utility values of CRC screening subjects for different 
screening tests based on the labelled and unlabelled DCE (Pearson correlation 0.54; p=0.01) 
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 9.5 Discussion 
 
This study shows that it is feasible to use realistic alternatives in labelled DCEs in a 
healthcare context. The labelled DCE led to a higher response rate, especially for the CRC 
screening group who had familiarity with the context. However, more respondents who 
were not familiar with the context failed the rationality test with the labelled design. The 
inclusion of labels appeared to play a significant role in individual choices, and increased 
non-trading behaviour. The convergent validity between both DCE variants was low, but 
better for respondents with CRC screening experience. 
In health economics there are no previous publications directly comparing labelled and 
unlabelled DCEs empirically. However, a DCE in ecological economics considered the 
effects of employing a labelled rather than an unlabelled DCE [31]. That study showed that 
the inclusion of alternative-specific labels reduced the attention which respondents gave 
to the attributes (i.e. increased non-trading behaviour). This is in line with our study, 
which showed that 24% and 21% of the CRC screening experienced and screening naïve 
respondents, respectively, only focused at the screening test labels. The ecological 
economics study also demonstrated convergent validity between a labelled and an 
unlabelled DCE contrary to our study.  
In line with the focus of this article, the results of the unlabelled and labelled DCE are 
only described briefly (for further detail information about the practical outcomes of 
these DCEs for colorectal cancer screening practice see Van Dam et al. [13] and Hol et al. 
[12]). The respondents in our labelled experiment are actually getting more and partly 
different information than in the unlabelled experiment, particularly if they have had 
experience of one of the options. This might be a possible explanation for the differences 
in our outcomes between the screening naïve and CRC screening respondents. Note that, 
if the reader wants to compare the beta-coefficients of CRC screening respondents and 
screening naïve respondents directly (see Appendix 9.A), it should be clear that scale 
effects might be an issue (for more detail information see Swait and Louviere [32]). 
The positive direction (effect) of the attribute ‘frequency of screening per 10 years’ in the 
unlabelled approach (Appendix 9.A) seems to be inconsistent with utility theory. 
However, these ‘irrational’ responses may be explained by respondents making additional 
assumptions or bringing additional information to the choice [33, 34]. As Ryan et al. [35] 
provided evidence that respondents assumed tests with higher costs would be of higher 
quality. Respondents in our study might associate higher frequency of screening with a 
more effective test. The differences in preferences for screening frequency between the 
two DCE approaches demonstrates the importance of continuing research into the biases 
present across these elicitation methods. Mixed methods may be useful to get more 
insight into the internal validity of the DCEs. Qualitative techniques, such as the think 
aloud technique, may show that seemingly ‘irrational’ choice behaviour may not be so 
irrational after all [35]. 
The predominant use of unlabelled experiments in health care may be a result of the 
perception that labelled experiments are difficult to construct. The design of a labelled 
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DCE does generally mean a larger sample size is required, because it is assumable that 
ost of time there are interactions between the alternative label and the attributes. 
nt. 
g behaviour due to alternative labels.   
een 
o different preferences for screening frequency. The choice for a 
m
Indeed, this may not be feasible in a health care setting (e.g. the target group of patients or 
medical specialists is too small). However, this is not only the case for labelled DCE, but 
also for unlabelled DCE in which all (two-way) interactions between attributes are taken 
into account. Unlabelled DCEs in which all (two-way) interactions between attributes are 
taken into account may be even much larger then a labelled DCE, because in a labelled 
DCE a lot of characteristics can be compressed in one label, whereas in an unlabelled 
DCE all possible interactions should be taken into accou
Another explanation for the predominant use of unlabelled experiments in health care 
may be that labelled DCEs in health care are not necessary (yet). Although it is not clear 
why labelled DCEs in health economics are rarely used, it has to be clear that the design 
should be made to fit the research objectives and not the other way around. If it is to be 
expected in the experiment that the alternative labels have important differences, then it 
may be desirable to go for a labelled DCE. Underestimating the role of the alternative 
labels may lead to worse or even wrong predictions of alternatives people actually prefer. 
On the other side, if the objective is to estimate attribute values, it may be desirable to use 
an unlabelled DCE to reduce non-tradin
This study had some limitations. First, we conducted two DCEs in two samples. It might 
have been preferable (from a theoretical point of view) to conduct the two DCEs in the 
same group of respondents (i.e. all respondents filled in one DCE, and then the other 
DCE; sequence in random order). However, that was not possible because of the 
respondent burden. As a result, we cannot directly compare the absolute values of the 
utility levels for the attributes and tests. Second, the design of both DCEs was not exactly 
the same. The combination of d-efficiency criteria and the use of alternative specific and 
generic attribute levels in the labelled and unlabelled DCE respectively, resulted in 
different choice sets presented to the respondents. We have no reason to believe that this 
has influenced the results to a large extent. Third, testing the convergent validity betw
unlabelled and labelled DCE was based on comparison of the total utility of alternatives. 
The labelled DCE had five attributes with one alternative specific level, and therefore a 
direct comparison of the coefficients of the attributes (taking scale factor into account) 
was not possible. Fourth, two attribute levels regarding the alternative specific attribute 
‘frequency’ of FOBT (3 and 30 times screening per 10 years) were not presented in the 
unlabelled DCE. Therefore, we could only include three total utility scores of 
(hypothetical) CRC screening programs with FOBT-test in our convergent validity test 
between both DCE variants. In conclusion, this study provides important insights in the 
feasibility and difference in results from labelled and unlabelled DCEs. The inclusion of 
labels appeared to play a significant role in individual choices, but reduced the attention 
respondents give to the attributes. There was low convergent validity between both DCE 
variants, largely due t
labelled or unlabelled DCE may depend on the type of respondents and the research 
question. Unlabelled DCEs may be more suitable to investigate trade-offs between 
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attributes and for respondents who do not have familiarity with the alternative labels, 
whereas labelled DCEs may be more suitable to explain real life choices such as uptake of 
cancer screening. 
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Appendix 9.A   
 
Multinomial logit results for unlabelled DCE 
 
CRC screening respondents Screening naïve respondents
coefficient error p-value coefficient error p-valueAtt
0.62 0.14 <0.001 0.25 0.13 0.05Co (screening test)
(base level 'no test')
fec
(bas
plication risk -0.13 0.06 0.04 -0.16 0.06 <0.01
(base level 'no risk')
Location 
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Preparation for patient <0.001 <0.001
(base level 'none')
enem
drin g 0.75l + fasting -0.22 0.12 -0.51 0.11
drin
(bas
2 tim
5 tim 0.33 0.10 0.40 0.10
10 ti
rtality re
(per 0.3%
ribute
nstant 
eening
(per 10 m
Side ef ts of screening -0.23 0.06 <0.001 -0.31 0.06 <0.001
e level 'no pain')
Com
of screening -0.01 0.06 0.83 -0.09 0.06 0.11
a no fasting -0.23 0.11 -0.37 0.10
kin
king 4l + fasting -0.88 0.11 -0.98 0.11
-0.03 0.01 <0.01 -0.03 0.01 <0.01Scr  duration               
in)
Frequency of screening <0.001 <0.001
e level 1 time)
es 0.24 0.09 0.28 0.09
es
mes 0.27 0.09 0.33 0.08
0.26 0.01 <0.001 0.32 0.01 <0.001Mo duction          
)
 
 183 
Chapter 9 
 184 
Appendix 9.B   
 
Multinomial logit results for labelled DCE 
 
coefficient error p-value coefficient error p-value
FOBT 0.49 0.11 <0.001 0.16 0.12 0.16
Sigmoidoscopy 1.09 0.11 <0.001 0.57 0.11 <0.001
Colonoscopy 1.18 0.11 <0.001 0.57 0.11 <0.001
Mortality reduction FOBT <0.001 <0.001
(base level from 3.0% to 2.7%)
from 3.0% to 2.3% 0.18 0.09 0.14 0.09
from 3.0% to 1.8% 0.64 0.10 0.58 0.11
Mortality reduction Sigmo <0.001 <0.001
(base level from 3.0% to 1.8%)
from 3.0% to 1.5% 0.30 0.08 0.09 0.09
from 3.0% to 0.9% 0.61 0.10 0.59 0.11
Mortality reduction Colono <0.001 <0.001
(base level from 3.0% to 0.8%)
from 3.0% to 0.5% 0.20 0.08 0.11 0.09
from 3.0% to 0.1% 0.39 0.10 0.29 0.10
Frequency of screening FOBT <0.001 <0.001
(base level 30 times)
10 times 0.60 0.09 0.59 0.09
3 times 0.62 0.10 0.78 0.11
Frequency of screening Sigmo <0.001 <0.001
(base level 10 times)
2 times 0.48 0.08 0.81 0.09
1 time 0.48 0.10 0.97 0.10
Frequency of screening Colono <0.001 <0.001
(base level 5 times)
2 times 0.49 0.08 0.66 0.09
1 time 0.36 0.10 0.66 0.09
Label (base level 'no test')
CRC screening 
respondentsAttribute
Screening naïve 
respondents
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10  Discrete choice experiments in health care: discussion 
 
This thesis addresses applications and theoretical aspects of DCE in health care. In this 
chapter, the main findings regarding the objectives of the thesis will be presented first. 
Subsequently, theoretical aspects of DCE and application possibilities of DCE will be 
discussed. This chapter ends with conclusions and recommendations for future research. 
 
 
 
10.1  Main findings 
 
Objective 1: To provide an overview of current DCE practice in health economics, and 
to compare and assess progress in methodological advances. 
 
We showed in Chapter 2 that between 2001-2008 114 DCE papers were published 
covering a range of policy questions. These included valuing patient experience factors, 
health outcomes, investigating trade-offs between health outcomes and patient experience 
factors, estimating utility weights within the QALY framework, investigating labour-
market choices amongst health care professional, priority setting frameworks at the 
local/national level and preferences regarding clinical decision making. This means that 
the applications today are much broader than to value patient experience factors, and 
shows that a DCE is a potentially useful tool for investigating preferences for all kind of 
health care issues. The condition is that the choice problem can be broken down into 
discrete choice options characterised by limited numbers of attributes and levels. Looking 
at the results of these DCE papers we think evidence is accumulating that DCEs can 
contribute to benefit measurement for use in economic evaluation. DCEs are useful to 
measure process attributes and non-health outcomes, and to determine the trade-offs 
between these attributes and health outcomes.  
We are less convinced that these stated preference outcomes are useful to predict actual 
behaviour (i.e. real preferences). No research has considered external validity (i.e., testing 
whether individuals behave in reality as they stated in the survey). A good development, 
regarding the technical quality of DCEs, is that there has been a shift towards using 
statistically efficient designs. The construction of the experimental design is a crucial part 
of any DCE. Constructing choices randomly do harm the precision of the parameter 
estimates or may even bias the results. We also showed in Chapter 2 that richer 
econometric models are beginning to be employed for analysis. On the one side we think 
that the application of richer econometric models is a positive development to relax 
assumptions such as ‘errors are independent and identically distributed’, ‘observed choices 
are independent’, and ‘preferences are homogenous’ that may bias the results. On the 
other side we discourage to use these richer models if data are insufficient (e.g. a small 
number of respondents), because in that case these models will do more harm than good.  
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Objective 2: To study the usefulness of DCE for real choice problems in health care for 
measuring benefits beyond health outcomes.  
 
We showed in chapters 3-8 that studies in this thesis illustrated the feasibility of DCE to 
elicit valuations for health and non-health outcomes of individuals aged 18-89 years for a 
wide range of health care interventions. Only a small fraction of respondents failed the 
rationality tests (1-13%). This suggests that adults can handle DCEs. However, the 
fraction of potential respondents who agreed to participate in the DCEs differed largely 
(31-86%), and was especially low (31-33%) for the general population who had not 
experienced the choice problem by themselves. We do not know the reasons of non-
response and the characteristics of the non-respondents neither. Therefore we have to 
make a marginal note that DCEs probably cause some extra selection bias compared with 
general questionnaire surveys due to the complexity of a DCE task. Given the complexity 
of a DCE task, selection of respondents by education level or language skill is likely.  
The DCE studies conducted in this thesis provided evidence that the DCE approach can 
be applied successfully in health care to directly compare the determinants of the 
preferences from different groups (e.g., health professionals, patients, general population).  
The DCE studies all gave insight into whether or not the given (non-)health attributes 
were important (according to a significant statistical test), the relative importance of the 
attributes, the rate at which individuals were willing to trade between attributes, and 
overall benefit scores for intervention alternatives. Confidence may be larger for the 
usefulness of results showing the importance of each attribute (i.e. relative values), than 
for in the usefulness of results as predictors for real choice (i.e. absolute values).   
 
Objective 3: To compare labelled versus unlabelled DCEs in health care in various 
aspects of feasibility, trading-behaviour, and convergent validity. 
 
We showed in Chapter 9 that it is feasible to use realistic alternatives in labelled DCEs in 
a healthcare context. The labelled DCE led to a higher response rate, especially for the 
CRC screening group who had familiarity with the context. However, more respondents 
who were not familiar with the context failed the rationality test with the labelled design. 
This suggests that unlabelled DCEs are more suitable for respondents who are not 
familiar with the alternative labels. The inclusion of labels appeared to play a significant 
role in individual choices, and increased non-trading behaviour. Labelled DCEs may be 
more useful to predict subjects’ behaviour, whereas unlabelled DCEs may be more useful 
to investigate the trade-offs between attributes of a health care intervention or service. 
Consequently, the choice of a labelled or an unlabelled DCE depends on the research 
question. Practical reasons can also play a role. Labelled DCEs quickly result in large 
experimental designs, which require a large number of respondents.  
The convergent validity between both DCE variants was low, but better for subjects with 
CRC screening experience. This outcome again stresses that the choice of a labelled or un 
unlabelled DCE depends on the research question. The current dominance of unlabelled 
designs in the health economic area may not be defensible.      
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10.2   Theoretical aspects of DCE 
 
10.2.1  Experimental design 
Constructing an experimental design is a crucial part of a DCE. A full factorial design 
includes all possible combinations of attributes and attribute levels in the choice set. 
When using a full factorial design all interaction terms between attributes and/or attribute 
levels can be estimated. However, a full factorial design often results in a large number of 
alternatives (i.e. profiles). Therefore experimental design methods are used to create a 
fractional factorial design. Several types of design exist to create a fractional factorial 
design. In health economics, mostly orthogonal arrays have been used. These arrays 
consider orthogonality and level balance. Choice sets can then be manually created. We 
observed a move from constructing choices randomly to constructing choices using the 
fold-over technique. The fold-over technique minimizes the overlap between attribute 
levels in a choice set. We demonstrated in various studies (chapters 4-7) that this method 
resulted in highly optimal designs (95-100% efficient), in which all main effects were 
uncorrelated.  
As demonstrated in Chapter 2, experimental design methods in health economics have 
progressed in recent years. We observed a move from orthogonal designs to constructing 
statistically efficient designs. D-efficiency (i.e. precision of parameter estimates) has been 
a popular criterion to measure statistical efficiency. Here the variance–covariance matrix 
is minimized and as a result information obtained from observed choices is maximised [1]; 
(orthogonal designs do not take dominant alternatives into account, whereas statistically 
efficient designs do). Whilst such designs consider orthogonality, level balance and 
minimum overlap, they do not necessary minimize these.  
We showed in Chapter 8 that a labelled DCE has to take into account all two-way 
interactions (since the alternative labels may be correlated with the attributes) and 
implausible combinations of attribute levels and labels. Orthogonal designs are not 
available in such circumstances. Using a statistically efficient design is more appropriate 
then [2]. Statistical efficient designs maximise D-efficiency or equivalently minimize D-
error. Using specific software as SAS software or Ngene software choice sets can be 
generate directly [3]. 
More recently, in other areas than health economics efficient choice sets are being created 
by making prior assumptions about the parameters to be estimated [4-16]. This Bayesian 
approach lets go of the principle of orthogonality and constructs designs in a manner that 
is intended to minimise the expected elements of the asymptomatic variance covariance 
(AVC) matrix that will be obtained from models estimated on data collected using that 
design. The primary advantage of this method is that the constructed design is related to 
the expected outcome of the modelling process. This method has not been used in health 
care (yet). Therefore research is needed to investigate its usefulness in a health care 
context. It may be worthwhile for the health economics community to link to other areas. 
Chapter 2 showed that a main effects-only fractional factorial design (i.e., assuming that 
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all interactions between attributes were zero) was used in 89% of the DCE studies 
conducted during 2001-2008 in health care. Also in the DCE studies in this thesis a main 
effects only fractional factorial design was commonly used. Although these generally 
account for 70 to 90% of explained variance in a DCE [17], specific combinations of 
attribute levels may have specific effects that remained unidentified. As a result the main 
effects-only fractional factorial designs used in our DCE studies were mentioned as a 
limitation. However, if a researcher intends to estimate interaction terms, more degrees of 
freedom are required for estimation purposes. More degrees of freedom mean larger 
designs. We support the recommendation of Lancsar and Louviere [18] to use designs 
which allow estimation of all two-way interactions to minimise the potential for bias.  
In Chapter 9 we advocated that unlabelled DCEs may be more suitable to investigate 
trade-offs between attributes and for respondents who do not have familiarity with the 
alternative labels, whereas labelled DCEs may be more suitable to explain real life choices 
such as uptake of cancer screening. It depends on the choice problem if choice sets 
should be generated in a labelled or unlabelled form. If in the experiment is expected that 
the alternatives have important differences, and are wished to be modelled, then a labelled 
experiment should be used. Therefore, the current dominant use of unlabelled DCEs in 
the health economic area may not be defensible.  
 
10.2.2  Estimation procedures 
After data are collected the analyst chooses a modelling strategy to analyse responses. 
McFadden’s multinomial logit (MNL) model provides a clear link between choice 
behaviour and utility and associated set of assumptions and properties. The MNL model 
assumes independent and identically Gumbel distributed error terms to characterise 
stochastic utility (ε) [19]. The undoubted popularity of the MNL is due to its simplicity and 
ease of estimation. This model has three assumptions: independence of irrelevant 
alternatives (IIA) (i.e., for a given individual, the ratio of the choice probabilities of any 
two alternatives is unaffected by other alternatives); constant error term across 
observations (therefore not allowing for multiple observations from respondents); and 
homogeneity of preferences. Recognition of the restrictive nature of these assumptions 
has led to developments of the MNL model. 
Chapter 2 showed that 10% of the DCE studies conducted between 2001-2008 used 
richer econometric methods (i.e. nested logit, mixed logit or latent logit models) 
compared with 3% of the DCE studies conducted between 1990-2000. It appears that 
using richer econometric models for estimation is slowly being taken up, particularly with 
respect to preference heterogeneity. Wansbeek et al. [20] has singled heterogeneity out as 
‘the most salient feature of consumer demand at the micro level’. However, caution is 
needed when choosing a more advanced model for analysis, given the data requirements 
of these more flexible econometric specifications [21]. Especially in case of relatively small 
number of cases, such as mentioned in Chapter 4 (n=39), the estimation of a mixed 
model will not make sense. The estimation might become instable, and the MNL model 
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might fit better. Therefore we recommend researchers to select the econometric model to 
analyse responses, which is in balance with the available data. 
In the area of econometric modelling outside health economics there have been many 
advances of late [22-29]. It may be worthwhile for the health economics community to link 
to these other areas for keeping pace with econometric modelling.  
 
10.2.3  Complexity of DCE 
The ability of respondents to fully comprehend valuation tasks has always been the 
subject of some scepticism. The difficulty of a DCE task and in other valuation tasks (e.g. 
the time trade-off (TTO) method, or standard gamble (SG) method) is an issue of 
attention. Craig et al. [30] showed that illiteracy and innumeracy can hinder implementation 
of complex preference elicitation techniques (TTO and VAS) in diverse settings and 
populations. Selection bias appears if subjects drop out in a valuation task due to their 
cognitive ability. This dropping out can take place in different ways. Subjects may not 
participate in the DCE task at all (unusual questionnaire), or if these subjects participate 
in the for them difficult DCE task they cause instable parameter estimates. Therefore, we 
recommend to keep the DCE survey simple: the questionnaire should be as clear as 
possible (e.g., difficult linguistic use must be avoided), and the DCE task should be as 
simple as possible (e.g., the number of attributes, and innumeracy and literacy problems 
must be taken into account). We also recommend to test if respondents can handle the 
DCE survey. If respondents can not handle the DCE survey (e.g., due to literacy 
problems or problems with rational decision-making), than do not conduct the DCE 
survey.  
Studies from other areas have found that task complexity affects DCE parameter 
estimates, increasing the unexplained model variance [31-36]. Furthermore, the concern of 
design strategies seeking to maximise statistical efficiency may come at the cost of lower 
respondent efficiency [37-38]. We do not know which specific aspects of a DCE survey are 
difficult for which group of respondents. Qualitative research methods may be useful in 
this respect. Huston and Rowan [39] found that qualitative research can provide important 
insights into questionnaire behaviour. Our DCE studies used qualitative methods as 
additional information for the selection of attributes and levels, and for piloting of 
questionnaires. We suggest to extend the role of qualitative research in the field of DCE, 
to investigate the choice processes in respondents who complete a DCE and to evaluate 
the precise meanings of their responses, using formal methods such as the Three-Step 
Test Interview [40]. In quite another research area, such research resulted in very useful 
insights for the interpretation of seemingly counterintuitive patterns of health-related 
quality of life scores found in men after treatment for localized prostate cancer [41]. 
 
10.2.4  Validity of DCE 
Given DCEs, like other health economic valuation techniques, rely on choices in 
hypothetical situations, investigating external validity of responses has been identified as 
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important [42]. Evidence of external validity (testing whether individuals behave in reality 
as they state in the hypothetical survey) is the strongest form of evidence for validity. 
Given that many applications of DCEs have taken place in countries with a publicly 
provided health care system, availability of data on actual choices to compare real and 
stated behaviour is limited [43]. DCE studies from other areas than health economics 
found evidence of external validity [44-48]. Chapter 2 showed that none of the DCE studies 
conducted during 2001-2008 in health care has considered external validity. Also none of 
the DCE studies conducted in this thesis was tested for external validity. Testing for 
external validity of the DCE approach seems to be difficult in a health care context. As a 
result, a number of internal validity tests have been applied. For example, testing 
theoretical validity (i.e. checking if the model coefficients have the sign expected given 
theory)  or ‘rationality’ of responses (checking if respondents prefer more of a good thing 
rather than less of it). 
The DCEs conducted in this thesis showed theoretical validity. Large fractions of our 
respondents passed the rationality tests (87-99%), which provided evidence to internal 
consistency. We tested the “rationality” of responses by including dominance tests (i.e. 
choice sets where one alternative is clearly superior). These tests have been criticised for 
being too easy to pass [49]. Empirical research is needed to find out if a transitivity test (i.e. 
if an individual prefers alternative A over B, and B over C then the individual should 
prefer A over C) or a Sen’s contraction property test (i.e. an individual who chooses 
alternative A in the first choice set of for example four alternatives (A, B, C, plus an opt-
out option) should not choose alternative B or the opt-out alternative in the reduced 
choice set of three alternatives (A, B, plus an opt-out option) [50]) are more appropriate to 
test the rationality of responses.  
Within study constraints it is important to continue with internal validity tests. 
Nevertheless, testing for external validity is crucial, an area health economists must get 
into. Again the health economics area can learn from other areas. For example, Carlsson 
and Martinsson [45], Chang et al. [46], and Lusk and Schroeder [47] used a laboratory 
experiment to test the external validity of DCEs. Making use of such external validity 
tests may be a way forward to test external validity in health care.  
 
 
10.3   Applications of DCE 
The DCEs conducted in this thesis provide valuable insights regarding benefit valuation 
beyond clinical outcomes of various health care interventions. They all gave insight into 
the relative importance of the attributes; the rate at which individuals were willing to trade 
between attributes; and overall benefit scores for intervention alternatives. Therefore our 
DCEs provide useful insights regarding benefit valuation of various health care 
interventions’ characteristics, which would be ‘ignored’ in clinical outcomes or QALYs, 
and might be useful as additional information in a medical-decision process about health 
care interventions or services. 
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Chapter 3 showed that the willingness to pay (WTP) for each (non-)health outcome 
attribute could be indirectly determined, because a cost attribute was included in that 
DCE. The possibility to estimate a WTP is an additional advantage of DCE. However, to 
our opinion this additional advantage is limited. Slothuus and Gyrd-Hansen [51] 
emphasised that interpretation of implicit WTP values should be tackled with caution. 
They showed that a wider cost range including higher payments is associated with lower 
parameter weight associated with the payment variable, and thus increased WTP values. 
Ryan and Watson [52] showed that the WTP estimate derived from the DCE was higher 
than that derived from the payment card contingent valuation, and Van der Pol et al. [53] 
showed that the mean WTP derived from an open-ended question was substantially lower 
than the mean derived from a DCE. As an aside, the inclusion of a cost-attribute has 
some important disadvantages such as it may be unrealistic for countries with a publicly 
provided health care system, or price sensitivity may change when the order of the cost 
attribute is moved in the alternative description [54]. In summary, the possibility to 
estimate a WTP is an additional option of DCE. Only if relevant in health care we 
recommend to include a cost attribute. However, the results should be interpreted with 
caution: the absolute WTP values derived from a DCE should be interpreted relatively 
(i.e. ranking order). 
A disadvantage of carrying out a DCE is that the statistical experimental design of a DCE 
and the econometric modelling have become quite complex. Practitioners using DCE for 
the first time are recommended to have expert help from a specialist. We are convinced 
that it is important to conduct a DCE methodological correctly and to do research on it. 
However, it should be balanced with the relevance of answering the research question. In 
other words, doing a lot of research to generate a methodologically perfect DCE does not 
make sense if respondents can not understand the valuation task anymore or if it will be 
unpractical in a health care context (e.g. too many patients are required). A DCE should 
be as good as needed, and does not have to be as good as possible. The preparation 
required for applying a DCE is another disadvantage. The determination of attributes and 
attribute levels are crucial, and the number of attributes in a DCE is limited, because 
increasing numbers of attributes would impact on the random component variability [17].  
As a result extensive literature research is needed and qualitative data collection is 
recommendable (e.g. focus groups, individual interviews with target subjects or experts). 
A pilot study is recommendable to ascertain that subjects can manage the length of the 
questionnaire and to examine the intelligibility, acceptability and validity of the 
questionnaire. A final issue we experienced was that we had to report the DCE approach 
and outcomes relatively simple to make it acceptable for clinical journals. As a result 
researchers who want to replicate our DCE studies will face some lack of methodological 
information.  
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10.4  Conclusions and recommendations for future research 
 
Conclusions 
 The DCEs conducted in this thesis provided valuable insights regarding benefit 
valuation beyond clinical outcomes of various health care interventions, and are 
therefore useful as additional information to clinical outcomes or QALYs in a 
medical decision-making process about health care interventions. 
 The DCE approach is a feasible instrument for the measurement of preferences of 
adults for all kind of health care interventions under the condition that the choice 
problem can be broken down into discrete choice options characterised by limited 
numbers of attributes and attribute levels.  
 The DCE approach is a useful tool in health care to directly compare the 
determinants of the preferences for health care interventions from different groups 
such as health professionals, patients, and general population. 
 DCE outcomes may be more appropriate to show the relative importance of the 
attributes of a health care intervention than to predict real choice. 
 Unlabelled DCEs may be more suitable to investigate trade-offs between attributes 
and for respondents who do not have familiarity with the alternative labels, whereas 
labelled DCEs may be more suitable to explain real life choices.  
 The possibility to estimate a WTP is an additional advantage of DCE, but the results 
should be interpreted relatively.  
 In terms of experimental design and estimation procedure it may be worthwhile for 
the health economics community to link with areas outside health economics. 
 More research to generate a methodologically perfect DCE is not useful if 
respondents can not understand the valuation task anymore or if it will be unpractical 
in a health care context. 
 
 
Recommendations for future research 
Future research is needed: 
 To define the place of DCEs versus other preference elicitation methods in health 
care. 
 To generate DCEs which are as easy as possible for respondents, but still provide 
adequate answers to the research question.  
 To optimise the design and analysis of DCEs, including issues as the usefulness of 
non-orthogonal efficient designs and dealing with ‘irrational’ responses. 
 To find opportunities to test the external validity of DCEs in health care. 
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Summary 
Summary   
 
Health economics is concerned with issues related to scarcity in the allocation of health 
care. The basic tasks of any economic evaluation are to identify, measure, value, and 
compare the costs and consequences of alternatives being considered. Traditional means 
of measuring benefits in the delivery of health care have concentrated on improvements 
in health outcomes using clinical outcomes and Quality Adjusted Life Years (QALY). 
However, additional to health outcomes valuing process outcomes (e.g. treatment 
location, route of drug administration) and non-health outcomes (e.g. amount of 
information) may be worthwhile. These might be relevant for individuals’ preferences and 
acceptability for specific health care interventions or programmes (i.e. demand-led health 
care), and for some interventions that do not provide reduction in morbidity or mortality 
(e.g. cosmetic surgery).    
The discrete choice experiment (DCE) approach provides opportunities for evaluation of 
process effects and non-health outcomes additional to traditional QALY analysis. The 
technique of DCE is an attribute-based measure of benefit, based on the assumptions 
that, first, alternatives (goods or services) can be described by their characteristics, known 
as attributes, and second, an individual’s valuation (i.e., benefit, utility, satisfaction or 
preference) depends upon the levels of these attributes. Within a DCE individuals are 
offered a series of choice sets, and are asked to choose in each choice set between two or 
more alternatives. The choice observed is assumed to reveal an underlying (latent) utility 
function. The DCE approach combines random utility theory with consumer theory, 
experimental design theory and econometric analysis. 
In comparison to other stated preferences techniques that require the individual to rank 
or rate alternatives, a DCE presents a reasonably straightforward task and one which 
more closely resembles a real world decision (i.e., trading off health outcomes, process 
attributes and/or non-health outcomes). DCEs have been used widely in marketing, 
transport economics, and environmental economics. The application of DCE to the field 
of health care seems promising.  
 
This thesis addresses the following objectives: 
1. To provide an overview of current DCE practice in health economics, and to compare 
and assess progress in methodological advances. (Chapter 2) 
2. To study the usefulness of DCE for real choice problems in health care for measuring 
benefits beyond health outcomes. (Chapters 3-8) 
3. To compare labelled versus unlabelled DCEs in health care in various aspects of 
feasibility, trading-behaviour, and convergent validity. (Chapter 9) 
 
Review of discrete choice experiments in health care 
 
Chapter 2 provides an overview of DCEs applied in health economics between 2001 and 
2008, and builds on a review of published papers between 1990-2000. This previous 
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review recommended to follow methodological developments taking place in other 
disciplines or areas of economics. Therefore, in our review consideration is given to three 
methodological issues (‘experimental design’; ‘methods of analysis’; and ‘validity’) to 
investigate if accumulating technical knowledge has been (more) often used in current 
DCEs. 
We identified 114 DCEs published between 2001 and 2008. Our review showed that, 
whilst the technique was introduced into health economics to value what might be called 
patient experience factors, the applications today are much broader. These included 
valuing patient experience factors, health outcomes, investigating trade-offs between 
health outcomes and patient experience factors, estimating utility weights within the 
QALY framework, investigating labour-market choices amongst health care professional, 
priority setting frameworks at the local/national level and preferences regarding clinical 
decision making.  
Regarding the technical quality of DCEs, there has been a shift towards more using 
statistically efficient designs and richer econometric models. Internal validity tests were 
largely incorporated in the DCE practice. However, much progress has still to be made 
towards external validity; i.e., testing whether individuals behave in reality as they stated in 
the survey. Also consideration needs to be given to incorporation of the results of a DCE 
into a decision-making frame-work by policy makers.  
 
 
Practical applications of discrete choice experiments in health care 
 
This thesis describes four applications of DCEs developed for real choice problems in 
health care to measure benefits beyond health outcomes. These four problems illustrate 
the potential of DCE to include non-health outcomes and process effects of health care 
interventions in preference elicitation.  
 
The first DCE focused on preferences for preventive osteoporosis drug treatment. 
Various practice guidelines recommend a case-finding approach to identify persons with a 
high risk of osteoporotic fractures. However, the usefulness of this approach depends on 
whether the identified persons are willing to take preventive osteoporosis drug treatment, 
and on what conditions.  
Chapter 3 showed that treatment attributes as effectiveness, side effects (nausea), total 
treatment duration, route of drug administration, and out-of-pocket costs all proved to be 
important for women’s choices. A reduction of the relative 10-year risk of hip fracture by 
40% or more by the drug was considered to compensate for nausea as a side effect. 
Women were prepared to pay an out-of-pocket contribution for the currently available 
drug treatment (bisphosphonate) if the fracture risk reduction was at least 12%.  
Differences in opinions on the desirability of treatment initiation may hamper the process 
and outcome of shared decision-making between physician and patient. Therefore, we 
compared general practitioners’ and patients’ preferences for preventive osteoporosis 
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drug treatment, and evaluated the determinants of the preference differences found 
(Chapter 4).  
We showed that general practitioners had a significantly less favourable attitude towards 
preventive osteoporosis drug treatment than patients; they placed significantly higher 
values on effectiveness of drug treatment and short total treatment duration than patients.  
 
The second DCE focused on preferences for idiopathic scoliosis brace treatment. The 
effectiveness of brace treatment in idiopathic scoliosis patients has not been established in 
randomized controlled trials (RCTs). Insight into patients’ preferences for (characteristics 
of) brace treatment will be useful for future trials and for the development of braces that 
may optimize compliance with brace treatment.  
We showed that treatment attributes as effectiveness (i.e. risk reduction of a surgical 
intervention), visibility of the brace, uncomfortable wearing of the brace, and treatment 
duration, all proved to be important for patients’ choices (Chapter 5). Effectiveness and 
discomfort in wearing a brace played the most important role in their choices. Patients 
were prepared to undergo treatment with a Boston brace for three years, if the brace 
would reduce the need for surgery by 32-74%. 
These results are important if RCTs would conclusively establish that bracing is effective, 
and show directions for the further technical development of braces to increase the 
compliance with brace treatment. 
 
Chapter 6 described the third DCE, which focused on (determinants of) women’s 
preferences for three breast reconstruction modalities. Patients’ preferences are important 
determinants in the decision for a specific type of breast reconstruction. Understanding 
women’s motivational factors can contribute to further improve patient information and 
to develop demand-led healthcare. Breast reconstructions were characterized by six 
treatment attributes: 1) material used, 2) number and duration of operations, 3) short- and 
4) long-term complication rate, 5) aesthetic result, and 6) waiting time. All these treatment 
attributes proved important for women’s choices. Our results show that (autologous) 
material and aesthetic result are the most important determinants for women’s choice for 
breast reconstruction. Autologous free flap breast reconstruction fitted in best with 
women’s preferences. 
 
The fourth DCE focused on preferences for colorectal cancer (CRC) screening 
programmes. Screening can reduce CRC mortality by early detection of CRC and 
endoscopic removal of premalignant precursors of CRC (adenomas). Uptake of CRC 
screening has remained low. Therefore, we determined the influence of different 
screening tests and their characteristics on individual preferences for CRC screening.  
Chapter 7 presents the results of a DCE in which the screening strategies were described 
by various test types (faecal occult blood test (FOBT), flexible sigmoidoscopy, and 
colonoscopy) accompanied by realistic screening intervals and CRC mortality reductions.  
Respondents preferred screening over no screening irrespective of the screening test. 
Screening test, interval and the risk on CRC mortality influenced subject's preferences for 
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CRC screening. Respondents were willing to sacrify 25% risk reduction on CRC mortality 
to obtain a five-yearly FS instead of a ten-yearly colonoscopy. Subjects in the target 
population preferred endoscopy screening to FOBT screening if realistic levels of the test 
characteristics were applied. 
Chapter 8 presents the results of a DCE in which the screening strategies were described 
by treatment characteristics as pain, risk of complications, screening location, preparation, 
duration of procedure, screening interval and risk reduction of CRC related death. All 
aspects significantly influenced the respondents’ preferences. Respondents required an 
additional relative risk reduction of CRC related death of 32% to utilise an extensive 
bowel preparation instead of no bowel preparation. Screening intervals shorter than 10 
years were significantly preferred to a 10-year screening interval. Especially type of bowel 
preparation, length of screening interval and mortality reduction influenced individuals’ 
trade-offs. These results provide insight in the decision-making process regarding the 
decision to participate in a CRC screening programme, thereby contributing to the 
improvement of information provided to CRC screening invitees, and they identify 
targets for increasing participation rates. 
 
 
Theoretical aspects of discrete choice experiments in health care 
 
A fundamental question that arises in the application of DCE is whether to present the 
choice sets in a labelled or unlabelled form. The unlabelled form involves assigning 
unlabelled alternatives in the choice set, such as ‘alternative A’, ‘alternative B’ and so on. 
The labelled form involves assigning labels that communicate information regarding the 
alternative. In marketing applications, labels tend to consist of brand names and logos, 
which consumers have learnt to associate with different product characteristics and 
feelings. In the context of health economics, labels tend to consist of generic or brand-
name medications, specific screening tests (e.g. colonoscopy, sigmoidoscopy), specific 
treatments (surgery vs conservative), or other descriptors. An advantage of assigning 
labels is that alternatives will be more realistic and the choice task less abstract, which 
adds to the validity of the results (i.e., responses reflect better the real preference 
structure) and hence, the results may be better suitable to support decision-making at 
policy level. However, by far most commonly applied DCEs in health economics used 
unlabelled alternatives.  
Chapter 9 empirically compared a labelled and an unlabelled DCE for CRC screening 
programs. The labelled version presented screening test alternatives as ‘FOBT’, 
‘sigmoidoscopy’, and ‘colonoscopy’, whereas the unlabelled version presented them as 
‘test A’ and ‘test B’. The labels played a significant role in individual choices; 
approximately 22% of subjects had dominant preferences for screening test labels. The 
convergent validity was modest to low (participants in CRC screening: r=0.54; p=0.01; 
non-participants: r=0.17; p=0.45).  
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Conclusion 
 
In Chapter 10 the findings of this thesis are summarised and discussed. All DCE studies 
in this thesis gave insight into whether or not the given (non-)health attributes is 
important (according to a significant statistical test), the relative importance of the 
attributes, the rate at which individuals were willing to trade between attributes, and 
overall benefit scores for intervention alternatives. However, it is questionable whether 
the results really present serious trade-offs that agree with their actual choice. As a result, 
we stress that DCE outcomes may be more appropriate to show the relative importance 
of the attributes of a health care intervention, than to predict real choice.   
The possibility to estimate a WTP is an additional option of DCE. However, to our 
opinion this additional option is limited. As a result, we recommend to include a cost 
attribute only if this is relevant in health care, and to interpret the WTP values derived 
from a DCE relatively. 
We showed that labelled DCE led to a higher response rate, especially for the group who 
had familiarity with the context. However, more respondents who were not familiar with 
the context failed the rationality test with the labelled design. The inclusion of labels 
appeared to play a significant role in individual choices, and increased non-trading 
behaviour. From our point of view therefore unlabelled DCEs may be more suitable to 
investigate trade-offs between attributes and for respondents who are not familiar with 
the alternative labels, whereas labelled DCEs may be more suitable to explain real life 
choices such as uptake of cancer screening.  
It may be worthwhile for the health economics community to link with areas outside 
health economics in terms of experimental design and estimation procedure. However, it 
should be realised that doing a lot of research to generate a methodologically perfect 
DCE is not useful if respondents can not understand the valuation task anymore or if it 
will be unpractical in a health care context. 
Further research is needed to 1) define the place of DCEs versus other preference 
elicitation methods in health care; 2) generate DCEs which are as easy as possible for 
respondents, but still provide adequate answers to the research question; 3) optimise the 
design and analysis of DCEs, including issues as the usefulness of non-orthogonal 
efficient designs and dealing with ‘irrational’ responses; 4) find opportunities to test the 
external validity of DCEs in health care. 
We conclude that the DCEs conducted in this thesis provided valuable insights regarding 
benefit valuation beyond clinical outcomes of various health care interventions, and are 
therefore useful as additional information to clinical outcomes or QALYs in a medical 
decision-making process about health care interventions. The DCE approach is a feasible 
instrument for the measurement of preferences of adults for all kind of health care 
interventions under the condition that the choice problem can be broken down into 
discrete choice options characterised by limited number of attributes and levels. It is a 
useful tool in health care to directly compare the determinants of the preferences for 
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health care interventions from different groups, such as health professionals, patients, and 
general population.  
 
 
 
Samenvatting 
Samenvatting 
 
Gezondheidseconomie is een deelgebied van de economische wetenschap waarin 
onderzoek wordt gedaan naar schaarste en de toewijzing van gezondheidszorg. De 
belangrijke taken van iedere economische evaluatie zijn het identificeren, het meten, het 
waarderen en het vergelijken van de kosten en consequenties van verschillende 
alternatieven. In de gezondheidseconomie wordt traditiegetrouw vooral gekeken naar de 
gezondheidswinst die een interventie oplevert door gebruik te maken van klinische 
uitkomsten en het aantal zogenoemde QALYs (Quality Adjusted Life Years; een maat 
waarmee voor kwaliteit gecorrigeerde levensjaren uitgedrukt worden). Echter, het kan 
waardevol zijn naast de gemeten gezondheidswinst ook procesuitkomsten (bv. de locatie 
van de behandeling of de wijze van medicatietoediening) en niet-gezondheidsuitkomsten 
(bv. de hoeveelheid verkregen informatie) te meten. Deze uitkomsten kunnen relevant 
zijn voor: 
 ... 
1. de preferenties van individuen en hun bereidheid om specifieke zorginterventies of 
programma’s te aanvaarden (de zogenoemde vraaggestuurde zorg) en  
2. voor medische interventies, die geen gezondheidswinst opleveren, maar wel 
geprefereerd worden (e.g. plastische chirurgie). 
 
Het discrete keuze experiment (DCE) kan proceseffecten en niet-gezondheidsuitkomsten 
evalueren naast de traditionele QALY analyse. De DCE techniek meet het nut van 
alternatieven (goederen of diensten) onder de aannames dat:  
 
1. de alternatieven beschreven kunnen worden door hun karakteristieken (ook wel 
attributen genoemd), en  
2. dat de waardering van een individu (ofwel het nut, utiliteit, tevredenheid of 
preferentie) afhangt van de niveaus (levels) van die karakteristieken.  
 
In een discrete keuze experiment krijgen individuen een aantal keuzesets gepresenteerd. 
In elke keuzeset van twee of meer alternatieven wordt de individuen gevraagd een keuze 
te maken. Er wordt aangenomen dat de geobserveerde keuze een onderliggende 
(verborgen) preferentiefunctie reflecteert. De DCE techniek combineert nutstheorie met 
consumententheorie, experimenteel ontwerptheorie en econometrische analyse.  
In vergelijking met andere preferentietechnieken die het individu vraagt om alternatieven 
een rangordening te geven of te waarderen, presenteert een discrete keuze experiment een 
redelijke recht-toe-recht-aan taak. De DCE-taak komt vrijwel overeen met een beslissing 
in de werkelijke praktijk; het gaat om het afwegen van gezondheidsuitkomsten, 
proceseffecten en/of niet-gezondheidsuitkomsten. DCEs zijn al veel toegepast in de 
marketing, in de transporteconomie en de milieueconomie. De toepassing van DCE op 
het gebied van gezondheidszorg lijkt veelbelovend. 
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Dit proefschrift heeft drie doelen: 
 
1. Een overzicht geven van huidige toegepaste discrete keuze experimenten (DCEs) in 
de gezondheidszorg en de vooruitgang beoordelen in de gebruikte werkwijze. 
(Hoofdstuk 2) 
2. Het nut van DCEs bestuderen voor enkele realistische keuzeproblemen in de 
gezondheidszorg. (Hoofdstukken 3-8) 
3. Een vergelijking maken van een DCE met gelabelde alternatieven met een DCE 
waarin de alternatieven een algemene benaming hebben op aspecten als 
uitvoerbaarheid, mate van afweging en convergente validiteit. (Hoofdstuk 9). 
 
 
Overzicht van discrete keuze experimenten in de gezondheidszorg  
 
Hoofdstuk 2 geeft een overzicht van toegepaste DCEs in de gezondheidseconomie 
tussen 2001 en 2008. Deze sluit aan op een overzichtsstudie van gepubliceerde DCE-
artikelen tussen 1990-2000, waarin werd aanbevolen om methodologische ontwikkelingen 
op andere economische terreinen te volgen. Daarom is in onze overzichtsstudie aandacht 
gegeven aan drie methodologische aspecten: 1) het ontwerp van een discrete keuze 
experiment, 2) de analysemethoden, en 3) de validiteit (validiteit is de mate waarin een 
meting, bewering of uitspraak juist is). 
Wij identificeerden 114 gepubliceerde DCEs tussen 2001 en 2008. Onze overzichtsstudie 
liet zien dat DCEs werden toegepast voor uiteenlopende doeleinden zoals: om 
gezondheidsuitkomsten te waarderen, om afwegingen tussen gezondheidsuitkomsten 
en/of procesuitkomsten en/of niet-gezondheidsuitkomsten in kaart te brengen, om 
gewichten te schatten binnen een QALY (kwaliteit gecorrigeerde levensjaar), en om te 
achterhalen welke behandelingen medisch personeel prefereert voor hun patiënten.  
Kijkend naar de technische kwaliteit van DCEs kunnen we constateren dat er een 
verschuiving is geweest; in de huidige discrete keuze experimenten werden meer 
statistisch efficiënte ontwerpen en vooruitstrevende econometrische modellen toegepast. 
Het toetsen van interne validiteit was grotendeels geïntegreerd in de DCE praktijk. 
Echter, bij geen enkele toegepaste DCE was de externe validiteit getoetst; ofwel toetsen 
of individuen zich werkelijk gedragen als ze zeiden dat ze zouden doen in het onderzoek. 
 
 
Praktische toepassingen van discrete keuze experimenten in de gezondheidszorg  
 
Dit proefschrift beschrijft vier DCEs, die ontwikkeld zijn voor realistische 
keuzeproblemen in de gezondheidszorg waarin (ook) effecten anders dan gezondheids-
winsten in acht werden genomen. Deze vier problemen illustreren de mogelijkheid van 
DCEs om proceseffecten en niet-gezondheidsuitkomsten van medische interventies mee 
te nemen bij het bepalen van voorkeuren voor die interventies. 
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De eerste DCE werd uitgevoerd om preferenties van patiënten en artsen te achterhalen 
voor medicatie om osteoporose (botontkalking) te voorkomen. In verschillende 
richtlijnen wordt aanbevolen om mensen met een verhoogde kans op osteoporotische 
facturen (meestal vrouwen) op te sporen door middel van een zogenoemde ‘case-finding’ 
benadering (case-finding is het zoeken door de hulpverlener of arts naar risicofactoren of 
beginnende afwijkingen bij mensen die om andere redenen een hulpverlener of arts 
bezoeken; het doel is vroegtijdig kunnen behandelen of erger voorkomen). Deze 
benadering is alleen succesvol als de opgespoorde personen ook bereid zijn om medicatie 
te gebruiken om osteoporose te voorkomen en op welke voorwaarden.  
Hoofdstuk 3 liet zien dat behandelingskarakteristieken als effectiviteit, bijwerkingen 
(misselijkheid), totale behandelingsduur, de wijze van medicatietoediening en de eigen 
financiële bijdrage een relevante invloed hadden op de keuzen. Misselijkheid als 
bijwerking van de medicatie werd geaccepteerd als de preventieve medicatie ervoor 
zorgde dat het relatieve 10-jaars risico op een heupfractuur met 40% gereduceerd werd. 
Vrouwen waren bereid een eigen bijdrage te betalen voor de huidige beschikbare 
preventieve medicatie (bisfosfonaat) als de kans op een fractuur met minstens 12% 
afnam.  
Meningsverschillen over het beginnen met een (preventieve) behandeling kan het nemen 
van een gezamenlijke beslissing van de arts en de patiënt in de weg staan. Daarom 
vergeleken wij de voorkeuren van huisartsen en patiënten met elkaar wat betreft 
preventieve medicatie voor osteoporose en evalueerden de determinanten (factoren die 
een toestand of een ontwikkeling (mede)bepalen) van de gevonden preferentieverschillen 
(Hoofdstuk 4).  
Wij toonden aan dat huisartsen een duidelijk minder positieve houding hadden tegenover 
preventieve medicatie dan patiënten; huisartsen hechtten meer waarde aan de effectiviteit 
van de medicatie en aan een korte totale behandelingsduur dan patiënten.  
 
De tweede DCE (Hoofdstuk 5) werd uitgevoerd om voorkeuren voor brace-
behandeling bij idiopatische scoliose (zijwaartse verkromming van de wervelkolom 
zonder duidelijke oorzaak) te onderzoeken. De effectiviteit van een brace-behandeling bij 
idiopatische scoliose patiënten is nog niet vastgesteld.  
Wij toonden aan dat behandelingskenmerken als effectiviteit (ofwel risico reductie op een 
chirurgische interventie), zichtbaarheid van de brace, het draagcomfort van de brace en de 
behandelingsduur allen belangrijk waren voor de keuzen van de patiënt. Effectiviteit en 
het draagcomfort van de brace waren het belangrijkst. Patiënten waren bereid een brace-
behandeling van drie jaar te ondergaan met een Boston brace (een korset gemaakt van 
lichtgewicht plastic, dat ontwikkeld is in de Amerikaanse stad Boston),  als dat de kans op 
een operatie met één tot tweederde zou reduceren.  
Deze resultaten zijn belangrijk 1) als gerandomiseerde gecontroleerde onderzoeken 
(effectonderzoeken waarbij twee groepen met elkaar worden vergeleken die door toeval 
zijn samengesteld) zouden aantonen dat brace-behandeling effectief is en 2) voor verdere 
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technische brace-ontwikkeling om het correct opvolgen van  een brace-behandeling door 
de patiënt te verhogen.  
 
Hoofdstuk 6 beschreef een derde DCE, die de (determinanten van) voorkeuren van 
vrouwen voor drie manieren van borstreconstructie onderzocht. De preferenties van 
vrouwen zijn belangrijke factoren in de beslissing voor een specifiek type 
borstreconstructie. Het begrijpen van de motivaties van vrouwen kan bijdragen aan het 
verder verbeteren van informatie voor de patiënt en om vraaggestuurde zorg te 
ontwikkelen. De borstreconstructies werden gekarakteriseerd door zes 
behandelingskenmerken: 1) gebruikte materiaal, 2) aantal operaties en operatieduur, 3) 
korte- en 4) lange termijn complicatiekansen, 5) esthetisch resultaat, and 6) wachttijd. Al 
deze behandelingskenmerken waren belangrijk voor de keuzen van vrouwen. Onze 
resultaten toonden aan dat (lichaamseigen weefsel) materiaal en esthetisch resultaat de 
belangrijkste factoren waren voor de keuze van vrouwen om een borstreconstructie te 
ondergaan. De huidige borstreconstructie met eigen weefsel kwam het best overeen met 
de voorkeuren van vrouwen. 
 
De vierde DCE (Hoofdstukken 7 en 8) onderzocht de voorkeuren voor dikke 
darmkanker screening. Screening (bevolkingsonderzoek) kan naar verwachting sterfte 
door dikke darmkanker reduceren door dikke darmkanker in een vroeg stadium op te 
sporen en kwaadaardige voorlopers van dikke darmkanker (adenomen) endoscopisch 
(ofwel met een inwendig kijkonderzoek) te verwijderen. Het deelnamepercentage aan 
dikke darmkanker screening is lager dan aan borstkanker screening. Daarom 
onderzochten we de invloed van (kenmerken) van verschillende screeningstesten op de 
voorkeuren van individuen voor dikke darmkanker screening.  
Hoofdstuk 7 geeft de resultaten weer van een DCE waarin de screeningsstrategieën 
werden beschreven door verschillende type testen (ontlastingstest, flexibele 
sigmoidoscopie (inwendig kijkonderzoek van het laatste deel van de dikke darm) en 
colonoscopie (inwendig kijkonderzoek van de gehele dikke darm)) vergezeld door 
realistische sterftereducties en screeningsintervallen (screeningstussenpozen; hoe vaak een 
individu in 10 jaar zou moeten komen voor het bevolkingsonderzoek). 
De respondenten prefereerden screening boven geen screening ongeacht welke 
screeningstest gebruikt werd. Zowel de screeningstest, het screeningsinterval als het risico 
op sterfte door dikke darmkanker beïnvloedden de voorkeuren van individuen voor dikke 
darmkanker screening. De respondenten leken bereid 25 procent risicoreductie op sterfte 
door dikke darmkanker op te offeren als ze daarvoor eens per vijf jaar een flexibele 
sigmoidoscopie kregen in plaats van eens per tien jaar een colonoscopie. De doelgroep 
prefereerde screening met een endoscoop boven screening met een ontlastingstest als 
realistische niveaus van testkenmerken en uitkomsten golden.  
Hoofdstuk 8 geeft de resultaten weer van een DCE waarin de screeningsstrategieën 
beschreven werden door testkenmerken als pijn, complicatierisico, screeningslocatie, 
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voorbereiding, screeningsduur, screeningsinterval en risicoreductie op sterfte door dikke 
darmkanker screening.  
Alle testkenmerken hadden een significante invloed op de preferenties van respondenten. 
Respondenten eisten een 32 procent additionele relatieve risicoreductie op mortaliteit 
door dikke darmkanker om een intensieve dikke darm voorbereiding te ondergaan in 
tegenstelling tot geen dikke darm voorbereiding. Screeningsintervallen korter dan tien jaar 
werden geprefereerd boven een screeningsinterval van eens per tien jaar. Vooral het type 
dikke darm voorbereiding, de tijdsinterval van screening en de mortaliteitreductie 
beïnvloedden de afwegingen van individuen. Deze resultaten leveren inzichten in het 
besliskundig proces omtrent de beslissing om aan dikke darmkanker screening deel te 
nemen en draagt bij om de informatie verstrekt aan de screeningsdoelgroep te verbeteren 
en om punten te identificeren om de deelname aan dikke darmkanker screening te 
verhogen.  
 
 
Theoretische aspecten van discrete keuze experimenten in de gezondheidszorg. 
 
Een belangrijke vraag in het uitvoeren van een discrete keuze experiment (DCE) is of de 
DCE gepresenteerd moet worden waarin de keuze opties (alternatieven) een specifiek 
label hebben of niet, respectievelijk een gelabelde DCE en ongelabelde DCE genoemd. 
Een ongelabelde DCE bevat keuze opties met een algemene benaming in een keuze set, 
zoals ‘ optie A’, ‘optie B’ enzovoort. Een gelabelde DCE bevat keuze opties met een 
specifiek etiket dat informatie geeft over die bepaalde keuze optie. Denk bijvoorbeeld in 
de marketing aan merken en logo’s, die voor consumenten bepaalde 
productkarakteristieken en gevoelens oproepen. Op gezondheidseconomisch gebied 
kunnen we denken aan de naam van een geneesmiddel, een specifieke screeningstest 
(colonoscopie, sigmoidoscopie), een specifieke behandeling (operatie, bestraling) 
enzovoort. Een voordeel van het toewijzen van specifieke benamingen aan de 
keuzeopties is dat de opties realistischer worden en de keuzetaak minder abstract, wat zou 
kunnen bijdragen aan de validiteit van de resultaten en dus geschikter is om beslissingen 
op beleidsniveau te ondersteunen. Echter, de meeste toegepaste discrete keuze 
experimenten in de gezondheidszorg gebruikten keuze opties met algemene (ofwel 
ongelabelde) benamingen. 
In Hoofdstuk 9 werden een gelabelde en een ongelabelde DCE op het gebied van dikke 
darmkanker screening empirisch vergeleken. De ongelabelde DCE presenteerde de 
screeningstest opties als ‘ontlastingstest’, ‘sigmoidoscopie’ en ‘colonoscopie’, terwijl de 
ongelabelde DCE de screeningstesten presenteerden als ‘screeningstest A’ en ‘ 
screeningstest B’.  De specifieke labels van de keuze opties speelden een duidelijke rol in 
de keuzen van individuen; ongeveer 22 procent van de respondenten had een dominante 
voorkeur voor het specifieke label van een screeningstest. De uitkomsten van de 
gelabelde en ongelabelde DCE kwamen gemiddeld tot slecht overeen. 
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Conclusie 
 
In Hoofdstuk 10 worden de bevindingen van dit proefschrift samengevat en besproken. 
Alle DCE studies in dit proefschrift gaven inzicht of de gegeven 
(niet)gezondheidskenmerken belangrijk waren (volgens een significante statistische test) 
voor de keuzen, in het relatieve belang van de kenmerken, in de mate waarin individuen 
bereid waren kenmerken met elkaar af te wegen en in de totale score van tevredenheid 
voor een interventie. Het is echter twijfelachtig of de resultaten werkelijk afwegingen 
representeren die overeenkomen met de uiteindelijke keuze. Wij stellen dat DCE 
uitkomsten geschikter lijken te zijn om de relatieve invloed van de kenmerken van 
gezondheidsinterventies op het keuzegedrag weer te geven dan om werkelijk gedrag te 
voorspellen. 
De mogelijkheid om een betalingsbereidheid te schatten is een extra voordeel van discrete 
keuze experimenten, maar naar ons inziens is dit voordeel beperkt. Wij bevelen aan om 
alleen een kostenkenmerk in een DCE mee te nemen als dit daadwerkelijk relevant is. 
Tevens bevelen wij aan om de geschatte betalingsbereidheid voor een medische 
interventie relatief te interpreteren en niet absoluut.  
Wij lieten zien dat een gelabelde DCE tot een hogere respons leidde, vooral voor de 
groep die bekend was of ervaring had met de gelabelde opties. Echter meer individuen die 
niet bekend waren met of geen ervaring hadden met de gelabelde opties zakten voor de 
rationaliteitstest (een test om te kijken of de individu een rationele keuze maakt) in het 
gelabelde DCE design.  Het toevoegen van specifieke labels voor de keuze opties in een 
DCE bleek een belangrijke rol te spelen in de keuzen van individuen, als gevolg dat 
individuen minder bereidheid waren om verschillende kenmerken van een medische 
interventie tegen elkaar af te wegen. Daarom zijn vanuit ons oogpunt DCEs met 
ongelabelde keuzeopties geschikter om de afwegingen tussen kenmerken van medische 
interventies te onderzoeken en voor individuen waarvoor de  gelabelde keuzeopties geen 
betekenis hebben, terwijl DCEs met gelabelde keuze opties geschikter zijn om werkelijk 
gedrag te verklaren zoals deelname aan kankerscreening. 
Voor de gezondheidseconomische onderzoeksgemeenschap kan het waardevol zijn om 
aansluiting te zoeken met andere gebieden buiten de gezondheidseconomie als het gaat 
om het ontwerp van een DCE en om de analysemethoden. Echter veel onderzoek doen 
om een methodologische perfecte DCE te genereren is weinig zinvol als de respondenten 
daardoor de waarderingstaak niet meer begrijpen. 
 
Verder onderzoek is nodig om: 
 
1. de plaats van DCE te definiëren ten opzichte van andere methoden om preferenties 
te onderzoeken; 
2. discrete keuze experimenten te genereren die zo makkelijk mogelijk zijn voor 
respondenten, maar toch adequate antwoorden leveren op de onderzoeksvraag;  
3. het design en de analyse van DCEs te optimaliseren; 
4. de externe validiteit van DCE in de gezondheidszorg te testen.  
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Wij concludeerden dat de discrete keuze experimenten (DCEs) uitgevoerd in dit 
proefschrift waardevolle inzichten opleverden bij de waardering van 
gezondheidsinterventies door rekening te houden met meer dan alleen klinische 
uitkomsten. Hierdoor zijn de resultaten aanvullend op de klinische uitkomsten of QALYs 
(kwaliteit gecorrigeerde levensjaren) in een besluitvormingsproces over 
gezondheidsinterventies. De DCE is een hanteerbaar instrument om preferenties van 
volwassenen te meten voor alle vormen van gezondheidsinterventies onder de 
voorwaarde dat het keuzeprobleem opgedeeld kan worden in discrete keuze opties die 
gekarakteriseerd worden door een aantal kenmerken en kenmerkniveaus. De DCE is een 
nuttig instrument in de gezondheidszorg om de factoren die van invloed zijn op de 
preferenties van verschillende groepen, zoals medische beroepsbeoefenaren, patiënten en 
algemene bevolking, voor gezondheidsinterventies direct met elkaar te vergelijken.  
 
  
Co-authors 
Co-authors 
 
 
Name      Affiliation 
 
E.M. Bunge, PhD    Department of Public Health, Erasmus MC,  
       Rotterdam 
  
F.C. van Biezen, MD    Department of Orthopaedics, Erasmus MC,  
       Rotterdam  
  
L. van Dam, MSc    Department of Gastroenterology and Hepatology, 
        Erasmus MC, Rotterdam 
 
T.H.C. Damen, MD    Department of Plastic and Reconstructive Surgery,  
       Erasmus MC, Rotterdam 
 
B. Donkers, PhD    Department of Business Economics, Erasmus 
     University, Rotterdam 
 
M.L. Essink-Bot, MD, PhD  Department of Social Medicine, Academic Medical 
        Centre, University of Amsterdam, Amsterdam;  
       Department of Public Health, Erasmus MC,  
       Rotterdam 
 
K.M. Gerard, PhD    School of Health Sciences, University of  
       Southampton, United Kingdom 
 
J.D.F. Habbema, PhD   Department of Public Health, Erasmus MC,  
       Rotterdam 
 
S.O.P. Hofer, MD, PhD, FRCS(C) Department of Plastic and Reconstructive Surgery,  
       Erasmus MC, Rotterdam; Division of Plastic 
       Surgery, University Health Network, University of 
Toronto, Toronto, Ontario, Canada 
 
L. Hol, MD     Department of Gastroenterology and Hepatology, 
        Erasmus MC, Rotterdam 
 
B.W. Koes, PhD    Department of General Practice, Erasmus MC,  
       Rotterdam 
 213 
Co-authors 
 214 
H.J. de Koning, PhD    Department of Public Health, Erasmus MC,  
       Rotterdam 
 
E.J. Kuipers, MD, PhD   Department of Gastroenterology and Hepatology, 
        Erasmus MC, Rotterdam; Department of Internal  
       Medicine, Erasmus MC, Rotterdam 
 
M.E. van Leerdam, MD, PhD  Department of Gastroenterology and Hepatology, 
        Erasmus MC, Rotterdam 
 
W.J. Meerding, PhD    Department of Public Health, Erasmus MC,  
       Rotterdam 
 
M.B. Menke-Pluijmers, MD, PhD Erasmus University Medical Centre/ Daniel den 
       Hoed Cancer Centre, Family Cancer Clinic, 
Department of Surgical Oncology, Rotterdam 
 
M.A.M. Mureau, MD, PhD   Department of Plastic and Reconstructive Surgery,  
       Erasmus MC, Rotterdam 
 
H.A.P. Pols, MD, PhD   Department of Internal Medicine, Erasmus MC,  
       Rotterdam 
 
M. Ryan, PhD, FRSE    Health Economics Research Unit, University of  
       Aberdeen, United Kingdom 
 
C. Seynaeve, MD, PhD   Erasmus University Medical Centre/ Daniel den 
        Hoed Cancer Centre, Family Cancer Clinic, 
Department of Medical Oncology, Rotterdam 
 
E.W. Steyerberg, PhD   Department of Public Health, Erasmus MC,  
       Rotterdam 
 
   
Dankwoord 
Dankwoord  
 
Met veel plezier heb ik de afgelopen vier jaar aan dit proefschrift gewerkt. Bij de 
totstandkoming van dit proefschrift zijn velen betrokken geweest. Ik wil deze ruimte dan 
ook benutten om allen hiervoor te bedanken, enkelen van hen in het bijzonder. 
 
Allereerst gaat mijn dank uit naar mijn promotor en co-promotor: Ewout en Marie-
Louise. Gedurende de jaren heb ik veel van jullie mogen leren. Ik bewonder jullie voor 
jullie kennis, opbouwende en snelle commentaar, creatieve denken, en bovenal jullie 
coachende werkwijze. Dat ik jullie in één adem noem is bewust. Jullie samenwerking is 
van bijzondere klasse: efficiënt en doelgericht, gecombineerd met de nodige humor. 
Ewout, jouw laagdrempeligheid en openheid zijn karaktereigenschappen die ik waardeer. 
Ik wil je bedanken voor de kansen die jij mij gegeven hebt en voor je inzet om mijn doel 
te verwezenlijken. Marie-Louise, jouw input op verschillende vlakken is voor mij van 
onschatbare waarde geweest. Het vertrouwen dat je in mij hebt, heeft mij de vrijheid 
gegeven mijzelf te kunnen ontplooien.  
 
Mijn dank gaat ook uit naar alle co-auteurs, met in het bijzonder Eveline, Tim, Lieke en 
Leonie. Dank voor jullie bijdrage en voor het delen van jullie klinische kennis. I also want 
to give special thanks to Mandy and Karen; writing a review paper is more challenging 
than writing up an empirical study. Thank you for teaching these important academic 
skills. En natuurlijk Bas; mijn helpdesk op DCE-gebied. Dank voor het delen van je 
kennis en praktische tips.  
 
Dit brengt mij bij de leden van de kleine commissie. Professor Brouwer, professor 
Hunink en professor Kuipers, bedankt voor het lezen en beoordelen van mijn 
proefschrift. 
 
Ook al mijn (oud) MGZ-collega’s wil ik hierbij bedanken voor de gezellige tijd en 
inspirerende werkomgeving. Tinneke, Eveline, Elin, Mirjam, Hester, Esther, Judith en 
Hilde, dank voor alle leuke (niet-)werkgerelateerde gesprekken. Kees en Sonja, bedankt 
voor jullie computer- en administratieve ondersteuning. Ida, Robine, Inge, Marjolein, 
Saskia en René, dank voor de  prettige samenwerking aan projecten buiten dit proefschrift 
om. Dit geldt ook voor mijn RIVM-collega’s, met in het bijzonder Lany, Johan, Nikkie en 
Matthijs.  
 
Dan natuurlijk mijn paranimfen, Suzanne en Iris. Ik vind het een eer dat jullie aan mijn 
zijde willen staan tijdens de promotieplechtigheid. Lieve Suzanne, je was een geweldige 
kamergenote de afgelopen 4 jaar. We hebben de nodige serieuze gesprekken gevoerd, 
maar bovenal veel gelachen. Lieve Iris, wat ben ik blij dat jij in Bleiswijk bent komen 
wonen. Ik heb genoten van onze gezamenlijke fietstochtjes naar huis waar menig 
onderwerp besproken werd. 
 
Mijn proefschrift had niet nu al af kunnen zijn zonder de leidsters en directie van 
Kinderdagverblijf de Petteflat te Bergschenhoek. Lieve Alke, Leonie, Esther, Esmeralda, 
 215 
Dankwoord 
 216 
Jessica, Marsha, Ellen, Lieke, Jamila, Belinda, Claudia, Anja, en alle anderen, jullie 
enthousiasme en verantwoordelijkheid hebben enorm bijgedragen aan dit proefschrift.  
 
Beste vrienden, hoewel ik probeerde om het proefschriftonderwerp te vermijden, bleven 
jullie interesse tonen. Bedankt voor jullie afleiding en betrokkenheid. Liebi Fründi us dr 
Schwiz. I ha öies schöne Land verla, um die Doktrarbeit z’mache. Obwou i froh bi, dä 
Schritt gemacht dsha, ha ig nie vergässe wie schöns bi öich gsi isch. Merci viumau.  
 
En dan natuurlijk mijn familie. Bea, Sjax, Grete, Bart, George, Hanneke, Rachèl, en Bas, 
dank voor de steeds weer getoonde interesse. Lieve Kiki, Dominique, Collin en Mats, 
bedankt voor jullie hartverwarmende afleiding.  
 
Lieve pa en ma, bedankt voor jullie onvoorwaardelijke vertrouwen en steun. Altijd waren 
jullie er voor mij wanneer dat nodig was. Bedankt voor alle mogelijkheden die jullie mij 
gegeven hebben om datgene te doen wat ik ambieer.  
 
Lieve Chayenne en Kenai, jullie zijn mijn drive geweest om het proefschrift zo snel 
mogelijk af te ronden. Jullie waren echte slaapkopjes wat een grote bijdrage is geweest aan 
de voortgang van mijn proefschrift. Mijn leven is zoveel mooier met jullie om mij heen.  
Lieve Lars, je hebt altijd voor honderd procent achter dit proefschrift gestaan. 
Stilzwijgend luisterde je naar al mijn ups en downs. Dank voor je onvoorwaardelijke 
steun. Zonder zo’n achterban was deze marathon een stuk vermoeiender verlopen. En ja, 
ook hier geldt: alles komt terecht.  
 
 
 
                                                                                 
 
Esther 
PhD portfolio summary 
PhD portfolio summary 
Summary of PhD training and teaching activities 
 
 
Name PhD student: Esther de Bekker-Grob       PhD period 2005-2009 
Erasmus MC Department: Public Health        Promotor: Prof. dr. E.W. Steyerberg 
               Supervisor: Dr. M.L. Essink-Bot 
 
 
PhD Training              Year    Workload  
 
Research skills 
Erasmus Summer Programme, Erasmus MC Rotterdam     
 Biostatistics         2005        20 hours 
Institute of Medical Technology Assessment, Rotterdam 
 Basic principles of discrete choice experiments   2005        20 hours 
Centre for microdata methods and practice (CEMMAP) –  
Institute for Fiscal Studies (IFS) – University College London 
 Discrete choice modelling       2006        40 hours 
Nihes, Erasmus MC Rotterdam        
 Planning and evaluation of screening     2006        40 hours 
Institute of Medical Technology Assessment, Rotterdam 
 Designing and modelling discrete choice experiments  2007        32 hours 
University of Glasgow, Public Health and Health Policy   
Section, Division of Community Based Science 
 Advanced modelling methods for health economic  2009        24 hours 
evaluation 
 
 
Presentations 
Landelijk Forum Medische Besliskunde, Rotterdam 
 Patient’s preferences for osteoporosis drug treatment:  2007        40 hours 
 a discrete choice experiment 
Seminar Public Health, Rotterdam 
 Patient’s preferences for osteoporosis drug treatment:  2007        20 hours 
 a discrete choice experiment 
International Society for Pharmacoeconomics and Outcomes  
 Research (ISPOR), Dublin, UK 
 Patient’s preferences for osteoporosis drug treatment:  2007        20 hours 
 a discrete choice experiment 
 217 
PhD portfolio summary 
 218 
                        Year    Workload  
 
Presentations (continued) 
Society of Medical Decision Making, Pittsburgh, US    
 GPs and patient’s preferences for osteoporosis drug   2007        40 hours 
 treatment: a discrete choice experiment 
Conjoint analysis in health Care, Delray Beach, US    
 Labelled versus unlabelled DCEs in health care:   2009        40 hours 
an application to colorectal cancer screening 
 
 
Seminars and workshops 
Attending seminars of the department of Public Health  2005-2009       80 hours 
Workshops on designing DCEs, Lund, Sweden    2007         20 hours 
Workshops on economic evaluation, Pittsburgh, US   2007        20 hours 
Workshops on DCEs, Delray Beach, US     2007          8 hours 
 
 
International conferences   
Society of Medical Decision Making, Pittsburgh, US    2007        24 hours 
International Health Economics Association,     2007        20 hours 
      Copenhagen, Denmark 
Conjoint analysis in health care, Delray Beach, US   2009        24 hours 
 
 
List of publications 
List of publications 
by September 1, 2009  
 
First authorships 
 
BEKKER-GROB EW de, Aa MNM van  der, Zwarthoff EC, Eijkemans MJC, Rhijn BW 
van, Kwast TH van der, Steyerberg EW. Non-muscle invasive bladder cancer surveillance 
in which cystoscopy is partly replaced by microsatellite analysis on urine: a cost-effective 
alternative? (CEFUB-trial). BJU International 2008; 104:41-47. 
 
BEKKER-GROB EW de, Bunge EM, Biezen FC van, Essink-Bot ML, Koning HJ de. 
Patients’ preferences for scoliosis brace treatment: a discrete choice experiment. Spine. In 
press. 
 
BEKKER-GROB EW de, Essink-Bot ML, Meerding WJ, Koes BW, Steyerberg EW. 
General practitioners’ and patients’ preferences for osteoporosis drug treatment: a 
discrete choice experiment. PharmacoEconomics 2009; 27(3):211-209. 
 
BEKKER-GROB EW de, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, 
Steyerberg EW. Patients’ preferences for osteoporosis drug treatment: a discrete choice 
experiment. Osteoporosis International 2008; 19(7):1029-1037. 
 
BEKKER-GROB EW de, Hol L, Donkers B, Dam L van, Habbema JDF, Leerdam ME 
van, Kuipers EJ, Essink-Bot ML, Steyerberg EW. Labelled versus unlabelled discrete 
choice experiments in health economics: an application to colorectal cancer screening. 
Submitted. 
 
BEKKER-GROB EW de, Polder JJ, Mackenbach JP, Meerding WJ. Towards a 
comprehensive estimate of national spending on prevention. BMC Public Health 2007; 
7:252. 
 
BEKKER-GROB EW de, Polder JJ, Witte KE, Mackenbach JP, Meerding WJ. Kosten 
van preventie in Nederland 2003. Bilthoven, 2006: RIVM report 270751011 
 
BEKKER-GROB EW de, Ryan M, Gerard KM, Steyerberg EW, Essink-Bot ML. 
Applying discrete choice experiments to value health and health care: a review of the 
literature. Submitted. 
 
 
 
Co-authorships  
 
Casteren NJ van, Jong J de, Stoop H, Steyerberg EW, BEKKER-GROB EW de, Dohle 
GR, Oosterhuis JW, Looijenga LH. Evaluation of testicular biopsies for carcinoma in situ: 
immunohistochemistry is mandatory. International Journal of Andrology. In press. 
 219 
List of publications 
 220 
Dam L van, Hol L, BEKKER-GROB EW de, Steyerberg EW, Kuipers EJ, Habbema 
JDF, Essink-Bot ML, Leerdam ME van. What influences individuals’ preferences for 
colorectal cancer screening tests? An application of the discrete choice experiment. Eur J 
Cancer. In press. 
 
Damen THC, BEKKER-GROB EW de, Mureau MAM, Menke-Pluijmers MB, Seynaeve 
C, Hofer SOP, Essink-Bot ML. Patients’ Preferences for Breast Reconstruction: a 
Discrete Choice Experiment. Submitted. 
 
Hol L, BEKKER-GROB EW de, Dam L van, Donkers B, Kuipers EJ, Habbema JDF, 
Steyerberg EW, Leerdam ME van, Essink-Bot ML. Population preferences for different 
screening strategies for colorectal cancer in the Netherlands; a discrete choice experiment. 
Submitted. 
 
Mello NM van, Mol F, Opmeer BC, BEKKER-GROB EW de, Essink-Bot ML, Ankum 
WM, Mol BW, Veen F van der, Hajenius PJ. Salpingostomy or salpingectomy in tubal 
ectopic pregnancy: what do women prefer? A discrete choice experiment. Submitted. 
 
Curriculum vitae 
Curriculum vitae  
 
Esther Wilhelmina Grob werd geboren op 15 december 1978 te Zevenaar. Ze behaalde in 
1997 haar Gymnasium diploma aan het Liemers College te Zevenaar. Na driemaal te zijn 
uitgeloot voor de studie Geneeskunde rondde zij in 2001 de opleiding HBO - Medische 
Beeldvormende en Radiotherapeutische Technieken af aan de Hogeschool Haarlem. In 
het zelfde jaar voltooide zij ook de opleiding Stralingsdeskundigheid Niveau 3 aan het 
Interuniversitair Onderzoeksinstituut voor Radiopathologie en Stralingsbescherming te 
Leiden. Gedurende 3 jaar werkte zij als radiotherapeutisch laborant en opleidings-
coördinator op de afdeling radiotherapie in het Inselspital te Bern, Zwitserland. In 2003 
behaalde ze haar managementdiploma aan de Management-Fachschule te Bern. Haar 
doctoraal diploma Public Health – Health Policy, Economics, and Management behaalde 
zij in 2005 aan de Universiteit Maastricht. Eveneens in 2005 werd zij aangesteld als junior 
onderzoeker op de afdeling Maatschappelijke Gezondheidszorg van het Erasmus 
Medisch Centrum te Rotterdam. Hier is zij ook nu nog werkzaam. Ze was als 
gezondheidseconoom betrokken bij diverse kosten(effectiviteit)studies en preferentie-
studies, waarover werd gerapporteerd op verschillende nationale en internationale 
congressen en in publicaties in medisch-wetenschappelijke tijdschriften. Tevens was zij als 
co-auteur betrokken bij de ‘Volksgezondheid Toekomst Verkenning 2006’ en bij het 
leerboek ‘Van kosten tot effecten – een handleiding voor evaluatiestudies in de 
gezondheidszorg’. 
Esther is getrouwd met Lars de Bekker en samen hebben zij een dochter Chayenne 
(2006) en een zoon Kenai (2008). 
 
 221 
